University of Pennsylvania

ScholarlyCommons
Publicly Accessible Penn Dissertations
2021

Interactions Of Highly Pathogenic Human Coronaviruses With
Dsrna-Induced Innate Immune Pathways
Courtney Elizabeth Comar
University of Pennsylvania

Follow this and additional works at: https://repository.upenn.edu/edissertations
Part of the Virology Commons

Recommended Citation
Comar, Courtney Elizabeth, "Interactions Of Highly Pathogenic Human Coronaviruses With Dsrna-Induced
Innate Immune Pathways" (2021). Publicly Accessible Penn Dissertations. 3705.
https://repository.upenn.edu/edissertations/3705

This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/3705
For more information, please contact repository@pobox.upenn.edu.

Interactions Of Highly Pathogenic Human Coronaviruses With Dsrna-Induced
Innate Immune Pathways
Abstract
In the last decade, two novel coronaviruses have emerged from zoonotic sources to humans. Middle East
Respiratory Syndrome Coronavirus (MERS-CoV) emerged in 2012 causing several outbreaks of severe
respiratory illness with a high case fatality ratio of 35%. Severe Acute Respiratory Syndrome Coronavirus
2 (SARS-CoV-2) emerged in late 2019 causing a devastating pandemic that has caused over 2.7 million
deaths in over 124 million cases as of March 2021. Coronaviruses are positive sense single-stranded RNA
viruses and are adept at delaying or suppressing activation of innate immune responses in their hosts,
despite detectable double-stranded (ds)RNA production during infection. Our goal was to understand how
the highly pathogenic human coronaviruses, MERS-CoV and SARS-CoV-2, interact with and evade the
dsRNA-induced innate immune pathways: type I and III interferon (IFN) production and signaling, protein
kinase R (PKR), and oligo adenylate synthetase ribonuclease L (OAS/RNase L). We found that MERS-CoV
evades activation of IFN, PKR and OAS/RNase L due to the activities of three different proteins. We show
during authentic MERS-CoV infection that dsRNA-binding accessory protein NS4a blocks PKR activation
and IFN mRNA expression, and that accessory protein NS4b blocks IFN induction through its
phosphodiesterase (PDE) activity and nuclear localization. Furthermore, we examined the role of
conserved coronavirus protein nsp15 endoribonuclease (EndoU) catalytic activity during MERS-CoV
infection. We found that inactivation of EndoU during MERS-CoV infection had mild effects on the dsRNAinduced innate immune pathways. However, inactivation of EndoU in combination with loss of expression
of accessory protein NS4a or inactivation of PDE activity of NS4b caused defects in infectious virus
production and robust activation of the innate immune pathways in MERS-CoV infected A549DPP4 cells.
This highlighted redundant functions of EndoU, NS4a, and NS4b that together lead to strong suppression
and evasion of dsRNA induced innate immunity during MERS-CoV infection. We also investigated the
interactions of SARS-CoV-2 with the dsRNA-induced pathways. We found that SARS-CoV-2, unlike MERSCoV, induced mild IFN expression and moderately activated PKR and OAS/RNase L in lung derived cell
lines. Our findings fill some of the gaps in knowledge of how highly pathogenic human coronaviruses
interact with the innate immune system.
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ABSTRACT

INTERACTIONS OF HIGHLY PATHOGENIC HUMAN CORONAVIRUSES
WITH DSRNA-INDUCED INNATE IMMUNE PATHWAYS
Courtney Elizabeth Comar
Susan R. Weiss, PhD
In the last decade, two novel coronaviruses have emerged from zoonotic sources to humans.
Middle East Respiratory Syndrome Coronavirus (MERS-CoV) emerged in 2012 causing several
outbreaks of severe respiratory illness with a high case fatality ratio of 35%. Severe Acute
Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) emerged in late 2019 causing a devastating
pandemic that has caused over 2.7 million deaths in over 124 million cases as of March 2021.
Coronaviruses are positive sense single-stranded RNA viruses and are adept at delaying or
suppressing activation of innate immune responses in their hosts, despite detectable doublestranded (ds)RNA production during infection. Our goal was to understand how the highly
pathogenic human coronaviruses, MERS-CoV and SARS-CoV-2, interact with and evade the
dsRNA-induced innate immune pathways: type I and III interferon (IFN) production and signaling,
protein kinase R (PKR), and oligo adenylate synthetase ribonuclease L (OAS/RNase L). We
found that MERS-CoV evades activation of IFN, PKR and OAS/RNase L due to the activities of
three different proteins. We show during authentic MERS-CoV infection that dsRNA-binding
accessory protein NS4a blocks PKR activation and IFN mRNA expression, and that accessory
protein NS4b blocks IFN induction through its phosphodiesterase (PDE) activity and nuclear
localization. Furthermore, we examined the role of conserved coronavirus protein nsp15
endoribonuclease (EndoU) catalytic activity during MERS-CoV infection. We found that
inactivation of EndoU during MERS-CoV infection had mild effects on the dsRNA-induced innate
immune pathways. However, inactivation of EndoU in combination with loss of expression of
accessory protein NS4a or inactivation of PDE activity of NS4b caused defects in infectious virus
production and robust activation of the innate immune pathways in MERS-CoV infected A549DPP4
vi

cells. This highlighted redundant functions of EndoU, NS4a, and NS4b that together lead to
strong suppression and evasion of dsRNA induced innate immunity during MERS-CoV infection.
We also investigated the interactions of SARS-CoV-2 with the dsRNA-induced pathways. We
found that SARS-CoV-2, unlike MERS-CoV, induced mild IFN expression and moderately
activated PKR and OAS/RNase L in lung derived cell lines. Our findings fill some of the gaps in
knowledge of how highly pathogenic human coronaviruses interact with the innate immune
system.
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CHAPTER 1: INTRODUCTION
1.1 CORONAVIRUSES: A GLOBAL PERSPECTIVE
Coronaviruses were first discovered in the 1930s, the first human coronaviruses identified in the
1960s, and currently there are seven known coronaviruses that infect humans. Since the turn of
the twenty-first century, three novel and highly pathogenic coronaviruses have emerged in
humans and caused epidemics or pandemics. Severe acute respiratory syndrome coronavirus
(SARS-CoV) caused an epidemic centered in China from 2002-2003. Middle East respiratory
syndrome coronavirus (MERS-CoV) emerged in 2012 and has continued transmission in the
Middle East. Most recently, SARS-CoV-2, the causative agent of coronavirus disease-2019
(COVID-19), emerged in late 2019 in China causing a devastating pandemic, infecting over 127
million people, killing over 2.7 million (as of March 29, 2021), and causing severe economic
losses worldwide.

The emergence of SARS-CoV-2 and the resulting COVID-19 pandemic have dramatically
exposed our society’s vulnerability to infectious diseases, especially to the emergence of highly
pathogenic novel coronaviruses. Without prior research and understanding of coronaviruses, we
would have been even less equipped to deal with the COVID-19 pandemic. Within one year of
the pandemic, there are 3 vaccines and 10 treatment regimens authorized for emergency use
and one treatment approved by the Food and Drug Administration in the USA, with more in
clinical trials and development. Many of these treatments and vaccines were possible because of
research on other pathogenic coronaviruses, MERS-CoV and SARS-CoV, as well as decades of
prior research on other coronaviruses such as mouse hepatitis virus (MHV). This underscores the
importance of understanding the basic biology and host-pathogen interactions between
coronaviruses and their human and animal hosts so that we may better understand and prepare
for the emergence of any future novel coronaviruses.
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In this chapter, I will introduce the basic biology of coronaviruses including their genome structure
and RNA replication and transcription processes. I will discuss the emergence of two highly
pathogenic coronaviruses, MERS-CoV and SARS-CoV-2. I will describe the double stranded
RNA-induced innate immune responses and the ways in which coronaviruses evade or block
these responses. Finally, I will introduce the overarching hypothesis, rationale, and goals of this
dissertation.
1.2 CORONAVIRUS BIOLOGY
Coronaviruses are classified by the International Committee on Taxonomy of Viruses
(ICTV) in the Order Nidovirales, Family Coronaviridae, and subfamily Coronavirinae.
Coronavirinae is further subdivided into genera, Alphacoronavirus, Betacoronavirus,
Deltacoronavirus, and Gammacoronavirus. The Betacoronavirus genus is divided into five
subgenera: Embecovirus (formerly lineage A), Sarbecovirus (formerly lineage B), Merbecovirus
(formerly lineage C), Nobecovirus (formerly lineage D), and Hibecovirus. Coronavirus genomes
are positive sense single stranded (+ss) ribonucleic acid (RNA) ranging 25-32 kilobases in length
and are longer than other RNA virus genomes (Payne, 2017).

Replicase locus (nsp#)

Fig 1.1 Betacoronavirus genome structure. Diagram demonstrating the general organization of
Betacoronavirus +ssRNA genomes (examples of viruses in 3 of the 5 subgenera). Conserved replicase
proteins (nsp) important for viral RNA replication and transcription, processing of viral proteins, and
antagonism of host antiviral responses are encoded in the 5’ two-thirds of the genome. The 3’ end of the
genome encodes the structural genes important for Betacoronavirus genome packaging of the viral genome
and the structure of the virus particle. The 3’ end also encodes the accessory genes of coronaviruses,
unique to each subgenera of coronaviruses.

2

The general coronavirus genome structure is diagrammed in figure (Fig) 1.1. The 5’ two thirds of
the genome encode the replicase locus in ORF1ab. The conserved replicase proteins have
several different functions including RNA replication and transcription, membrane rearrangement,
and RNA and protein processing. The 3’ one third of the genome encodes the structural and
accessory genes. The structural protein spike (S) is the viral glycoprotein that studs the virus
particle and is the visually distinctive feature after which coronaviruses are named (corona; Latin
for crown). S binds to the receptor and facilitates viral entry. This interaction is the main
determinant for coronavirus host specificity and in part determines tissue tropism. Coronavirus
entry occurs by two pathways: cleavage of S by a protease at the plasma membrane, followed by
fusion of viral and cellular membranes, or endocytosis followed by S cleavage by the cellular
protease cathepsin, promoting fusion of the viral and endosomal membranes (Bos et al., 1996;
Fehr and Perlman, 2015). The structural proteins envelope (E) and membrane (M) are important
for assembly and virus particle structure and, when expressed together, can form virus-like
particles (Fehr and Perlman, 2015). Finally, nucleocapsid (N) complexes with the viral RNA
during infection as well as in the assembled virus particle (Fehr and Perlman, 2015). The
accessory proteins differ between subgenera of coronaviruses, and they serve various
pathogenesis functions, including blocking innate immunity of the host. This will be discussed
further in section 1.4.

After coronavirus and cellular membranes fuse, the genome is released into the cytoplasm and
replication and transcription are initiated. First, the large open reading frames (ORF) 1a and 1ab
of the viral genome are translated into polyproteins, pp1a and pp1ab, with pp1ab translation
occurring via ribosomal frameshifting at the end of ORF1a (Fehr and Perlman, 2015). Virus
encoded proteases with papain-like and chymotrypsin-like folds cleave pp1a and pp1ab into 16
individual non-structural proteins (nsps) (Sawicki et al., 2007). Many of the nsps are important for
assembling the replication and transcription complex and carrying out the processes of RNA
replication and transcription, capping at 5’ ends of mRNAs, and antagonizing host antiviral
3

defenses. Replication occurs when the full-length positive sense viral genome is copied to make
a full-length, negative sense anti-genome. This full-length minus strand can then serve as
template to make copies of the full-length virus genome.

The mechanisms by which coronavirus transcription occur still remain to be fully elucidated.
Nidoviruses are classified by their nested sub-genomic RNA synthesis (nido; Latin for nest). The
current model proposes that in discontinuous extension of negative strand RNA, the viral RNAdependent RNA polymerase (RdRp) along with the nascent RNA strand “jumps” from the
transcription regulatory sequence (TRS) (at the start of every ORF) and continues transcribing at
the TRS at the 3’ end of the leader sequence (sequence at the 5’ end of the RNA genome)
(Sawicki et al., 2007). These sub-genomic minus strand RNAs are then used as templates to
synthesize sub-genomic mRNAs which can then be translated into proteins encoded downstream
of ORF1ab. Each protein is translated starting from the 5’ ORF of that sub-genomic mRNA. Due
to the unique coronaviral transcription process, there are consistent patterns in relative
RNA/mRNA expression levels: the sub-genomic mRNA for the shortest mRNA (Nucleocapsid) is
the most abundant while the full-length genome is the least highly expressed (Sawicki et al.,
2007; Sethna et al., 1989). Minus strand template RNA is present at only approximately one
percent the level of positive sense RNAs during infection (Sawicki et al., 2007; Sethna et al.,
1991; Sethna et al., 1989). Finally, coronaviruses can recombine their RNA, likely playing an
important role in coronavirus evolution as well as in mRNA synthesis (Gribble et al., 2021; Keck
et al., 1987; Lai et al., 1985). Coronavirus RNA replication and transcription are summarized in
Fig 1.2.
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Fig 1.2 Coronavirus replication and transcription. Coronaviruses replicate their genome by synthesizing
a full-length anti-genome that serves as a template for making new full-length genome. Subgenomic minus
strand RNAs serve as templates for subgenomic mRNAs. Positive-sense RNAs contain the leader sequence
and negative-sense RNAs an antileader. There are transcriptional regulatory sequences (TRSs) upstream of
each ORF. ORF1ab is translated from the full-length genome and downstream ORFs from subgenomic
mRNAs.

Coronaviruses extensively remodel the endoplasmic reticulum (ER) to set up the replicasetranscriptase complex (RTC). RTCs are formed on double-membraned vesicles (DMV) composed
of replicase proteins nsp3, nsp4, and nsp6 (Angelini et al., 2013; Gosert et al., 2002; Hagemeijer
et al., 2014). Indeed, the ectopic expression of nsp3 and nsp4 proteins together in cultured cells
will induce membrane folds and rearrangements similar to those observed during infection
(Hagemeijer et al., 2014; Oudshoorn et al., 2017). Electron microscopy and tomography have
been used extensively to map how coronaviruses remodel the ER for replication and
transcription. The replication complex is comprised of an interconnected network of membranes
derived from the ER with convoluted membranes, many connected DMVs, and vesicle packets
(Knoops et al., 2008). A possible mechanism for viral RNA transport out of the DMVs was not
known until recently, a molecular pore containing nsp3 was detected that crosses the DMVs
(Wolff et al., 2020). However, many details of replication complex formation remain to be
determined including understanding host factor involvement and transport of viral RNA out of the
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DMVs. DMV shielding of dsRNA from host antiviral immune defenses will be discussed more in
section 1.5.

Coronaviruses assemble in the ER-Golgi intermediate complex, exit from the cell via vesicles,
and are released by exocytosis (Fehr and Perlman, 2015). Coronaviruses spike proteins are
expressed on the plasma membrane and in some cases cause fusion with non-infected cells,
resulting in syncytia and increased virus spread.
1.3 EMERGENCE OF PATHOGENIC HUMAN CORONAVIRUSES IN THE LAST DECADE
Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
In June 2012, a 60-year-old man presented to a hospital in Saudi Arabia with fever, cough, and
shortness of breath. Two days after admission he was placed on mechanical ventilation for
severe pneumonia, and he expired from progressive renal and respiratory failure 11 days after
admission (Zaki et al., 2012). Through virus culture techniques and PCR, the patient was
identified to have been infected with a novel betacoronavirus. The identification of this novel
coronavirus was the first of its lineage/subgenera of betacoronaviruses (initially lineage C, now
Merbecovirus) observed to cause disease in humans. The virus was named Middle East
respiratory syndrome coronavirus (MERS-CoV), and has caused over 2500 known infections and
killed over 880 people, for a case fatality ratio of ~35% according to the World Health
Organization (as of February 2021). This case fatality may be an overestimate as mildly or
asymptomatic cases likely go undetected. MERS-CoV has caused many hospital-associated
outbreaks, as well as some travel-associated outbreaks. MERS-CoV disease presentation in
humans is typically fever, cough, shortness of breath and can lead to pneumonia and acute
respiratory distress syndrome (ARDS). There has only been one published autopsy report of
MERS-CoV infection, in which infection of lower airway cells including type 2 alveolar
pneumocytes was observed (Ng et al., 2016).
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Since its emergence in 2012, sustained transmission of MERS-CoV persists mainly in the Middle
East, primarily in Saudi Arabia (WHO). This may be due to sustained human interaction with the
natural reservoir for MERS-CoV, dromedary camels. Camels exhibit symptoms of mild upper
respiratory infections, and MERS-CoV infection is not fatal in this host (Adney et al., 2014).
Interestingly, serological surveys of banked camel serum from the Horn of Africa , the main
source of camels in the Arabian Peninsula, dating back to the 1980s revealed the presence of
neutralizing antibodies against MERS-CoV, indicating the circulation of MERS-CoV or a MERSCoV-like virus since that time (Corman et al., 2014b; Muller et al., 2014). It is not understood why
the emergence of MERS-CoV into humans was not observed until 2012, and furthermore why
human cases have not been observed in northeast Africa where there is evidence of MERS-CoV
circulation in dromedary camels. It remains to be seen if the absence of cases in northeast Africa
is due to missed surveillance/lack of detection or infections not occurring there. At the time of
MERS-CoV discovery, the only known viruses in the same lineage/subgenera were both bat
viruses, HKU4 and HKU5, pointing to bats as a suspected reservoir of MERS-CoV or an ancestor
of MERS-CoV (Zaki et al., 2012). Merbecoviruses have been discovered with wide global
distribution in bats (Anthony et al., 2017b; Anthony et al., 2013; De Benedictis et al., 2014; Góes
et al., 2013; Lelli et al., 2013; Wacharapluesadee et al., 2013). Close sequence similarity across
the genome, with the exception of S1 spike subunit, of MERS-CoV with two bat Merbecoviruses,
NeoCoV and PREDICT/PDF-2180, further supports the idea that MERS-CoV descended from an
ancestral bat virus (Anthony et al., 2017a; Corman et al., 2014a).

To date there are no approved vaccines or drugs to treat MERS-CoV. However, some promising
candidates for vaccines and antivirals have been studied to prevent and treat MERS-CoV, and
these studies laid the foundation for the rapid development of mRNA vaccines and antivirals for
prevention and treatment of SARS-CoV-2 infection (Corbett et al., 2020; Sheahan et al., 2020).
The application of studies of MERS-CoV to the most recent coronavirus pandemic highlights the
importance of understanding coronavirus biology.
7

Severe Acute Respiratory Syndrome Coronavirus-2
In late 2019, reports of an outbreak of severe respiratory illness of unknown origin were
connected to a seafood market in Wuhan, Hubei Province, China. In January 2020, this was
identified as a novel coronavirus, initially called 2019 novel coronavirus (2019-nCoV), but later
renamed SARS-CoV-2 and the disease named coronavirus disease-2019 (COVID-19)
(Gorbalenya et al., 2020; Zhu et al., 2020). SARS-CoV-2 rapidly spread within Wuhan and to the
rest of China leading to widespread lockdowns across the country. The virus quickly spread all
over the globe, leading to the WHO declaration of a pandemic in March 2020, with widespread
lockdowns and stay at home orders.

SARS-CoV-2 infections can cause a wide range of symptoms in patients. Common COVID-19
symptoms include fever/chills, cough, muscle aches, and shortness of breath. One of the major
challenges of COVID-19 containment in comparison to the other highly pathogenic human
coronaviruses, SARS-CoV and MERS-CoV, has been asymptomatic or pre-symptomatic spread
of SARS-CoV-2. There are varying estimates of COVID-19 spread without symptoms; one metaanalysis estimated 17% of cases are asymptomatic, but that transmission is lower from
asymptomatic individuals (Byambasuren et al., 2020). Other more severe symptoms or
complications include reduced blood oxygen levels, difficulty breathing, severe pneumonia, blood
clots, and ARDS. A major issue has been the high amount of hospitalizations worldwide, typically
in older adults or people with underlying chronic health conditions such as kidney, heart, and lung
issues/disease. Furthermore, many patients experience symptoms of infection long after the virus
is cleared. These “COVID long haulers” have persisting symptoms including fatigue, headache,
body aches, heart problems, or hypertension and the mechanism for these long-lasting symptoms
is unknown (Carfì et al., 2020; Couzin-Frankel, 2020; Tenforde et al., 2020). Children mostly have
mild to asymptomatic self-limiting disease, but in rare cases some patients develop a severe
condition called multisystem inflammatory syndrome in children (MIS-C) with symptoms of fever
and other inflammatory symptoms with multisystem involvement (cardia, renal, respiratory,
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hematologic, gastrointestinal, or neurological), according to the Centers for Disease Control. It is
still unknown why some patients develop severe disease while others have mild or asymptomatic
infections. Several factors including age, prior/underlying health conditions, dose of exposure,
and levels of innate immune response likely play a role in determining disease severity.

Currently, the origin/reservoir of SARS-CoV-2 is unknown, but investigations of its origin are
ongoing. The virus was initially identified and named for its similar genome sequence homology
and gene arrangement to SARS-CoV, a human coronavirus that caused an epidemic of
respiratory illness in 2002-2003 (Gorbalenya et al., 2020). Viruses with similar sequences to
SARS-CoV-2 have been identified in bats and pangolin, supporting the hypothesis that bats are a
natural reservoir with a possible intermediate host(s) (Lam et al., 2020; Zhou et al., 2020).
Another factor that may affect future SARS-CoV-2 spread is its host range, with reports of mink,
cat, ferrets, and other animals being susceptible to SARS-CoV-2 infection (El Masry, 2020;
Halfmann et al., 2020; Shi et al., 2020a).

Since the emergence of SARS-CoV-2, research on coronaviruses has rapidly expanded. Prior
research on other coronaviruses laid the foundation for rapid vaccine and drug development and
deployment. Furthermore, new viral variants with worrying trends of increased transmission,
potentially signaling adaptation to human transmission, have emerged which could potentially
delay the control of the pandemic or may lower the efficacy of available vaccines. Emergence of
highly pathogenic zoonotic coronaviruses over the past 20 years underscores the importance of
understanding how these viruses interact with the host, so that we may be more prepared for the
future emergence of novel zoonotic coronaviruses.
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1.4 ANTIVIRAL dsRNA-INDUCED INNATE IMMUNITY
Innate immunity is one of the body’s first line defenses from an assault by a pathogen. One way
that innate immune responses are triggered is when a pattern recognition receptor (PRR) detects
the presence of a pathogen associated molecular pattern (PAMP), indicating that a pathogen has
invaded its host. Recognition of a PAMP by different PRRs activate downstream signaling
pathways meant to limit, stop, or kill the pathogen that has invaded. PAMPs are highly diverse
and the PRRs that recognize them mediate specific responses based on the nature of the
pathogen (e.g. responses targeting extracellular pathogens, intracellular bacteria, or different
viruses). For the scope of this work, I will focus solely on innate immune pathways induced by
dsRNA PAMPs in the cytoplasm: type I and III interferon (IFN) production and signaling, protein
kinase R (PKR), and oligo adenylate synthetase/ribonuclease L (OAS/RNase L). Activation of
these pathways by coronaviruses is summarized in Fig 1.3. Coronavirus evasion of these
pathways will be discussed more in depth in section 1.5.

Fig 1.3 Activation of dsRNA-induced cytoplasmic antiviral pathways by coronaviruses. dsRNA is
generated during coronavirus replication and transcription. This dsRNA can be sensed by various host
PRRs including MDA5, PKR, and OAS leading to activation of innate immune pathways. Detection of
dsRNA by MDA5 leads to IFN induction and downstream IFN signaling, resulting in an antiviral state. PKR is
activated when it binds dsRNA, autophosphorylates, then phosphorylates the translation initiation factor
eIF2a leading to translation arrest. OAS3 binds dsRNA and produces the small molecule 2-5A which
activates RNase L causing subsequent cleavage of host and viral ssRNAs. Figure created with
BioRender.com.

10

Type I and III interferon response
A major component of innate immunity to viruses is the type I and III IFN response (from now on
called IFN response). This signaling pathway can be induced by several different sensors in the
host cell. For RNA viruses, the RIG-I-Like Receptors (RLRs), retinoic acid-inducible gene I (RIG-I)
and melanoma differentiation-associated protein 5 (MDA5) are the major cytoplasmic sensors of
viral PAMPs (Hur, 2019). For coronaviruses, MDA5 is thought to be the major sensor of viral
dsRNA in the cytoplasm, although reports of RIG-I detection do exist (Li et al., 2010; Roth-Cross
et al., 2008; Thorne et al., 2020). MDA5 binds dsRNA, with preference for long stretches of
dsRNA, forming filaments (Peisley et al., 2012). Caspase activation recruitment domain (CARD)
interactions between MDA5 and mitochondrial antiviral-signaling protein (MAVS) leads to MAVS
oligomerization and activation of downstream transcription factors (Hou et al., 2011; Seth et al.,
2005; Wu and Hur, 2015). MAVS activates TANK binding kinase 1 (TBK1) and IκB kinase epsilon
(IKKε), which then leads to the phosphorylation and activation of the transcription factors, IFNregulatory factor (IRF) 3 and IRF7 (Rehwinkel and Gack, 2020). Phosphorylated IRFs enter the
nucleus and lead to transcription of type I IFN genes (including IFNA and IFNB) or type III IFN
genes (IFNL).

After IFN mRNA expression and protein production, IFNs are released from the cell and can
signal in an autocrine or paracrine fashion by binding to their respective receptor on the surface
of the cell. Type I IFNs, including IFNa and IFNβ, can be detected by all nucleated cells
expressing the IFN a/β receptor (IFNAR). Type III IFN (IFNλ) is important at mucosal barriers of
the host, such as the airway and gut, and is detected by IFNλ receptor whose expression is
limited primarily to epithelial cells and innate immune cells (Ye et al., 2019). After IFNs bind their
respective receptor, Janus Kinase 1 (JAK1) and Tyrosine Kinase 2 (TYK2) undergo
phosphorylation and activation, leading to signal transducer and activator of transcription (STAT)1
and STAT2 phosphorylation. This leads to STAT heterodimer formation and association with
IRF9. This complex termed IFN-stimulated gene factor 3 (ISGF3) can enter the nucleus and bind
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to the IFN-stimulated response element (ISRE) promoter regions of IFN stimulated genes (ISGs)
thereby inducing transcription of these genes (Ye et al., 2019). These ISGs encode proteins with
various different functions that act to restrict virus replication and spread (Rehwinkel and Gack,
2020; Ye et al., 2019).
PKR
Protein kinase R (PKR) is a cytoplasmic dsRNA-induced antiviral pathway. PKR contains a
dsRNA binding motif that can bind to dsRNA, leading to dimerization of PKR. PKR autophosphorylates and then phosphorylates its substrate translation initiation factor, eIF2a (Hur,
2019). Phosphorylation of eIF2a prevents recycling of active eIF2 required during translation
initiation, thus blocking initiation (Hur, 2019). This causes arrest of nascent protein synthesis and
can be detrimental to the virus as it requires host translation machinery to replicate. Activation of
PKR can also lead to stress granule formation (McCormick and Khaperskyy, 2017). Furthermore,
PKR activation and translation shut off can lead to cell death. PKR is an ISG, and as such, its
expression is upregulated by IFN signaling. However, PKR can also be activated independently
of MAVS-mediated IFN induction (Li et al., 2021).
OAS/RNase L
The 2’-5’ oligo adenylate synthetase/ribonuclease L (OAS/RNase L) pathway is another
cytoplasmic dsRNA-induced antiviral pathway. The OAS/RNase L pathway is activated when
OAS3 binds to dsRNA and then produces a small molecule 2’-5’oligo adenylates (2-5A) (Li et al.,
2016). This short oligonucleotide binds to the constitutively expressed and inactive enzyme
RNase L, leading to its dimerization and activation (Silverman, 2007). Active RNase L can cleave
both host and viral single-stranded (ss)RNA. Cleavage of ssRNA can have devastating effects on
the virus including viral genome and mRNA cleavage, inhibition of translation by cleavage of
ribosomal RNA, and even lead to cell death (Silverman, 2007). As OAS genes are ISGs, their
protein expression can be induced or increased by IFN signaling, however this pathway can be
activated independent of MAVS-mediated IFN induced signaling as well (Birdwell et al., 2016; Li
et al., 2019; Li et al., 2021; Whelan et al., 2019).
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Consequences of innate immune activation
Activation of innate immune pathways have several consequences to the invading pathogen and
the host. Obvious consequences of innate immune activation are to limit virus replication and/or
spread. RNA viruses require cell protein synthesis machinery to complete their replication cycles.
As mentioned above, PKR and OAS/RNase L activation leads to reduced protein synthesis which
can limit virus replication by limiting viral and/or host factor protein synthesis (McCormick and
Khaperskyy, 2017; Silverman, 2007). Another consequence of innate immune activation is cell
death. Cell death, including apoptosis, will kill infected cells and even neighboring cells leaving
less uninfected cells for the virus to infect. Furthermore, activation of innate immunity is important
for clearance of a pathogen as well as informing adaptive immune responses. IFNs and other
inflammatory cytokines act as important signals to induce different arms of the adaptive immune
responses, critical for clearing and preventing subsequent infections (Fuertes et al., 2013; Ye et
al., 2019). Finally, timing of the IFN response with respect to coronavirus infection is emerging as
an important indicator and determiner of host outcomes. In studies on SARS-CoV and MERSCoV in mice, timing of IFN induction was critical for control of viral replication as well as morbidity
and/or mortality from infection. Early IFN response or treatment controlled virus replication and
led to better outcomes, while delayed IFN response or treatment resulted in poorer outcomes and
more pathogenic inflammation (Channappanavar et al., 2016; Channappanavar et al., 2019). The
roles of timing and magnitude of innate immune responses to SARS-CoV-2 infection are
emerging as important factors of COVID-19 outcomes as well (Bastard et al., 2020; Israelow et
al., 2020).
1.5 CORONAVIRUS EVASION OF INNATE IMMUNITY
Innate immunity is important for the host to detect and defend from viruses. However,
coronaviruses are adept at evading induction of innate immunity in their hosts. Compared to
many other RNA viruses, coronaviruses induce little and delayed IFN responses as well as PKR
and RNase L activation, despite the presence of dsRNA created during coronavirus replication
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and transcription in the cell during infection (Fig 1.4). There are two different ways that
coronaviruses likely evade these pathways.

Fig 1.4 dsRNA production during coronavirus infection. MERS-CoV infected A549DPP4 cells at 24 hours
post infection, MOI=5. Infected cells were stained by immunofluorescence and imaged by widefield
microscopy with nuclei shown in blue and dsRNA (detected by J2 antibody) shown in green. Uninfected cells
are shown for comparison.

DMVs are a hallmark of coronavirus replication complexes and are thought to sequester viral
dsRNA PAMPs from detection by host cell sensors. Using electron microscopy immunogold
staining, dsRNA was detected inside the DMVs and thought to be a byproduct of active RNA
replication (Knoops et al., 2008). Alternatively, Hagemeijer et al. suggested that the dsRNA
detected in DMVs later in infection is leftover replication byproducts that were hidden in DMVs,
not RNA actively participating in transcription or replication (Hagemeijer et al., 2012). It is logical
that the RTC is important for shielding coronavirus RNA and replication components from host
sensors. However, other aspects of coronavirus biology are also important for evasion of innate
immunity, and I will focus on those for the remainder of this section as they relate more to the
experimental questions of this work.

Coronaviruses have some of the largest known RNA virus genomes. This affords them the
capacity to encode many viral proteins with functions beyond those necessary for RNA replication
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and virus particle structure. Coronaviruses encode numerous proteins that interact with,
modulate, or antagonize various host cell machinery and pathways, including the dsRNA-induced
innate immune pathways.
Replicase proteins: innate immune antagonists
Several conserved replicase proteins have been shown to counteract the host innate immune
system in different coronaviruses. Nsp1 has been shown to limit IFN signaling in SARS-CoV,
MERS-CoV, and mouse hepatitis virus (MHV) infection (Lokugamage et al., 2015; Narayanan et
al., 2008; Narayanan et al., 2015; Züst et al., 2007). Various activities of nsp3 including deubiquitination and de-ISGylation have been shown to antagonize IFN (Clementz et al., 2010;
Frieman et al., 2009; Lei et al., 2018; Niemeyer et al., 2018; Volk et al., 2020; Yang et al., 2014).
Nsp13 has been implicated in interferon evasion (Xia et al., 2020; Yuen et al., 2020). Nsp14
encodes 3′-to-5′ exoribonuclease activity (ExoN), which performs a proofreading function needed
for high-fidelity replication and plays a role in resistance to activation of innate immunity in MHV
infection (Case et al., 2018). Nsp16 encodes a 2′-O-methyltransferase that plays an important
role to evade induction of IFN and virus RNA sensing during infection (Menachery et al., 2014;
Zust et al., 2011). Matrix (M) and Nucleocapsid (N) structural proteins have also been implicated
in blocking IFN as well (Kopecky-Bromberg et al., 2007; Lu et al., 2011; Lui et al., 2016; Yang et
al., 2013).
Nsp15: a conserved protein encoding an endoribonuclease domain
Nsp15 is a conserved protein encoded in ORF1b of the replicase locus of the coronavirus
genome. Nsp15 contains an endoribonuclease (EndoU) domain that is conserved among all the
groups within the Order Nidovirales that infect vertebrates including coronaviruses, arteriviruses
(encoded in nsp11), and toroviruses (Deng and Baker, 2018). This domain contains two
conserved catalytic histidine residues, and early biochemical studies showed that in vitro the
nsp15 EndoU domain could cleave both single and double stranded RNA at 3’ side of
pyrimidines, with preference for uridylates, leaving 2′, 3′-cyclic phosphate and 5′-hydroxyl ends
(Bhardwaj et al., 2006; Ivanov et al., 2004). EndoU catalytic activity is not necessary for viral
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replication in cell culture as was initially proposed upon its discovery (Deng and Baker, 2018;
Kang et al., 2007; Snijder et al., 2003; Ulferts and Ziebuhr, 2011). EndoU activity was later
discovered to be a pathogenesis factor that robustly blocks dsRNA innate immune induction
during MHV infection (Deng et al., 2017; Kindler et al., 2017). Mutation of one of the two catalytic
histidines in the EndoU domain severely attenuated MHV infection in vivo and in primary bone
marrow-derived macrophages (BMMs) and caused activation of three innate pathways compared
to wild type (WT) virus. IFN production was significantly enhanced, RNase L and PKR were
activated, downstream protein translation was inhibited, and apoptosis was induced during
EndoU mutant MHV infection. Deletion of IFNAR or double knock out of both PKR and RNase L
genes rescued replication of EndoU mutants in BMMs. Furthermore, Kindler et al. showed that
during infection with this mutant more dsRNA was detected compared to WT MHV (Kindler et al.,
2017). This increase in dsRNA is likely the reason for robust activation of the innate immune
pathways. Interestingly, Deng et al. found that there was more dsRNA detected outside of the
replication complexes by immunofluorescence staining and Hackbart et al. confirmed that more
overall dsRNA was detected during infection (Deng et al., 2017; Hackbart et al., 2020). Similarly,
mutation of EndoU causes increased innate immune activation and attenuated replication of
human coronavirus 229E and porcine epidemic diarrhea virus (PEDV) (Deng et al., 2019; Kindler
et al., 2017).

Until recently the substrate RNA of EndoU during coronavirus infection had not been identified,
only in vitro substrates were examined. Two groups found differing results by using different
methods, however both indicated that cleavage of ssRNA to limit dsRNA production was a likely
mechanism of EndoU activity. Ankar et al. used cyclic phosphate cDNA sequencing to map the
EndoU cleavage sites during MHV infection of BMMs to identify the RNA targets of EndoU and
found that EndoU targets viral positive strand RNA, cleaving to the 3’ side of pyrimidines with a
strong preference for U↓A and C↓A sequences (Ancar et al., 2020). Hackbart et al. pulled RNA
during WT and EndoU mutant MHV infection using an anti-dsRNA antibody, K1. They found that
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the majority of RNA pulled down was negative sense RNA and concluded that EndoU cleaves 5′polyuridines from negative-sense viral RNA (termed PUN RNA). They found that EndoU cleavage
limits generation of PUN RNA and that PUN RNA can serve as a PAMP to activate interferon
(Hackbart et al., 2020).

As the role of nsp15 in viral replication and pathogenesis becomes clearer, it emerges as an
attractive target for novel anti-coronavirus drugs or even a potential target for attenuation for a
vaccine candidate due to its conserved domains and the attenuation observed during in vivo
infections with EndoU mutants. The role of nsp15/EndoU has not been extensively explored
during infection with highly pathogenic coronaviruses. Fully understanding its role during infection
in MERS-CoV infection is imperative to understanding how this virus successfully evades
activation of innate immunity. Furthermore, it is critical to understand the consequences of
impairing this catalytic EndoU activity during infection with the highly pathogenic human
coronaviruses as it arises as an antiviral target.
Accessory proteins: modulators of innate immunity
As described in section 1.2, coronaviruses encode unique subgenera specific accessory genes in
the 3’ end of their genome. For many of these genes, the functions remain unknown. However,
some have been identified as pathogenesis factors or modulators of the innate immune response.
For example, MHV accessory protein NS2 is a member of the 2H phosphodiesterase family of
enzymes that contains a phosphodiesterase domain which specifically cleaves 2-5A, thus
preventing activation of RNase L during infection (Zhao et al., 2012). Mutation of one of the two
catalytic histidine residues of the NS2 phosphodiesterase domain renders the virus completely
attenuated for replication in the liver. Clearly, for MHV, this accessory protein plays an important
role in controlling innate immune activity by RNase L in vivo. ORF6 of SARS-CoV and SARSCoV-2 have been identified as a potent innate immune antagonists that block IFN induction as
well as IFN signaling by blocking transcription factor activation and STAT translocation to the
nucleus (Frieman et al., 2007; Kopecky-Bromberg et al., 2007; Lei et al., 2020; Miorin et al., 2020;
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Xia et al., 2020; Yuen et al., 2020). Orf5 of MERS-CoV has also been identified as a potential IFN
and NFκB antagonist (Menachery et al., 2017; Yang et al., 2013). As interest in coronavirus
research has spiked during the COVID-19 pandemic, unknown functions of other coronavirus
accessory proteins may be elucidated.
MERS-CoV mRNA 4 encodes two innate immune antagonists
mRNA 4 of MERS-CoV encodes two different accessory proteins, NS4a and NS4b. Several
groups identified them to robustly block IFN activity in the context of over expression (Niemeyer
et al., 2013; Siu et al., 2014; Yang et al., 2015b; Yang et al., 2013).

NS4a was identified as a potential innate immune antagonist because of its predicted dsRNA
binding motif. Indeed, NS4a binds dsRNA, as demonstrated by pulldown of a synthetic dsRNA
mimic, polyinosinic-polycytidylic acid (poly IC) (Niemeyer et al., 2013; Siu et al., 2014). Several
groups showed that overexpressed NS4a potently prevents IFN promoter activity or expression
(Niemeyer et al., 2013; Siu et al., 2014; Yang et al., 2013). NS4a was also shown to block PKR
activation and stress granule formation by overexpression or replacing a PKR antagonist with
NS4a in a heterologous RNA virus (Rabouw et al., 2016). Furthermore, NS4a deletion resulted in
PKR activation during MERS-CoV infection (Nakagawa et al., 2018). NS4a may also modulate
NFκB activity (Weston et al., 2019). Despite these compelling data with ectopic expression of
NS4a, at the start of this work there had been little to no examination of the function of NS4a and
the consequences of NS4a deletion on innate immunity during authentic MERS-CoV infection.
NS4b, similar to NS4a, was identified as a potential innate immune antagonist using
overexpression studies and during MERS-CoV infection (Canton et al., 2018; Chu et al., 2018;
Yang et al., 2015b; Yang et al., 2013). Interestingly, NS4b encodes a nuclear localization signal
(NLS) and primarily localizes to the nucleus during overexpression and infection (Thornbrough et
al., 2016; Yang et al., 2013). One nuclear function of NS4b is to block NFκB from entering the
nucleus through binding competition with its importin (Canton et al., 2018). Another important
innate immune antagonism function of NS4b was discovered by the Weiss lab, when we found
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that the predicted protein structure was similar to that of MHV NS2. Thornbrough et al. discovered
that NS4b encodes a phosphodiesterase domain, similar to MHV NS2, and that NS4b could block
RNase L activity by the same mechanism (Thornbrough et al., 2016). NS4b appears to have
multiple functions to block various innate immune pathways; however, the mechanism of action
by which NS4b blocks IFN expression has yet to be determined.
1.6 EXPERIMENTAL QUESTIONS
It is clear from the literature that coronaviruses are adept at avoiding and/or delaying activation of
the innate immune response, allowing the virus to replicate undetected by the host cell.
Coronaviruses, especially MERS-CoV, are quite sensitive to IFN treatment, indicating they are
quite susceptible to pathways downstream of IFN (Kindler et al., 2013; Lokugamage et al., 2020).
Furthermore, the timing of the innate immune response is emerging as an important factor in
determining outcomes of infection with highly pathogenic coronaviruses, such that early and
robust responses are beneficial and late responses are pathogenic (Channappanavar et al.,
2016; Channappanavar et al., 2019). MERS-CoV induces little innate immune activation, and at
the start of this work there was little investigation into which proteins were responsible for
blocking innate immunity during authentic infection, instead of overexpression. The literature
described above leaves us with general questions about how highly pathogenic coronaviruses so
adeptly evade innate immune sensing and activation. For example, to what degree does protein
function versus RNA localization play in this evasion? Are conserved or accessory proteins more
important or are both required for coronavirus evasion of innate immunity? These questions are
imperative to answer, especially as novel coronaviruses, such as SARS-CoV-2, emerge. To
answer to these broad questions, the intricacies of individual proteins and coronavirus
interactions with innate pathways must first be elucidated.

Therefore, the overarching question I address with this work asks how the highly pathogenic
human coronavirus, MERS-CoV, evades activation of the dsRNA-induced cytoplasmic innate
immune pathways. I hypothesized that accessory proteins NS4a and NS4b would be important
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modulators of innate immunity during authentic MERS-CoV infection, due to NS4a blocking IFN,
PKR, and RNase L and NS4b blocking IFN and RNase L activation. We tested this hypothesis in
chapter 2 of this work and found that NS4a blocked activation of PKR and IFN mRNA expression
and NS4b blocked activation of IFN mRNA expression through its phosphodiesterase activity and
nuclear localization. However, the effects we observed during infection were mild; this led us to
hypothesize that nsp15 EndoU domain is the dominant innate immune antagonist and that
inactivation of EndoU would result in activation of all three dsRNA-induced pathways (IFN, PKR,
OAS/RNase L) during MERS-CoV infection. This hypothesis is investigated in chapter 3, where
we found that the functions of NS4a, NS4b, and nsp15 EndoU are redundant and work together
to completely block innate immune activation during MERS-CoV infection. Finally, the emergence
of SARS-CoV-2 during this dissertation work led us to characterize its interaction with the dsRNAinduced innate immune pathways and to compare SARS-CoV-2 to MERS-CoV infection in
chapter 4. Ultimately, the goal of this work is to unveil how highly pathogenic human
coronaviruses, such as MERS-CoV and SARS-CoV-2, evade detection by the human host innate
immune response, leading to a better understanding of the host-pathogen interactions of
coronaviruses.
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CHAPTER 2: ANTAGONISM OF dsRNA-INDUCED INNATE
IMMUNE PATHWAYS BY NS4A AND NS4B ACCESSORY
PROTEINS DURING MERS-CoV INFECTION

This chapter appears as the previously published article:
Courtney E. Comar*, Stephen A. Goldstein*, Yize Li, Boyd Yount, Ralph S. Baric, Susan R.
Weiss. 2019. Antagonism of dsRNA-induced innate immune pathways by NS4a and NS4b
accessory proteins during MERS coronavirus infection. mBio 10: e00319-19.

*These authors made equal contributions
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2.1 ABSTRACT
Middle East respiratory syndrome coronavirus (MERS-CoV) was first identified in 2012 as a novel
etiological agent of severe respiratory disease in humans. As during infection by other viruses,
host sensing of viral double-stranded RNA (dsRNA) induces several antiviral pathways. These
include interferon (IFN), oligoadenylate synthetase (OAS)-RNase L, and protein kinase R (PKR).
Coronaviruses, including MERS-CoV, potently suppress the activation of these pathways,
inducing only modest host responses. Our study describes the functions of two accessory
proteins unique to MERS-CoV and related viruses, NS4a and NS4b, during infection in human
airway epithelium-derived A549 cells. NS4a has been previously characterized as a dsRNA
binding protein, while NS4b is a 2′,5′-phosphodiesterase with structural and enzymatic similarity
to NS2 encoded by mouse hepatitis virus (MHV). We found that deletion of NS4a results in
increased interferon lambda (IFNL1) expression, as does mutation of either the catalytic site or
nuclear localization sequence of NS4b. All of the mutant viruses we tested exhibited slight
decreases in replication. We previously reported that, like MHV NS2, NS4b antagonizes OASRNase L, but suppression of IFN is a previously unidentified function for viral
phosphodiesterases. Unexpectedly, deletion of NS4a does not result in robust activation of the
PKR or OAS-RNase L pathways. Therefore, MERS-CoV likely encodes other proteins that
contribute to suppression or evasion of these antiviral innate immune pathways that should be an
important focus of future work. This study provides additional insight into the complex interactions
between MERS-CoV and the host immune response.
2.2 IMPORTANCE
Middle East respiratory syndrome coronavirus (MERS-CoV) is the second novel zoonotic
coronavirus to emerge in the 21st century and cause outbreaks of severe respiratory disease.
More than 2,200 cases and 800 deaths have been reported to date, yet there are no licensed
vaccines or treatments. Coronaviruses encode unique accessory proteins that are not required
for replication but most likely play roles in immune antagonism and/or pathogenesis. Our study
describes the functions of MERS-CoV accessory proteins NS4a and NS4b during infection of a
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human airway-derived cell line. Loss of these accessory proteins during MERS-CoV infection
leads to host antiviral activation and modestly attenuates replication. In the case of both NS4a
and NS4b, we have identified roles during infection not previously described, yet the lack of
robust activation suggests much remains to be learned about the interactions between MERSCoV and the infected host.
2.3 INTRODUCTION
Middle East respiratory syndrome coronavirus (MERS-CoV), is a recently emerged, highly
pathogenic coronavirus first identified in the Middle East in 2012 (van Boheemen et al., 2012;
Zaki et al., 2012). Following the 2002-2003 severe acute respiratory syndrome (SARS)-CoV
pandemic, MERS-CoV is the second zoonotic coronavirus discovered in the 21st century. Though
cases have been largely concentrated on the Arabian Peninsula, a large travel-associated
outbreak in South Korea in 2015 highlights that MERS-CoV remains a global concern. MERSCoV circulates in dromedary camels in Africa and the Middle East, having established a reservoir
in camels, while closely related viruses are found in African bats, suggesting a bat origin for
MERS-CoV or its direct ancestors (Anthony et al., 2017a; Corman et al., 2014a; Geldenhuys et
al., 2018; Khalafalla et al., 2015; Reusken et al., 2014; Wernery et al., 2015).

Like all coronaviruses, MERS-CoV has a large positive-sense single-stranded RNA (ssRNA)
genome of 30,119 nucleotides in length. The 5’ two-thirds of the genome encode the functionally
conserved replicase proteins, while a core set of structural proteins are encoded by all viruses of
the Betacoronavirus genus in the 3’ 10 kb. Additionally, found in the 3’ end of the genome are
accessory genes specific to each Betacoronavirus subgenus, interspersed with structural genes.
The MERS-CoV accessory genes are found only in other betacoronaviruses of the subgenus
Merbecovirus (formerly lineage C) while betacoronaviruses of other subgenera such as mouse
hepatitis virus (MHV) (Embecovirus/lineage A) and SARS-CoV (Sarbecovirus/lineage B) encode
unique accessory genes.
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Several accessory proteins encoded by MHV and SARS-CoV have been identified as antagonists
of the innate immune response (Liu et al., 2014), as have some MERS-CoV accessory proteins
(Canton et al., 2018; Menachery et al., 2017; Niemeyer et al., 2013; Rabouw et al., 2016; Yang et
al., 2013). Several studies utilizing ectopically expressed protein and reporter systems have
identified NS4a, NS4b, and NS5 as putative interferon (IFN) antagonists, but these studies may
not faithfully recapitulate the complex interactions between viral and host factors present during
infection (Matthews et al., 2014; Niemeyer et al., 2013; Siu et al., 2014; Yang et al., 2015b; Yang
et al., 2013). More recent studies utilizing recombinant MERS-CoV have more completely
elucidated the functions of some of these proteins, but conflicted with early reporter studies.
NS4a, a double-stranded RNA (dsRNA) binding protein, prevents the generation of PKR-induced
stress granules in some cell types (Nakagawa et al., 2018). We reported previously that NS4b is
a homolog of the NS2 protein of MHV and closely related betacoronaviruses of the subgenus
Embecovirus (formerly lineage A), has 2’,5’ phosphodiesterases (PDE) activity, and acts as an
antagonist of the oligoadenylate synthetase-ribonuclease L (OAS-RNase L) pathway
(Thornbrough et al., 2016). In contrast to the Embecovirus PDEs, NS4b has an N-terminal
nuclear localization signal (NLS) and is localized primarily to the nucleus of infected cells
(Matthews et al., 2014; Thornbrough et al., 2016). NS4b has also been reported to antagonize
NFkB nuclear translocation during MERS-CoV (Canton et al., 2018; Nakagawa et al., 2018;
Rabouw et al., 2016; Thornbrough et al., 2016), as has NS5 (Menachery et al., 2017).

Building on our previous study characterizing NS4b as an OAS-RNase L antagonist
(Thornbrough et al., 2016), we have used recombinant MERS-CoV to further elucidate the roles
of NS4a and NS4b during infection of human airway epithelium-derived A549 cells (Giard et al.,
1973). Consistent with earlier studies, NS4a prevents phosphorylation of PKR and the induction
of IFN and interferon-stimulated gene (ISG) expression. However, PKR activation in the absence
of NS4a does not result in phosphorylation of eIF2a or translation arrest in A549 cells, in contrast
to recent findings in a different cell type (Nakagawa et al., 2018). Unlike other viral dsRNA binding
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proteins such as Vaccinia virus E3L (Liu and Moss, 2016) and influenza virus NS1 (Min and Krug,
2006), NS4a does not play a significant role in OAS-RNase L antagonism during MERS-CoV
infection, as deletion of NS4a does not result in RNase L activation or enhance RNase L
activation in the context of MERS-CoV encoding catalytically inactive NS4b.

Our studies of NS4b reveal that in addition to antagonizing OAS-RNase L and preventing NFkB
activation, NS4b antagonizes IFNL1 expression, with this function dependent on both its catalytic
activity and nuclear localization and independent of its interaction with the OAS-RNase L
pathway. This is a unique role for virus-encoded phosphodiesterases, which otherwise lack an
NLS and act solely as OAS-RNase L antagonists (Canton et al., 2018; Goldstein et al., 2016;
Roth-Cross et al., 2009; Zhao et al., 2013; Zhao et al., 2012). Together, the results demonstrate
that NS4a and NS4b mediate both expected and unexpected functions during MERS-CoV
infection, and further demonstrate the importance of studying the function of these proteins in the
context of infection to uncover the full range of their interactions with the innate immune
response.
2.4 MATERIALS AND METHODS
Recombinant viruses. Recombinant WT MERS-CoV and mutants were derived from the
EMC/2012 strain cDNA clone all by introducing mutations into cDNA fragment F assembling the
genome fragment and recovering infectious virus as described previously (Scobey et al., 2013).

To ablate expression of MERS NS4a, PCR was performed with primers EMCmut4A (5’NNNNNNTTAATTAACGAACTCTATTGATTACGTGTCTCTGCTTAATCAAATTTGACAGAAGTA
CCTTAACTC-3') and MERS:F3941 (5’-CACCGAAATGCATGCCAGCC-3'). The position of the
F3941 within the MERS genome is 28,321 to 28,302. This product was digested
with PacI and NcoI, gel purified, and then ligated into the MERS F plasmid which had been
similarly digested.
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To remove MERS NS4a and NS4b expression, PCR was performed with primers delta4AB (5’NNNNNNTTAATTAAGTTCATTCTTATCCCATTTTACATC-3’) and MERS:F3415 (5’GAGGGGGTTTACTATCCTGG-3’). This product was digested with PacI and SanDI, gel purified
and then ligated into the MERS F plasmid which had been similarly digested. The delta4AB
primer uses the PacI site just upstream of NS4a, then the rest of this primer’s sequence is from
26,795 to 26,819 in the MERS genome. The deletion removes nucleotides 25,844 to 26,794 in
the MERS genome, and does not disrupt either the ~40 nucleotides upstream of or the
transcription regulatory sequence (TRS) of NS5.

MERS-NS4bH182R was previously described (Thornbrough et al., 2016). MERS-4bNLSmut was
constructed by substituting residues 31, 33, 36, 37, 38 and 43 each with alanine. Briefly,
one PCR product was generated using primers MERS:F1376 (5’-GTTTCTGTCGATCTTGAGTC3’) and MERS4bR (5’NNNNNNCGTCTCGCAACGTAGGCCAGTGCCTTAGTTGGAGAATGGCTCCTC-3’). A
second PCR reaction was performed with the primers MERS4bF (5’NNNNNNCGTCTCCGTTGCGGCTGCATTTTCTCTTCTGGCCCATGAAGACCTTAGTGTTATTG3’) and MERS:F3415 (5’-GAGGGGGTTTACTATCCTGG-3’). The position of the F1376 primer in
context of the MERS genome is 25,748-25,767, while the position for the reverse F3415 primer is
27,815-27,796. The products were gel isolated, digested with BsmBI (underlined in the above
primers) and ligated with T4 DNA ligase. The resultant product was digested
with PacI and SanDI, gel purified, and then used to replace the corresponding region in the
MERS F plasmid which had been similarly digested. All recombinant viruses were isolated as
previously described (Scobey et al., 2013).

Sindbis virus Girdwood (G100) (SINV) was obtained from Dr. Mark Heise, University of North
Carolina, Chapel Hill, and prepared as previously described (Suthar et al., 2005) and Sendai virus
(SeV), Cantell strain was obtained from Dr. Carolina Lopez, University of Pennsylvania,
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Philadelphia and prepared as previously described (Basler et al., 2003).
Cell lines. Vero CCL81 cells were cultured in DMEM+10% FBS, penicillin-streptomycin,
gentamicin, sodium pyruvate, and HEPES. Human A549 cells were cultured in RPMI 1640
supplemented with 10% FBS and penicillin-streptomycin. A549DPP4 and 293TDPP4 cells were
constructed by lentivirus transduction of DPP4. The plasmid encoding the cDNA of DPP4 was
purchased from Sino Biological. The cDNA was amplified using forward primer:
5’-GACTCTAGAATGAAGACACCGTGGAAGGTTCTTC-3’ and reverse primer: 5’TCGAGACCGAGGAGAGGGTTAGGGATAGGCTTACCAGGTAAAGAGAAACATTGTTTTATG3’. A V5 tag was introduced to the 3’ end of the cDNA by PCR to enable easy detection of DPP4.
The amplicon was cloned into pCR4-TOPO TA cloning vector (Invitrogen #K457502), to make
pCR4-DDP4-V5. The fragment containing DPP4-V5 was digested by XbaI/SalI restriction
enzymes from the pCR4-DPP4-V5 and was cloned into pLenti-GFP in place of GFP, generating
pLenti-DPP4-V5. The resulting plasmids were packaged in lentiviruses pseudotyped with VSV-G
to establish the gene knock in cells as previously described (Li et al., 2016). Forty-eight hours
after transduction cells were subjected to hygromycin (1mg/ml) selection for 3 days and singlecell cloned. Clones were screened for DPP4 expression and susceptibility to MERS-CoV
replication. RNase L knockout A549DPP4 cells were generated as previously described for parental
A549 cells (Li et al., 2016). A549mCEACAM-1 cells were generated as described above for A549DPP4
cells, but by insertion of mouse Ceacam-1 (Genbank accession #: NM_001039185.1) into the
lentivirus vector rather than human DPP4.
NS4b expression from pCAGGs plasmid. WT NS4b and the indicated mutant NS4b constructs
were synthesized and purchased from Bio Basic in vector pUC57 flanked by restriction sites
ClaI/XhoI. pUC57 plasmids were digested and NS4b fragments gel purified for ligation into
pCAGGS expression vector. Ectopic expression was conducted using lipofectamine 2000
transfection reagent (Thermo Fisher # 11668027) following the provided protocol. 24 hours posttransfection cells were fixed and stained as described below.
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MERS-CoV infections and titration. Viruses were diluted in serum-free RPMI and added to cells
for absorption for 45 minutes at 37°C. Cells were washed three times with PBS and fed with
RPMI+2% FBS. 150 µl of supernatant was collected at the times indicated and stored at -80°C for
titration by plaque assay on Vero CCL81 cells as previously described (Scobey et al., 2013). All
infections and virus manipulations were conducted in a biosafety level 3 (BSL3) laboratory using
appropriate personal protective equipment and protocols.
Immunofluorescent staining. At indicated times post-infection cells were fixed with 4%
paraformaldehyde for 30 minutes at room temperature. Cells were then washed three times with
PBS and permeabilized for 10 minutes with PBS+0.1% Triton-X100. Cells were then blocked in
PBS and 2% BSA for 45-60 minutes at room temperature. Primary antibodies were diluted in
block buffer and incubated on a rocker at room temperature for one hour. Cells were washed
three times with block buffer and then incubated rocking at room temperature for 30 minutes with
secondary antibodies diluted in block buffer. Finally, cells were washed twice with block buffer
and once with PBS, and nuclei stained with DAPI diluted in PBS. Coverslips were mounted onto
slides for analysis by confocal microscopy. NS4b was detected using anti-NS4b rabbit serum at
1:500 and NS4a with anti-NS4a rabbit serum at 1:500 (both obtained from Dr. Luis Enjuanes,
Spanish National Centre for Biotechnology) (Canton et al., 2018). DsRNA was detected using
commercial antibody J2 at 1:1000 and nsp8 using anti-nsp8 guinea pig serum (obtained from Dr.
Mark Denison, Vanderbilt University). Secondary antibodies were all highly cross-adsorbed IgG
(H+L) from Invitrogen: goat anti-rabbit AF594 (Cat #:A11037), goat anti-mouse AF488 (Cat
#:A11029), goat anti-rabbit AF647 (Cat #:A32733), goat anti-guinea pig AF594 (Cat #:A11076),
goat anti-guinea pig AF568 (Cat #:A11075).
Western immunoblotting. Cells were washed twice with ice-cold PBS and lysates harvested at
indicated times post infection with lysis buffer (1% NP40, 2mM EDTA, 10% glycerol, 150mM
NaCl, 50mM Tris HCl) supplemented with protease inhibitors (Roche – cOmplete mini EDTA-free
protease inhibitor) and phosphatase inhibitors (Roche – PhosStop easy pack). After 5 minutes
lysates were harvested, incubated on ice for 20 minutes, centrifuged for 20 minutes at 4°C and
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supernatants mixed 3:1 with 4x Laemmli sample buffer. Samples were heated at 95°C for 5
minutes, then separated on 4-15% SDS-PAGE, and transferred to polyvinylidene difluoride
(PVDF) membranes. Blots were blocked with 5% nonfat milk and probed with the following
antibodies diluted in the same block buffer: anti-PKR (phospho-T446) [E120] rabbit mAb at
1:1000 (Abcam 32036), anti-PKR (D7F7) rabbit mAb at 1:1000 (Cell Signaling Technology
12297), anti-GAPDH (14C10) rabbit mAb (Cell Signaling Technology 2118) at 1:1000,
SinoBiological anti-MERS N mouse mAb at 1:1000, anti-NS4a rabbit serum at 1:500 (obtained
from Dr. Luis Enjuanes, Spanish National Centre for Biotechnology) (Canton et al., 2018), and
anti-NS4b rabbit serum at 1:500 (obtained from Dr. Robert Silverman, Cleveland Clinic) (Canton
et al., 2018). For detection of eIF2α and phosphorylated eIF2α, blots were blocked with 5% BSA
and probed with the following antibodies diluted in the block buffer: phospho-eIF2α (Ser51)
antibody at 1:1000 (Cell Signaling Technology 9721). Secondary antibodies used were: Santa
Cruz goat anti-mouse IgG-HRP secondary antibody (SC2005) at 1:5000 and Cell Signaling
Technology anti-rabbit IgG, HRP-linked secondary antibody (CS7074) at 1:3000. Blots were
visualized using Thermo Scientific SuperSignal west chemiluminescent substrates (Cat #: 34095
or 34080). Blots were probed sequentially with antibodies and in between antibody treatments
stripped using Thermo scientific Restore western blot stripping buffer (Cat #: 21059).

Protein synthesis was assessed by treatment of cells with 10µg/ml puromycin for 10 minutes prior
to protein harvest (Schmidt et al., 2009). Lysates were harvested and run on SDS-PAGE gels as
described above. For detection of puromycin, anti-puromycin mouse mAb (Millipore clone 4G11
MABE342) was used at 1:6000, and the secondary antibody used was goat anti-mouse IgG-HRP
Thermo Scientific (31430) at 1:3000. For detection of total protein by Coomassie staining, cell
lysates (as prepared above) were separated by 4-15% SDS-PAGE. Gels were fixed and stained
with 0.05% Coomassie Brilliant Blue R250 (Biorad 161-0400) in 50% methanol, 10% acetic acid
solution for 2 hours at a gentle rock at room temperature. Gels were de-stained with 7% methanol
and 5% acetic acid for several hours and then imaged.
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Quantitative real time PCR (qRT-PCR). At indicated times post-infection cells were lysed with
buffer RLT Plus (Qiagen RNeasy Plus #74136) and RNA extracted following the prescribed
protocol. cDNA was synthesized according to the protocol for Thermo Scientific Superscript III
reverse transcriptase (Thermo Scientific #18080044). qRT-PCR was performed under conditions
validated for the indicated primer set. Primer sequences are as follows: IFNL1 (F: 5’CGCCTTGGAAGAGTCACTCA-3’ R: 5’-GAAGCCTCAGGTCCCAATTC-3’), OAS2 (F: 5’TTCTGCCTGCACCACTCTTCACGAC-3’ R: 5’-GCCAGTCTTCAGAGCTGTGCCTTTG-3’), IFIT2
(F: 5’-CTGAGAATTGCACTGCAACCATG-3’ R: 5’-TCCCTCCATCAAGTTCCAGGTGAA-3’), IFNB
(F: 5’-GTCAGAGTGGAAATCCTAAG-3’ R: 5’-ACAGCATCTGCTGGTTGAAG-3’), GAPDH (F: 5’GCAAATTCCATGGCACCGT-3’ R: 5’-TCGCCCCACTTGATTTTGG-3’). Fold changes in mRNA
were calculated using the formula 2-∆(∆Ct)(ΔCt = Ctgene of interest – CtGAPDH) and expressed as fold
infected/mock-infected.
Analyses of RNase L-mediated rRNA degradation. RNA was harvested with buffer RLT
(Qiagen RNeasy #74106) and analyzed on an RNA chip with an Agilent Bioanalyzer using the
Agilent RNA 6000 Nano Kit and its prescribed protocol as we have described previously (Cat #:
5067-1511).
Statistical analysis. Plotting of data and statistical analysis were performed using GraphPad
Prism software (GraphPad Software, Inc., CA). Statistical significance for viral replication curves
was determined by two-way ANOVA and for qRT-PCR by unpaired student’s t-test.
2.5 RESULTS
Construction and characterization of recombinant NS4a and NS4b MERS-CoV mutants.
In order to study the effects of NS4a and NS4b on MERS-CoV interactions with the host innate
immune system we used a panel of recombinant MERS-CoV mutants. Deletion mutants MERSDNS4a, MERS-DNS4ab were generated from the MERS-CoV infectious clone derived from the
MERS-EMC2012 strain (Scobey et al., 2013) as follows and are described in detail in Materials
and Methods and diagramed in Fig 2.1A-B. Briefly, MERS-DNS4a was generated by altering the
start codon (ATGàATT) and adding an in-frame stop codon ten codons downstream
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(TGGàTGA) to ablate synthesis of the NS4a protein. MERS-DNS4ab was generated by
engineering a 951nucleotide deletion of ORF4a and the majority of ORF4b without disrupting the
transcription regulatory sequence (TRS) of NS5. To verify the loss of NS4b and/or NS4a
expression by these mutants, human A549 cells stably expressing the MERS-CoV receptor DPP4
(A549DPP4) were infected with MERS-CoV mutants at an MOI of 10 and protein lysates harvested
at 24 and 48 hours post-infection to assess protein expression by western blot. As expected,
NS4a is not synthesized during infection with MERS-DNS4a, and neither protein is detectable
during MERS-DNS4ab infection (Fig 2.1C).
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Fig 2.1 MERS-CoV NS4a and NS4b recombinant mutants. (A) MERS-CoV genome RNA with open
reading frames shown. (B) NS4a and NS4b proteins expressed by wild-type and mutant MERS-CoVs. The
catalytic His residues of the PDE are shown, and the vertical black bar indicates the NLS of NS4b; the red
lettering indicates amino acid substitutions of the catalytic His residue and within the NLS. (C) Expression of
viral proteins from recombinant MERS-CoV viruses. A549DPP4 cells were infected at an MOI of 10 with WT
MERS-CoV, MERS-ΔNS4a, MERS-ΔNS4ab, MERS-NS4bH182R, or MERS-NS4bNLSmut or mock infected. Cell
lysates were prepared at 24 and 48 h postinfection, analyzed by SDS-PAGE, and probed by Western
blotting with rabbit antiserum against NS4a and NS4b or mouse monoclonal antibodies against MERS
nucleocapsid protein (N) and GAPDH. The Western blot data are from one representative of three
independent infections. Contributors: CEC and SAG
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To further investigate the functional domains of NS4b, we utilized two mutant viruses with
targeted mutations in either the phosphodiesterase domain or the NLS. MERS-NS4bH182R
encodes NS4b with a catalytically inactive phosphodiesterase domain, which was generated from
the MERS-CoV infectious clone as previously described (Scobey et al., 2013; Thornbrough et al.,
2016). The NS4b NLS was previously described as bipartite (RKR11KRR), with the first basic
motif more potently determining nuclear localization (Canton et al., 2018; Matthews et al., 2014).
However, this first motif overlaps with the upstream ORF4a and so mutation of the RKR motif
without causing amino acid changes in ORF4a is impossible. To determine how to construct
NS4bNLSmut we mapped the nuclear localization sequence (NLS) by expressing WT and various
NLS-mutant NS4b genes from a pCAGGS vector in A549 cells and detecting NS4b proteins by
immunofluorescent staining (Fig 2.2A). These plasmids expressed NS4b proteins with mutations
of the RKR motif, the downstream KRR motif, and a previously undescribed basic motif that lies
between the two previously characterized motifs (RKR5KKLR2KRR). All mutant proteins exhibited
primarily cytoplasmic localization, thus we engineered mutation of the central (KKLR) and
downstream (KRR) motifs into the MERS-CoV infectious clone to generate MERS-NS4bNLSmut
(Fig 2.1B), as described in detail in Materials and Methods (Scobey et al., 2013).

While NS4b expressed during MERS-CoV infection is primarily expressed in the nucleus, during
infection with MERS-NS4bNLSmut, NS4b exhibits predominantly cytoplasmic localization, as
expected (Fig 2.2B). During infection with MERS-NS4bH182R and MERS-NS4bNLSmut, slightly less
NS4b was synthesized than during wild-type (WT) MERS-CoV infection (Fig 2.1C), consistent
with previous studies of viral PDEs in which mutant protein expressed was less robust than
expression of wild-type protein (Thornbrough et al., 2016). We consistently detected an extra
lower band when probing for NS4b. This will be addressed in the Discussion.
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Fig 2.2 Subcellular localization of MERS-CoV NS4b expression. (A) The nuclear localization signal
(NLS) was mapped by mutating basic residues in pCAGGS-NS4b, and NS4b was ectopically expressed in
A549 cells by DNA transfection. Twenty-four hours post transfection, cells were fixed and stained for NS4b
using anti-NS4b rabbit serum and goat anti-rabbit AF594 secondary antibody. (B) A549DPP4 cells were
infected with WT MERS-CoV, MERS-NS4bH182R, or MERS-NS4bNLSmut (MOI = 5). Cells were fixed 24 h
postinfection and stained with anti-NS4b rabbit serum and goat anti-rabbit AF594 secondary antibody. The
images shown in both panels are representative of at least three fields of cells from three independent
experiments. Contributor: SAG
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NS4a colocalizes with dsRNA around RTCs.
Previous studies have shown that overexpressed NS4a binds to dsRNA (Niemeyer et al., 2013;
Siu et al., 2014). Additionally, NS4a is broadly cytoplasmic when overexpressed in uninfected cells,
but co-localizes with dsRNA during infection (Canton et al., 2018; Niemeyer et al., 2013; Yang et
al., 2013). We infected A549DPP4 cells with MERS-CoV and used immunofluorescent microscopy
to determine NS4a localization. NS4a exhibits primarily punctate, perinuclear distribution with some
diffuse distribution in the cytoplasm (Fig 2.3). Cells were co-stained for NS4a with J2 antibody to
detect dsRNA and antiserum against the viral primase, nsp8, a component of the viral polymerase
complex and therefore a marker for virus RTCs (te Velthuis et al., 2012). NS4a co-localizes with
dsRNA and both are largely co-localized with nsp8, though dsRNA/NS4a appear more broadly
distributed (Fig 2.3). This may indicate either that some dsRNA and NS4a localized outside the
RTC, or that sensitivity of the assay is insufficient to detect all of the nsp8.

Fig 2.3 NS4a colocalizes with dsRNA around replication/transcription complexes (RTC) during
MERS-CoV infection. A549DPP4 cells were infected with WT MERS-CoV (MOI = 5), fixed 24 h postinfection,
and stained with rabbit anti-NS4a serum, mouse anti-dsRNA J2, and guinea pig anti-nsp8 serum and then
with secondary antibodies goat anti-rabbit AF647, goat anti-mouse AF488, and goat anti-guinea pig AF568.
The images shown are representative of at least three fields of cells from three independent experiments.
Contributors: CEC and SAG
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NS4a and NS4b deletion mutants are modestly attenuated in A549DPP4 cells.
To assess the impact of NS4a and NS4b mutation on viral replication, we carried out growth
curves in Vero and A549DPP4 cells with MERS-∆NS4a and MERS-∆NS4ab. Vero cells lack a type I
IFN response and were used to ensure recombinant viruses are not inherently replicationdeficient. We infected both cell types with WT or mutant MERS-CoV at MOI=1 and harvested
supernatant at pre-determined times post-infection for titration by plaque assay. All viruses
replicated with equivalent kinetics to WT MERS-CoV and to equal titers in Vero cells, indicating
that deletion of NS4a and NS4b does not disrupt critical aspects of the viral life-cycle (Fig 2.4A).
In contrast, deletion of NS4a and/or NS4b modestly attenuated MERS-CoV replication in
A549DPP4 cells at an MOI of 1, with the reductions in titer significant at most time points (Fig 2.4BC). Deletion of both NS4a and NS4b resulted in a slightly greater attenuation than deletion of
NS4a alone, though this difference was not statistically significant. That replication of these
mutant viruses is attenuated in A549DPP4 cells and not in permissive Vero cells strongly suggests
that the deficiency is linked to the intact antiviral responses in A549 cells.
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Fig 2.4 MERS-CoV NS4a and NS4b mutants are attenuated in IFN competent cells. (A) Vero cells were
infected in triplicate at an MOI of 1 with WT MERS-CoV, MERS-ΔNS4a, and MERS-ΔNS4ab. Supernatants
were collected at indicated times postinfection, and infectious virus was quantified by plaque assay. (B)
A549DPP4 cells were infected in triplicate at an MOI of 1 with WT MERS-CoV, MERS-ΔNS4a, and MERSΔNS4ab, and replication was quantified as in panel A. (C) Statistical significance for mutant virus replication
versus WT was calculated by two-way ANOVA. Data are from one representative of three independent
experiments. In panel A, the 72-h postinfection data point was only assessed in one out of three
experiments. Data are displayed as means ± standard deviation (SD). *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001;
****, P ≤ 0.0001. Contributor: CEC
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NS4a and NS4b modestly suppress IFN expression.
Previous studies of NS4a and NS4b, have conflicted on the role of these proteins in suppressing
the IFN response (Canton et al., 2018; Nakagawa et al., 2018; Niemeyer et al., 2013; Rabouw et
al., 2016; Yang et al., 2015b; Yang et al., 2013). We aimed to systematically characterize the role
of NS4a and NS4b in antagonism of IFN induction during MERS-CoV infection. To ensure that
our newly generated A549DPP4 were a suitable platform for investigating MERS-CoV suppression
of the IFN response, we infected them with Sendai virus (SeV), Sindbis virus (SINV), and WT
MERS-CoV. In contrast to SeV and SINV, which robustly induced IFN and ISG expression by 12
hpi, MERS-CoV induced little IFNL1 or IFNB expression throughout a 36-hour course of infection
(Fig 2.5A-B).

To determine if NS4a and/or NS4b contribute to suppressing IFN expression, we infected
A549DPP4 cells with WT MERS-CoV, MERS-∆NS4a, and MERS-∆NS4ab and at 24 and 36 hours
post-infection compared gene expression of IFN and selected ISGs by qRT-PCR. In contrast to
the minimal increases observed during WT MERS-CoV infection over mock-infected cells, MERS∆NS4a or MERS-∆NS4ab infection resulted in significantly elevated levels of IFNL1 mRNA and
representative ISGs OAS2 and IFIT2 mRNAs. Interestingly there was no significant induction of
type I IFN (Fig 2.5C). We did not observe any significant additive effect on antiviral gene
expression from the additional deletion of NS4b. However, deletion of ORFs 4a and/or 4b (Fig
2.5C) did not result in IFN induced approaching the levels we observed in response to SeV and
SINV infection (Fig 2.5B), suggesting MERS-CoV encodes additional, potent IFN antagonists
and/or utilizes other mechanisms such as sequestration of dsRNA in membrane-bound RTCs to
sensing by antiviral receptors.
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Fig 2.5 NS4a and NS4b antagonize IFN expression. (A) A549DPP4 cells were mock infected or infected in
triplicate with WT MERS-CoV at an MOI of 5. RNA was harvested, and gene expression was quantified by
qRT-PCR and expressed as fold change over mock infected using the 2−Δ(ΔCT) formula. (B) A549DPP4 cells
were infected in triplicate with SeV or SINV at an MOI of 5, and at 12 h postinfection, expression of the
indicated genes in infected/mock-infected cells was calculated as in panel A. (C) A549DPP4 cells were mock
infected or infected in triplicate with WT MERS-CoV, MERS-ΔNS4a, and MERS-ΔNS4ab at an MOI of 5 and
RNA was harvested at the indicated times postinfection. IFNL1, IFNB, OAS2, and IFIT2 mRNA levels were
quantified by qRT-PCR and calculated over mock-infected cells as in panel A. Data are from one
representative of three independent experiments and are displayed as means ± standard errors of the mean
(SEM). Statistical significance was calculated by unpaired Student's t test: *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤
0.001; ****, P ≤ 0.0001. Contributors: CEC and SAG
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NS4b is a novel IFN antagonist.
We previously reported that MERS-CoV NS4b is a member of the 2H-phosphoesterase
superfamily of proteins and antagonizes OAS-RNase L activation during MERS-CoV infection
through its 2’,5’ PDE activity (Mazumder et al., 2002; Thornbrough et al., 2016). Unlike previously
studied viral PDEs such as mouse hepatitis virus (MHV) NS2, the torovirus pp1a C-terminal
domain and the rotavirus VP3 C-terminal domain which exhibit primarily cytoplasmic localization
(Goldstein et al., 2016; Zhao et al., 2012) NS4b localizes primarily to the nucleus (Fig 2.2B),
suggesting additional functions. Earlier studies suggested that NS4b nuclear localization might be
important for suppressing IFN expression (Yang et al., 2015b), but no previous studies have
specifically addressed the role of its catalytic activity in IFN antagonism (Chu et al., 2018). To
characterize the function of the NS4b PDE domain and NLS we used recombinant MERSNS4bH182R and MERS-NS4bNLSmut. In Vero cells both mutant viruses replicated with equivalent
kinetics to WT MERS-CoV and to equal titers (Fig 2.6A). In A549DPP4 cells both viruses are
modestly and similarly attenuated at late time points at an MOI of 1, and throughout the course of
infection at an MOI of 0.1 where two out of three independent experiments yielded significant
differences (Fig 2.6B-C). qRT-PCR analysis demonstrated that mutation of either the catalytic site
or NLS results in significantly increased IFN and ISG expression during MERS-CoV infection (Fig
2.6D).

To further investigate whether PDE-dependent IFN antagonism is unique to MERS-CoV NS4b,
we infected A549 cells stably expressing the MHV receptor CEACAM-1 (A549mCEACAM-1) with WT
MHV or MHV encoding catalytically inactive NS2 (MHV-NS2H126R), its native PDE. Both viruses
induced slightly more IFNL1 expression than we observed for MERS-CoV, but MHV-NS2H126R did
so to an identical degree as WT MHV (Fig 2.6E) demonstrating that the MHV PDE does not
antagonize IFN induction in this cell type, consistent with our previous observation in murine cells
(Zhao et al., 2011).
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Fig 2.6 MERS-CoV NS4b NLS and PDE catalytic mutants are attenuated in A549 cells and exhibit
increased type III IFN expression. (A) Vero cells were infected in triplicate at an MOI of 1 with WT MERSCoV, MERS-NS4bNLS, and MERS-NS4bH182R. Supernatants were collected at indicated times postinfection
and infectious virus quantified by plaque assay. (B) A549DPP4 cells were infected in triplicate at an MOI of 1
or 0.1 with WT MERS-CoV, MERS-NS4bNLS, and MERS-NS4bH182R, and replication was quantified as in
panel A. Data are from one representative of three independent experiments and are displayed as means ±
standard deviation (SD). (C) Statistical significance for mutant virus replication versus WT was determined
by two-way ANOVA: *, P ≤ 0.05; **, P ≤ 0.01, ***, P ≤ 0.001; ****, P ≤ 0.0001. (D) A549DPP4 cells were mock
infected or infected in triplicate at an MOI of 5 with WT MERS-CoV, MERS-NS4bNLS, and MERS-NS4bH182R,
and RNA was harvested at the indicated times postinfection. Gene expression over mock-infected cells was
measured by qRT-PCR and calculated over mock-infected cells using the 2−Δ(ΔCT) formula. Data are from
one representative of three independent experiments and expressed as mean ± SEM. Statistical
significance was determined by unpaired Student's t test: *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤
0.0001. (E) A549mCEACAM-1 cells were mock treated or infected with WT MHV or MHV-NS2H126R at an MOI of
5, and RNA was harvested at 6 and 12 h postinfection. IFNL1 expression was determined as in panel D.
Data are from one representative experiment of three. Contributor: SAG
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Finally, to confirm that NS4b antagonism of IFN expression is a novel viral PDE function and
uncoupled from its interaction with the OAS-RNase L pathway we assessed immune activation by
MERS-CoV and NS4b mutants in A549DPP4 cells ablated of RNase L expression by CRISPRCas9 as previously described (Li et al., 2016). Both MERS-NS4bH182R and MERS-NS4bNLSmut
induced greater IFNL1, OAS2, and IFIT2 expression than WT MERS-CoV (Fig 2.7A) in RNase L
KO cells, recapitulating the results we observed in wild-type A549DPP4 cells. To confirm that these
cells were indeed unable to activate RNase L, cells were infected with SINV, a known potent
activator of OAS-RNase L (Li et al., 2016), and rRNA integrity was analyzed by Bioanalyzer as
previously described (Thornbrough et al., 2016; Zhao et al., 2012).

Fig 2.7 NS4b antagonizes IFN expression independently of RNase L activation. (A) RNase L KO
A549DPP4 cells were mock infected or infected in triplicate at an MOI of 5 with MERS-CoV, MERS-NS4bNLS,
and MERS-NS4bH182R. RNA was harvested at the indicated times postinfection, mRNA levels expression
was quantified by qRT-PCR in and expression in infected/mock-infected cells calculated using the
2−Δ(ΔCT) formula. Data are from one representative experiment of three, expressed as mean ± SEM, and
statistical significance was determined by unpaired Student's t test: *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001;
****, P ≤ 0.0001. (B) A549DPP4 and RNase L (RL) KO A549DPP4 cells were mock treated or infected with SINV
at an MOI of 1 with SINV, and RNA was harvested at 24 h postinfection. RNA was assessed for rRNA
degradation using an Agilent Bioanalyzer. The positions of 28S and 18S rRNA are indicated. Contributor:
SAG
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NS4a does not contribute to OAS-RNase L antagonism during MERS-CoV infection.
DsRNA binding proteins encoded by viruses such as Vaccinia virus (E3L) and Influenza A virus
(NS1) antagonize activation of the antiviral OAS-RNase L pathway, presumably by sequestration
of viral RNA (Liu and Moss, 2016; Min and Krug, 2006; Rivas et al., 1998). Since RNase L
activation by MERS-NS4bH182R is less robust than by other viruses such as SINV in A549DPP4 cells
(Fig 2.7) we hypothesized that NS4a may contribute to antagonism of this pathway during MERSCoV infection. To test this hypothesis, we infected A549DPP4 cells at an MOI of 5 and harvested
RNA 48 hours-post infection and assessed rRNA degradation using a Bioanalyzer (Thornbrough
et al., 2016; Zhao et al., 2012). We included SINV as a control for robust RNase L activation (Li et
al., 2016). RNase L activation is inferred from RNA degradation depicted by the banding pattern
in the pseudogel image. MERS-NS4bH182R and MERS-DNS4ab induced more rRNA degradation
than WT MERS-CoV indicating activation of RNase L (Fig 2.8). Infection with MERS-NS4bNLSmut
also did not result in increased rRNA degradation, as expected given previous work
demonstrating cytoplasmic PDE localization mediates RNase L antagonism (Gusho et al., 2014)
However, infection with MERS-DNS4a also did not induce increased rRNA degradation relative to
WT MERS-CoV indicating that the absence of NS4a alone is not enough to activate RNase L in
this cell type (Fig 2.8). Infection with MERS-DNS4ab did not induce more robust rRNA
degradation than MERS-NS4bH182R, suggesting that NS4a does not play a significant role in
antagonism of RNase L during MERS-CoV infection. This result demonstrates that NS4a has
both functional similarities and differences to other viral dsRNA binding proteins.
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Fig 2.8 Loss of NS4a does not activate RNase L during MERS-CoV infection. A549DPP4 cells were mock
infected or infected with WT MERS-CoV, MERS-ΔNS4a, MERS-ΔNS4ab, MERS-NS4bH182R, MERSNS4bNLSmut (MOI = 5), or SINV (MOI = 1). RNA was harvested at 48 h postinfection for MERS-CoV infection
and at 24 h postinfection for SINV infection and assessed for rRNA degradation by Agilent Bioanalyzer. 28S
and 18S rRNA positions are indicated. Data are from one representative of four independent experiments.
Contributor: CEC

NS4a antagonizes PKR activation, but not protein synthesis, during MERS-CoV infection.
A recent study showed that loss of NS4a during infection led to PKR activation, translational
arrest, and stress granule formation, but only in certain cell types (Nakagawa et al., 2018). We
investigated whether NS4a antagonizes the dsRNA binding antiviral effector Protein Kinase R
(PKR) during MERS-CoV infection in A549DPP4 cells. A549DPP4 cells were infected with WT
MERS-CoV and MERS-DNS4a at an MOI of 3, lysed at 24 hours post-infection and analyzed for
PKR activation by western blot. MERS-DNS4a, but not WT MERS-CoV induced PKR
phosphorylation (Fig 2.9A). PKR phosphorylation during MERS-DNS4a infection was also
observed at 16 and 48 hours post-infection (data not shown). However, despite the activation of
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PKR, we did not detect phosphorylation of eIF2a above background levels, suggesting that
activation of PKR by MERS-DNS4a in A549DPP4 cells is not sufficient to engage downstream
elements of this pathway or that MERS-CoV encodes an additional antagonist that blocks steps
downstream of PKR phosphorylation. In contrast, SINV infection promotes robust phosphorylation
of PKR and eIF2a in the same cells, indicating the lack of eIF2a phosphorylation during MERSDNS4a is not due to a deficiency of this pathway in A549DPP4 cells (Fig 2.9A).

Although we did not detect eIF2a phosphorylation by immunoblotting, we wanted to confirm that
PKR activation during MERS-DNS4a infection does not mediate translation arrest in A549DPP4
cells. Thus, we compared protein synthesis during infection with MERS-DNS4a and WT MERSCoV. We either mock infected or infected A549DPP4 cells with WT MERS-CoV or MERS-DNS4a.
We treated cells 18 and 24 hours post-infection with puromycin for 10 minutes to label nascent
proteins prior to protein harvest. We used immunoblotting with an anti-puromycin antibody to
specifically detect newly synthesized proteins and used Coomassie staining to assess total
protein levels (Schmidt et al., 2009). Decrease in puromycin signal indicates translation arrest.
Puromycin signal was not lower in MERS-DNS4a infected A549DPP4 cells compared to WT
MERS-CoV, indicating PKR phosphorylation did not induce downstream translation arrest (Fig
2.9B).

In contrast to A549DPP4 cells, we observe no phosphorylation of PKR during MERS-DNS4a
infection in 293TDPP4 cells (Fig 2.9C). Furthermore, MERS-CoV shut down protein synthesis
during infection of these cells as previously reported with no enhancement of translation arrest
from deletion of NS4a (Fig 2.9D) (Lokugamage et al., 2015). This confirms the observed loss of
protein synthesis occurs by an NS4a-independent mechanism and highlights that differences in
cell type may affect levels of activation of the dsRNA-induced innate immune pathways.
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Fig 2.9 Loss of NS4a activates PKR but does not lead to eIF2α phosphorylation or translation arrest
in A549DPP4. A549DPP4 cells were mock infected or infected with WT MERS-CoV and MERS-ΔNS4a
(MOI = 3) or SINV (MOI = 1). (A) Cell lysates were harvested at 24 h postinfection, and proteins were
separated by SDS-PAGE and immunoblotted with antibodies against phosphorylated PKR (p-PKR), PKR,
phosphorylated eIF2α (p-eIF2α), eIF2α, MERS-CoV N, and GAPDH. (B) Prior to cell lysate harvest, at 18
and 24 h postinfection, cells were treated with puromycin (10 μg/ml) for 10 min. Proteins were separated by
SDS-PAGE and analyzed either by immunoblotting with antibodies against puromycin, MERS N protein, or
GAPDH or Coomassie stain for labeling of total proteins. (C) 293TDPP4 cells were infected and cell lysates
harvested as in panel A. (D) 293TDPP4 cells were infected and cell lysates harvested as in panel B. Data are
from one representative of four (A), three (B), or two (C and D) independent experiments. Contributor: CEC

46

2.6 DISCUSSION
Studies from other labs as well as data presented herein have demonstrated that MERS-CoV
only modestly induces three major antiviral pathways, IFN production and signaling, OAS-RNase
L and PKR. This is likely due largely to viral antagonists of dsRNA-induced host responses. Our
study as well as recent reports from other labs have shown that deletion of MERS-CoV accessory
proteins from recombinant viruses leads to enhanced activation of antiviral pathways. However,
these effects are relatively small compared to other RNA viruses, and deletion of these accessory
proteins only mildly attenuates replication. This is in contrast to early studies utilizing
overexpression and reporter plasmids or ectopic expression from heterologous virus studies
showing robust suppression of IFNB induction by NS4a and NS4b (Matthews et al., 2014;
Niemeyer et al., 2013; Rabouw et al., 2016; Yang et al., 2015b; Yang et al., 2013). Thus, caution
is warranted in extrapolating from studies that rely only on ectopic expression.

We have used recombinant MERS-CoV mutants to study interactions between the accessory
proteins NS4a and NS4b and the host immune response. All of the viruses with mutations or
deletions in NS4a and NS4b were modestly attenuated compared to WT MERS-CoV in A549DPP4
cells. These modest differences are consistent with previous studies of MERS-CoV accessory
proteins (Canton et al., 2018; Chu et al., 2018; Menachery et al., 2017; Nakagawa et al., 2018;
Rabouw et al., 2016). Furthermore, there is a clinical report of human isolates with a 16 amino
acid deletion in NS4a (Lamers et al., 2016b) and West African camel MERS-CoV isolates with
ORF3 and ORF4b deletions, likely due to founder effects upon introduction into these populations
(Chu et al., 2018). The isolation of these viruses supports findings that MERS-CoV accessory
proteins are not definitive determinants of viral replication. However, all other known circulating
MERS-CoV isolates and MERS-CoV-like viruses encode intact accessory ORFs, strongly
suggesting that these proteins do play important roles in promoting viral fitness.
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We found roles for both NS4a and NS4b in suppressing IFNL1 expression in response to MERSCoV infection, which is notably muted compared to other RNA viruses (Fig 2.5, 2.6). The lack of a
similar increase in IFNB expression in response to mutant MERS-CoV infection is likely due to
generally less robust expression of IFNB in A549 cells, which preferentially express IFNL1 like
other epithelial cells derived from barrier surfaces (Wells and Coyne, 2018). We found that NS4b
IFN antagonism was dependent on nuclear localization, confirming an earlier report (Yang et al.,
2015b), and its catalytic activity.

NS4b is the first viral phosphodiesterase known to suppress antiviral pathways in addition to
RNase L, distinguishing it from phosphodiesterases found in the genomes of other coronavirus
subgenera (Fig 2.6). While the exact mechanism of NS4b IFN antagonism remains unclear,
several host-encoded PDEs within the same protein family are known or believed to participate in
various steps of RNA processing (Hilcenko et al., 2013; Mazumder et al., 2002). Whether, like
some cellular PDEs (Nomura et al., 2018), NS4b can cleave 3’-5’ linked phosphodiester bonds in
addition to 2’-5’ oligoadenylates and whether it mediates any of its immune antagonist functions
through directly or indirectly acting on host RNAs is an ongoing area of study. Finally, our data
demonstrate that NS4b antagonism of IFN is distinct from its RNase L antagonist activity (Fig 2.7)
demonstrating that NS4b has at least two independent functions.

We observed reduced expression of mutant NS4b compared to WT protein, as we reported
previously (Thornbrough et al., 2016). It is not known whether this reduced expression is due to
reduced protein stability or to the antibody not recognizing the mutant protein as efficiently as the
WT protein. However, the abundance of NS4b during infection with MERS-NS4bNLSmut, though
lower than WT protein, is sufficient to fully prevent RNase L activation, indicating mutation does
not reduce NS4b levels below an effective concentration (Fig 2.7) (Gusho et al., 2014; Zhang et
al., 2013; Zhao et al., 2012). Thus, it is unlikely that decreased mutant protein abundance is
responsible for the observed IFN phenotype (Goldstein et al., 2016). We observed a faster
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migrating protein, also staining with antiserum directed against NS4b (Fig 2.1C). We presume
that this faster migrating protein was not detected in NS4b mutant infected cells due to its lower
expression level relative to full-length NS4b and because it is weakly expressed even in WT
MERS-CoV NS4b cells. We do not know the identity of this band. However, we speculate it could
be a breakdown product of full length NS4b or more interestingly a protein initiated at one of
several ATGs located downstream and in frame with the NS4b initiation site.

Activation of RNase L during MERS-NS4bH182R infection is less robust than during infection with
MHV-NS2H126R in macrophages (Zhao et al., 2012) or SINV infection of A549 cells (Fig 2.7) (Li et
al., 2016), suggesting MERS-CoV may have redundant mechanisms for inhibiting this pathway.
Based on the role of the viral dsRNA binding proteins NS1 of Influenza and E3L of Vaccinia virus
(Liu and Moss, 2016; Min and Krug, 2006; Rivas et al., 1998) in blocking RNase L activation as
well as IFN and PKR, we hypothesized that NS4a contributes to antagonism of OAS-RNase L.
Surprisingly, infection with MERS-DNS4a did not induce increased rRNA degradation compared
to wild-type virus, nor did NS4a deletion produce any additive effect on RNase L activation in
combination with deletion of NS4b. Nevertheless, the lack of robust RNase L activation even
when NS4b is catalytically inactive suggests the possibility MERS-CoV does encode additional
antagonists. One intriguing possibility is nsp15; its MHV ortholog has recently been described as
contributing to evasion of multiple dsRNA-sensing pathways (Deng and Baker, 2018; Deng et al.,
2017; Kindler et al., 2017). Alternatively, as has been speculated for MHV, MERS-CoV dsRNA
may, even in the absence of NS4a, be contained in viral replication/transcription complexes
(RTCs) and therefore hidden from antiviral sensors (Versteeg et al., 2007; Zhou and Perlman,
2007).

Due to its dsRNA-binding activity, we also hypothesized that NS4a inhibits PKR activation. One
previous study showed that ectopically expressed NS4a inhibits PKR activation and can
functionally replace the native PKR antagonist of encephalomyocarditis virus (Rabouw et al.,
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2016). Deletion of NS4a within recombinant MERS-CoV has previously been shown to result in
enhanced translation arrest compared to WT MERS-CoV in HeLa cells (Nakagawa et al., 2018).
Consistent with this, we found that deletion of NS4a results in PKR phosphorylation, but in
A549DPP4 cells this did not lead to phosphorylation of eIF2a above background levels, and MERSDNS4a did not induce more translation arrest than WT MERS-CoV. In 293TDPP4 cells, MERS-CoV
induced translation arrest as previously reported (Lokugamage et al., 2015), but we did not
observe a more robust effect during MERS-DNS4a infection. Furthermore, PKR was not
phosphorylated in 293TDPP4 cells during MERS-DNS4a infection, confirming the PKR-independent
mechanism of translational arrest and highlighting differences between cell types in antiviral
pathway activation. These differences demonstrate the importance of using multiple model
systems to fully elucidate interactions between viral proteins and host immune pathways.

Despite the lack of robust replication phenotypes, studies of MERS-CoV accessory proteins from
other labs as well as our own have identified novel and important virus-host interactions that likely
contribute in important ways to maintenance of MERS-CoV in its ecological niche and possibly
during infection of the human respiratory tract. Future work on MERS-CoV accessory proteins in
animal models and in vitro systems that more faithfully recapitulate the human airway should
more fully answer the question of how these proteins contribute to replication under immune
pressure and to pathogenesis.
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CHAPTER 3: MERS-CoV USES ENDOU ACTIVITY IN
COMBINATION WITH ACCESSORY PROTEINS NS4A AND NS4B
TO EVADE dsRNA-INDUCED INNATE IMMUNITY DURING
INFECTION

*The contents of this chapter are in progress with contributions from the following authors:
Courtney E. Comar, Clayton J. Otter, David M. Renner, Yousef Alhammad, Jessica
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3.1 SUMMARY
Middle East Respiratory Syndrome Coronavirus (MERS-CoV) emerged into human populations in
2012, causing outbreaks of severe respiratory disease. Despite detectable double-stranded
(ds)RNA production during infection, MERS-CoV and other coronaviruses are adept at evading,
delaying, or suppressing activation of innate immune responses in their hosts, especially the
dsRNA-induced innate immune pathways: type I and III interferon (IFN) production and signaling,
PKR, and OAS/RNase L. We previously found that MERS-CoV accessory proteins NS4a and
NS4b played roles in evading innate immune induction during infection, but inactivation or
ablation of these proteins caused only minimal to moderate activation the of IFN, PKR, and
OAS/RNase L pathways. The function of EndoU, a conserved coronavirus enzyme domain
encoded in nsp15 and potent innate immune antagonist, had yet to be examined during MERSCoV infection. Here we show that inactivation of EndoU catalytic activity alone caused little or no
effect on activation of the innate immune pathways: IFN, PKR, and RNase L during MERS-CoV
infection. However, inactivation of the EndoU activity in combination with mutation of the genes
encoding accessory proteins NS4a or NS4b caused a defect in infectious virus production and
robust activation of the innate immune pathways in MERS-CoV infected A549DPP4 cells. This
indicates that EndoU plays a complimentary or redundant role with accessory proteins NS4a and
NS4b, leading to strong suppression/evasion of dsRNA-induced innate immunity during MERSCoV infection.
3.2 INTRODUCTION
Middle East respiratory syndrome coronavirus (MERS-CoV) first emerged in 2012, in Saudi
Arabia (Zaki et al., 2012), and was the second of three novel coronaviruses to emerge into
humans in the 21st century, following severe acute respiratory syndrome coronavirus (SARSCoV) in 2002 and preceding SARS-CoV-2 in 2019. MERS-CoV is a highly pathogenic
betacoronavirus that has caused 882 deaths in 2567 laboratory confirmed cases (as of February
2021) according to the World Health Organization. MERS-CoV circulates in its natural reservoir,
dromedary camels, and closely related viruses have been found bats, suggesting that MERS53

CoV descended from a bat virus (Anthony et al., 2017a; Corman et al., 2014a; Geldenhuys et al.,
2018; Khalafalla et al., 2015; Reusken et al., 2014; Wernery et al., 2015).

MERS-CoV, like many coronaviruses, is adept at evading or delaying activation of doublestranded (ds)RNA-induced innate immune pathways. These innate immune pathways play a
crucial role in host detection and response to insults from pathogens. When coronaviruses
undergo replication and transcription, dsRNA intermediates form. dsRNA is a pathogen associate
molecular pattern (PAMP) that can be detected by several different host pattern recognition
receptors (PRR) (Hur, 2019). MDA5, the major sensor for coronaviruses, is a PRR that detects
long dsRNA and induces signaling through MAVS, activation of interferon regulatory factors
(IRF), leading to transcription of type I and III interferons (IFN) (Rehwinkel and Gack, 2020; RothCross et al., 2008). These IFNs are produced and released by the infected cell and can signal in
auto- or paracrine fashion to their receptors. Type I IFNs (a and β) bind to their receptor found on
several different cell types and type III IFNS (λ) bind to their receptor on cells at mucosal barriers
including the airway and gut epithelium (Ye et al., 2019). Downstream JAK/STAT signaling and
phosphorylation leads to induction of the IFN antiviral response, characterized by expression of
several hundred interferon stimulatory genes (ISGs), which act to restrict virus replication and
spread. Protein Kinase R (PKR) is another cytoplasmic PRR activated by dsRNA. Upon sensing
dsRNA, PKR autophosphorylates and then phosphorylates its substrate, translation initiation
factor eIF2a leading to translation arrest (Hur, 2019). Oligo adenylate synthetases (OAS) 3 is a
third PRR that binds dsRNA and produces 2’-5’ oligoadenylate (2-5A) that activates the host
enzyme ribonuclease L (RNase L) which cleaves viral and host single-stranded (ss)RNA (Li et al.,
2016; Silverman, 2007). These pathways, when activated, restrict virus replication; however,
many viruses including coronaviruses have evolved mechanisms for avoiding or overcoming
activation of these pathways.
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MERS-CoV is a betacoronavirus with a positive sense single stranded (+ss) RNA genome that is
30,119 nucleotides long. The 5’ two-thirds of the genome encode the replicase proteins in
ORF1ab, involved in several processes such as RNA replication and transcription, RNA capping
processing, proteolytic cleavage, and host innate antagonism. The 3’ one-third of the genome
encodes the structural genes and the unique, subgenera-specific accessory genes. The MERSCoV genome encodes genes for several proteins that have been shown to play roles in evasion
or antagonism of innate immune induction (Goldstein and Weiss, 2017; Kindler et al., 2016). Two
accessory proteins of interest are both encoded on mRNA4 by ORFs4a/4b, NS4a and NS4b.
Accessory protein NS4a is a dsRNA binding protein that has previously been shown to block IFN
induction and PKR activation (Nakagawa et al., 2018; Niemeyer et al., 2013; Rabouw et al., 2016;
Siu et al., 2014; Yang et al., 2013). NS4b contains a phosphodiesterase (PDE) domain and
nuclear localization signal (NLS), and has been shown to block NFκB translocation to the
nucleus, prevent IFN induction, and to antagonize activation of RNase L (Canton et al., 2018;
Chu et al., 2018; Matthews et al., 2014; Thornbrough et al., 2016; Yang et al., 2015b). Previously
we showed that in the absence of NS4a, PKR was mildly activated and IFN expression was
weakly induced (Comar et al., 2019). We also saw that abrogation of the PDE activity of NS4b led
to mild activation of RNase L and IFN induction during MERS-CoV infection (Comar et al., 2019;
Thornbrough et al., 2016). Nsp15 is a conserved coronavirus replicase protein that contains an
endoribonuclease (EndoU) domain characterized by two catalytic histidine residues. This EndoU
domain has been shown to limit dsRNA production and potently prevent induction of IFN,
OAS/RNase L, and PKR pathways during murine coronavirus (MHV) infection (Deng et al., 2017;
Kindler et al., 2017). The exact mechanism is unknown although it appears that cleavage of viral
ssRNA limits excessive dsRNA expression (Ancar et al., 2020; Hackbart et al., 2020). The
function of EndoU activity has yet to be examined during MERS-CoV infection.

Building on our previous work showing that MERS-CoV accessory proteins NS4a and NS4b play
roles in preventing innate immune induction, here we investigate the role of the conserved
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coronavirus EndoU enzyme during MERS-CoV infection. We used recombinant MERS-CoV
viruses with various combinations of mutations in genes encoding nsp15’s EndoU, NS4a, and
NS4b to uncover the role of nsp15 EndoU activity during MERS-CoV infection and to better
understand how MERS-CoV so adeptly evades activation of innate immune responses.
3.3 MATERIALS AND METHODS
Recombinant viruses. Recombinant MERS-CoV viruses were made using lambda red
recombination l with the MERS-CoV Bacterial Artificial Chromosome (BAC) as previously
described (Almazan et al., 2013; Fehr, 2020). The following primers were made to generate the
mutations (bolded) to create the recombinant viruses:
MERS-nsp15H231A:
F 5’-GTGATGTTTTCATTAAGAAGTATGGCTTGGAAAACTATGCTTTTGAGGCCGTAGTCTATGGAGACTT-3’
R 5’-CGCCTAACGTAGTATGAGAGAAGTCTCCATAGACTACGGCCTCAAAAGCATAGTTTTCCA-3’

MERS-D NS4a: (amino acids 11 and 12 replaced by stop codons)
F 5’-GAACTCTATGGATTACGTGTCTCTGCTTAATCAAATTTGATAGAAGTACCTTAACTCACC-3’
R 5’-TGTACAAACAAGTAGTATACGGTGAGTTAAGGTACTTCTATCAAATTTGATTAAGCAGAG-3’

MERS-NS4bH182R:
F 5’-GTTCAGGGATTTTCCCTTTACCATAGTGGCCTCCCTTTACGTATGTCAATCTCTAAATTG-3’
R 5’-GTAACATCATCCAGTGCATGCAATTTAGAGATTGACATACGTAAAGGGAGGCCACTATGG-3’

MERS-nsp15H231A/DNS4a: the same mutations as above combined on one BAC
MERS-nsp15H231A/ NS4bH182R: the same mutations as above combined on one BAC
All amplified KanI using the following additions onto the above primers:
F 5’-AGGATGACGACGATAAGTAGGG-3’

R 5’-GCCAGTGTTACAACCAATTAACC-3’

Passage 0 (P0) viruses were launched by Invitrogen™ Lipofectamine™ 2000 transfection
reagent on African Green Monkey VeroCCL81 cells using 1.25ug of BAC DNA. Cells were
monitored for cytopathic effect and cells and supernatant harvested 5-7 days after transfection.
P0 virus was freeze thawed, cells removed by centrifugation and passaged onto Vero CCL81
cells to generate P1 stock. A P2 stock was generated by using low MOI (0.05) of P1 stock and
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infecting Vero CCL81 cells, freeze thawed to harvest, cells removed and supernatant used as the
stock virus for experiments. Quantification of infectious virus was done by standard viral plaque
assay on Vero CCL81 cells (Li et al., 2021).

Recombinant viruses used that were constructed with the infectious clone system: WT-MERSCoV, MERS-DNS4a, MERS-NS4bH182R, MERS-DNS4ab (Comar et al., 2019). Sindbis virus
Girdwood (G100) (SINV) was obtained from Dr. Mark Heise, University of North Carolina, Chapel
Hill, and prepared as previously described (Suthar et al., 2005).
Cell lines. Vero CCL81 cells were cultured in DMEM+10% FBS, sodium pyruvate, and HEPES.
Human A549DPP4 cells were cultured in RPMI 1640 supplemented with 10% FBS and penicillinstreptomycin. A549DPP4 were constructed as previously described (Comar et al., 2019).
MERS-CoV infections and titration. Viruses were diluted in serum-free DMEM and added to cells
for adsorption for 1 hour at 37°C. Cells were washed three times with PBS (for growth curves and
RNA, no washes for protein or immunofluorescence samples) and fed with RPMI+2% FBS for
A549DPP4 or DMEM+2%FBS for Vero CCL81. 150 µl of supernatant was collected at the times
indicated and stored at -80°C for titration by plaque assay on Vero CCL81 cells as previously
described (Li et al., 2021). All infections and virus manipulations were conducted in a biosafety
level 3 (BSL3) laboratory using appropriate personal protective equipment and protocols.
Immunofluorescence (IF) and fluorescent in situ hybridization (FISH) staining. At indicated
times post-infection cells were fixed with 4% paraformaldehyde for 30 minutes at room temperature.
Cells were then washed three times with PBS and then dehydrated with increasing amounts of
ethanol: 50%, 70%, and 100% for 5 minutes each. Samples were stored at 100% ethanol at -20°C
overnight. Cells were rehydrated with 70% then 50% ethanol for 2 minutes each, washed with PBS
once and then permeabilized for 10 minutes with PBS+0.1% Triton-X100. Cells were then blocked
in PBS+0.1% Triton-X100 and 2% BSA containing RNaseOUTTM (InvitrogenTM Cat #10777019) for
30 minutes at room temperature. Primary antibodies were diluted in block buffer and incubated at
room temperature for one hour. Cells were washed three times with PBS and then incubated at
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room temperature for 30 minutes with secondary antibodies diluted in block buffer. All steps
following secondary antibody addition were carried out in the dark. Cells were washed three times
with PBS, and then fixed again with 4% paraformaldehyde for 10 minutes at room temperature. For
FISH staining, cells were washed with 2X SSC for 5 minutes and then 5 minutes with FISH wash
buffer (10% formaldehyde in 2x SSC). FISH probes complementary to the N gene of MERS-CoV
(Table 3.1) conjugated to CAL Fluor Red 610 (Stellaris custom order) were diluted 1:50 in nuclease
free water. Then probes were diluted 1:50 in hybridization buffer (10% w/v dextran sulfate in 10%
formaldehyde in 2x SSC) and incubated with samples overnight at 37°C in a humid chamber.
Samples were washed with FISH wash buffer for 30 minutes at 37°C, nuclei stained with DAPI
diluted in FISH wash for 5 minutes at room temperature, and then cells were washed for 5 minutes
with 2X SSC. Coverslips were mounted onto slides using Invitrogen™ ProLong™ Diamond
Antifade Mountant for analysis by widefield microscopy. DsRNA was detected using commercial
monoclonal antibody J2 (Scions) at 1:500 and nsp8 using anti-nsp8 rabbit serum 1:500 (obtained
from Dr. Mark Denison, Vanderbilt University). Secondary antibodies were diluted 1:1000, all highly
cross-adsorbed IgG (H+L) from Invitrogen: goat anti-mouse AF488 (Cat #: A11029) and goat antirabbit AF647 (Cat #: A32733).
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5'

MERS-CoV N+ssRNA probes
TTTTGGATTACGTCCTCTAC
AGTGTTATTTGGTGCAGCTC
TAAGCCCAGTGTACCAAGAG
CCAGGTGGAAAGGTAAGAGG
TTGGCATTAAGAGGTACACC
TAATTTTTCTGTCCTGTCTC
CAGTTGCTTAATTCCATTCC
TCCAGTGTAGTAGAAGTACC
TTAACAGCCCGGAATGGGAG
ATGGACCCAAACGATGCCAT
TCCCAAAAGTTGAAGGAGCA
GAATCATTGTTAGGGTTCCG
GGGCGCGAATTGTGTAACAA
CCCTCAATGTGGAAGTTTTT
TGATTGACTATTGCCTCCAG
TTAAGCTAGAGGCTCTTGAA
CTAGATCTGGAAGAGTTTCT
CAGATGGACCTGGAGAAGTG
AAGTAGATCACCTCCTACTG
GCTTGTAGTCTGTTCAGAAG
CTTTACTTTGCCAGACTCAA
TGATTACTTTTGGCTGCGAT
AACTTTTGGTGGAAGTGCGC
AAGACCAAAAGCTTGCACCA
GAAGATCACCAAAGTTTCCC
TCAGTGCCGAGTTTATTCAA
TCAGCAATTTGGGGCCAACG
AAAAGCACTGGCTGTAGGAG
GTTTAAATTGCGACATACCC
TCATCATTGTTCTGATGGGT
ACCGAAGGAAGTACACAGGG
TCAAGTTTAATGGCTCCACT
AGGTTCAGACATTTGGTCTG
TGAGTGATGCTACCTTGCAC
AACACTTGGACGGGTGCGAG
ACATCAATCATTGGACCAGG

3'

Table 3.1 MERS-CoV N+ssRNA FISH probes conjugated to CAL Fluor Red 610.

Widefield microscopy was done using either Nikon Eclipse Ti2 using a Nikon 40x/0.95NA Plan APO
objective and NikonDS-Qi1Mc-U3 12-bit camera or Nikon Eclipse Ti2 using a Nikon 20x objective
and Hamamatsu digital camera C13440. Fiji was used for quantification of dsRNA: N +ssRNA
staining was used to generate a mask by setting a threshold (using same set threshold applied
across all images). These thresholded images were as a mask to mark infected regions of interest
(ROI). These ROIs, due to syncytia formation, marked infected areas of cells not singular cells. The
mean gray value (MGV) of fluorescence signal of dsRNA or nsp8 was measured within each ROI
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across several images per infection condition. The ratio of MGV of dsRNA over MGV of nsp8 was
recorded for each individual ROI and plotted using Prism software.
Western immunoblotting. Cells were washed once with ice-cold PBS and lysates harvested at
indicated times post infection with lysis buffer (1% NP40, 2mM EDTA, 10% glycerol, 150mM
NaCl, 50mM Tris HCl) supplemented with protease inhibitors (Roche – cOmplete mini EDTA-free
protease inhibitor) and phosphatase inhibitors (Roche – PhosStop easy pack). After 5 minutes
lysates were harvested, incubated on ice for 20 minutes, centrifuged for 20 minutes at 4°C and
supernatants mixed 3:1 with 4x Laemmli sample buffer. Samples were heated at 95°C for 5
minutes, then separated on 4-15% SDS-PAGE, and transferred to polyvinylidene difluoride
(PVDF) membranes. Blots were blocked with 5% nonfat milk or 5% BSA in TBST and probed with
the following antibodies diluted in the same block buffer:
Primary Antibody

Antibody
species

Blocking
buffer

Dilution

Catalog number

p-PKR (phospho-T446) [E120]

rabbit

5% milk/TBST

1:1000

PKR (D7F7)

rabbit

5% milk/TBST

1:1000

peif2α (S51)

rabbit

5% BSA/TBST

1:1000

eif2α

rabbit

5% BSA/TBST

1:1000

GAPDH (14C10)

rabbit

5% milk/TBST

1:2000

MERS-CoV N

mouse

5% milk/TBST

1:2000

Abcam 32036
Cell Signaling Technology
12297S
Cell Signaling Technology
9721S
Cell Signaling Technology
9722S
Cell Signaling Technology
2118S
40068-MM10 (Sino
Biological)

Secondary Antibody
goat anti-rabbit IgG

HRP linked

goat anti-mouse IgG

HRP linked

same as
primary
same as
primary

1:3000
1:3000

Cell Signaling Technology
7074S
Cell Signaling Technology
7076S

Table 3.2 Western blot antibodies

Blots were visualized using Thermo Scientific SuperSignal west chemiluminescent substrates (Cat
#:34095 or 34080). Blots were probed sequentially with antibodies and in between antibody
treatments stripped using Thermo Scientific Restore western blot stripping buffer for 1 hour at room
temperature (Cat #: 21059).
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Protein synthesis was assessed by treatment of cells with 10µg/ml puromycin for 10 minutes prior
to protein harvest (Schmidt et al., 2009). Lysates were harvested and equal protein amounts
determined by Bio-Rad protein assay (Cat#5000006). Equal protein amounts were run on SDSPAGE gels as described above. For detection of puromycin, anti-puromycin mouse mAb
(Millipore clone 4G11 MABE342) was used at 1:6000, and the secondary antibody (1:1000) used
was horse anti-mouse HRP-conjugated (CST #7076S). For detection of total protein by
Coomassie staining, cell lysates (as prepared above) were separated by 4-15% SDS-PAGE. Gels
were fixed and stained with 0.05% Coomassie Brilliant Blue R250 (Biorad 161-0400) in 50%
methanol, 10% acetic acid solution for 1 hour at a gentle rock at room temperature. Gels were destained with 7% methanol and 5% acetic acid for several hours and then imaged.
Quantitative PCR (qRT-PCR). At indicated times post-infection cells were lysed with buffer RLT
Plus (Qiagen RNeasy Plus #74136) and RNA extracted following the prescribed protocol. RNA
was reverse transcribed into cDNA with a High Capacity cDNA Reverse Transcriptase Kit
(Applied Biosystems). cDNA was amplified using specific qRT-PCR primers (see Table 3.3), iQÔ
SYBRÒ Green Supermix (Bio-Rad), and the QuantStudioÔ 3 PCR system (Thermo Fisher). Fold
changes in mRNA level compared to mock infected were calculated using the formula 2-∆(∆Ct)(ΔCt
= Ctgene of interest – Ct18S) and expressed as fold infected/mock-infected. Absolute quantification of
MERS-CoV genome was calculated using a standard curve generated from serially diluted known
concentrations of a digested plasmid containing the region of interest. cDNA MERS-D1 (Scobey
et al., 2013) containing base pairs 12259–15470 of the MERS-CoV genome was digested with
BgII. and purified by Qiagen QIAquick PCR Purification Kit. Copy numbers were generated by
standard curve analysis in the QuantStudioÔ 3 software, and copy numbers per ug RNA were
calculated based on the volume of cDNA used in the qPCR reaction, and concentration of RNA
used to generate cDNA. Primer sequences are as follows:
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Forward primer (5’ to 3’)
IFNL1
CGCCTTGGAAGAGTCACTCA
OAS2
TTCTGCCTGCACCACTCTTCACGAC
IFIT1
5’-TGGTGACCTGGGGCAACTTT
IFNB
GTCAGAGTGGAAATCCTAAG
IFIH1
GCACAGAGCGGTAGACCCTGCTT
18S rRNA
TTCGATGGTAGTCGCTGTGC
MERS-CoV genome (nsp7) GCACATCTGTGGTTCTCCTCTCT
Table 3.3 Primers for qRT-PCR

Reverse primer (5’ to 3’)
GAAGCCTCAGGTCCCAATTC
GCCAGTCTTCAGAGCTGTGCCTTTG
AGGCCTTGGCCCGTTCATAA
ACAGCATCTGCTGGTTGAAG
AGGCCTTGGCCCGTTCATAA
CTGCTGCCTTCCTTGAATGTGGTA
AAGCCCAGGCCCTACTATTAGC

Analyses of RNase L-mediated rRNA degradation. RNA was harvested with buffer RLT plus
(Qiagen RNeasy Plus #74136) and analyzed on an RNA chip with an Agilent Bioanalyzer using
the Agilent RNA 6000 Nano Kit and its prescribed protocol (Cat #: 5067-1511).
Statistical analysis. Plotting of data and statistical analysis were performed
using GraphPad Prism software (GraphPad Software, Inc., CA). Statistical significance was
determined by comparing mutant viruses to WT MERS-CoV using repeated measures two-way
ANOVA for viral replication curves and qRT-PCR and by one-way ANOVA for dsRNA
quantification. Displayed significance is determined by p-value (P), where * = P < 0.05; ** = P <
0.01; *** = P < 0.001; **** = P < 0.0001; ns = not significant and in some figures, ns is not
displayed on the graph.
3.4 RESULTS
Replication of MERS-CoV recombinant viruses in VeroCCL81 and A549DPP4 cells
In order to study the effects of EndoU activity on the dsRNA-induced antiviral innate immune
pathways during MERS-CoV infections, several recombinant mutants were derived from a
Bacterial Artificial Chromosome (BAC) encoding the full-length MERS-CoV genome using
previously described methods and described in more detail in the Material and Methods section
(Fehr, 2020). Recombinant viruses with mutations in nsp15 EndoU catalytic site H231A (H2278A
of ORF1b), interruption of NS4a expression by insertion of stop codons at amino acid positions
11 and 12, and NS4b phosphodiesterase catalytic site (H182R) were constructed (summarize in
Fig 3.1).
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Replicase locus
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Fig 3.1 Recombinant MERS-CoV design. Several recombinant MERS-CoV viruses were derived from the
BAC reverse genetics system to study the effects of these mutations on activation of dsRNA-induced innate
immune responses.

African Green Monkey kidney Vero CCL81 (Vero) cells were infected at MOI=1 and supernatant
samples harvested at 2, 24, 48, and 72 hours-post infection (hpi). Quantification of infectious
virus was completed by standard viral plaque assay on IFN-deficient Vero cells as previously
described (Li et al., 2021). Mutant viruses replicated to similar levels as WT MERS-CoV in two
(for MERS-DNS4a, MERS-NS4bH182R, and MERS-nsp15H231A/NS4bH182R) or three (for MERSnsp15H231A and MERS-nsp15H231A/ MERS-DNS4a) independent experiments (Fig 3.2A). This
indicates that there were no inherent replication defects in the mutant viruses. To investigate the
possible effects of dsRNA-induced innate immune activity on replication of these viruses,
A549DPP4 cells (with intact IFN, PKR, and RNase L pathways) were infected at MOI=1 and
infectious virus quantified same as above. At 48 and 72 hpi, we observed that there was
approximately 1 log10 PFU/mL decrease in infectious virus produced in the MERSnsp15H231A/DNS4a (2 of 3 experiments) and MERS-nsp15H231A/NS4bH182R mutant (2 of 2
experiments) compared to WT MERS-CoV (Fig 3.2B). Interestingly mutation of the EndoU
catalytic site alone, MERS-nsp15H231A, did not result in a large replication defect (small but
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significant defect in 2 of 3 experiments at either 48 or 72hpi) and neither did MERS-DNS4a or
MERS-NS4bH182R (significantly lower at 72hpi in 1 of 2 experiments), similar to mild effects on
viral replication observed previously in the absence of these two accessory proteins (Comar et
al., 2019). To further investigate the role of these proteins during infection, we next characterized
the activation of the dsRNA-induced innate immune pathways during infection with the
recombinant MERS-CoV mutants.
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Fig 3.2 MERS -nsp15H231A/DNS4a and -nsp15H231A/NS4bH182R are attenuated in A549DPP4 cells. (A) Vero
cells were infected in triplicate at an MOI of 1. Supernatants were collected at the indicated hours
postinfection (hpi), and infectious virus was quantified by standard viral plaque assay. (B) A549DPP4 cells
were infected in triplicate at an MOI of 1 and replication was quantified as in panel A. Data are displayed as
means ± standard deviation (SD). Statistical significance compared to WT MERS-CoV was calculated by
repeated measures two-way ANOVA: *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001. Data that
were not statistically significant are not labeled. Data are from one representative of two (for MERS -DNS4a,
-NS4bH182R, and -nsp15H231A/NS4bH182R) or three (for WT MERS-CoV and MERS -nsp15H231A and nsp15H231A/DNS4a) independent experiments. Contributor: CEC
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MERS -nsp15H231A/D NS4a and - nsp15H231A/NS4bH182R induce interferon expression
To investigate if the type I/III IFN pathway was activated during infection with MERSnsp15H231A/DNS4a and MERS-nsp15H231A/NS4bH182R, we infected A549DPP4 cells at MOI=5 and
collected total cellular RNA at 24 and 48 hpi. We used quantitative reverse transcription
polymerase chain reaction (qRT-PCR) to measure mRNA expression of select IFN genes (IFNL1
and IFNB) and IFN stimulated genes (ISGs). We found that expression of IFNL1 and IFNB were
significantly increased at 48hpi in MERS-nsp15H231A/DNS4a and MERS-nsp15H231A/NS4bH182R
infection compared to WT MERS-CoV. Expression of select ISGs, IFIH1, OAS2, IFIT1, was also
significantly increased in MERS-nsp15H231A/DNS4a and MERS-nsp15H231A/NS4bH182R infections
compared to WT MERS-CoV. Additionally, ISG expression was significantly increased in MERSnsp15H231A infection or MERS-DNS4a alone, although less than in MERS-nsp15H231A /DNS4a and
- /NS4bH182R, compared to WT-MERS-CoV at 48hpi.
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Fig 3.3 MERS-nsp15H231A/DNS4a and - nsp15H231A/NS4bH182R induce IFN/ISG expression in A549DPP4
cells. A549DPP4 cells were mock infected or infected in triplicate at an MOI of 5. Total RNA was harvested at
24 and 48hpi and gene expression of IFNL1, IFNB, IFIH1, OAS2, and IFIT was quantified by qRT-PCR and
expressed as fold change over mock infected using the 2−Δ(ΔCT) formula. Data are displayed as means ±
standard deviation (SD). Data are from one representative of two (for MERS -DNS4a, -NS4bH182R, and nsp15H231A/NS4bH182R) or four (for WT MERS-CoV and MERS -nsp15H231A and -nsp15H231A/DNS4a)
independent experiments. Statistical significance compared to WT MERS-CoV was calculated two-way
ANOVA: *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001. Data that were not statistically significant
are not labeled. Contributors: CJO and CEC
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RNase L is activated in the absence of NS4b and EndoU catalytic activities
We wanted to determine if RNase L would be activated in the absence of EndoU catalytic activity
alone or in combination with loss of NS4a expression or NS4b catalytic activity. Previous work
with MHV found that in the absence of EndoU activity, RNase L was activated even in the
presence of the phosphodiesterase accessory protein NS2 (Deng et al., 2017; Kindler et al.,
2017). Furthermore, our previous work showed that RNase L was mildly activated during infection
with MERS-NS4bH182R but not with MERS-DNS4a (Comar et al., 2019; Thornbrough et al., 2016).
Thus, we infected A549DPP4 cells with several MERS-CoV recombinants at MOI=5, harvested
total cellular RNA at 24 and 48hpi, and determined RNase L activation by cleavage of rRNA as
indicated by the Agilent RNA Nano 6000 assay (Fig 3.4). SINV infection at 24 hpi was used as a
positive control. Interestingly, we found that inactivation of EndoU alone (MERS-nsp15H231A) did
not lead to strong RNase L activation in A549DPP4 cells, unlike was observed in MHV infection of
bone marrow-derived macrophages. MERS- nsp15H231A/DNS4a infection slightly activated RNase
L as evidenced by mild 28S and 18S rRNA degradation. MERS-nsp15H231A/NS4bH182R infection
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Fig 3.4 RNase L activation during MERS-nsp15H231A/NS4bH182R infection. A549DPP4 cells were mock
infected or infected at MOI=5 and total cellular RNA harvested at 24 and 48hpi. rRNA degradation was
assessed by Agilent Bioanalyzer. 28S and 18S rRNA positions are indicated. Data are from one experiment
for MERS-nsp15H231A/NS4bH182R and one representative of two experiments for MERS-nsp15H231A and
MERS-nsp15H231A/DNS4a. Contributor: CEC and CJO
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Fig 3.4 RNase L activation during MERS-nsp15H231A/NS4bH182R infection. A549DPP4 cells were mock infected or
infected at MOI=5 and total cellular RNA harvested at 24 and 48hpi. rRNA degradation was assessed by Agilent
Bioanalyzer. 28S and 18S rRNA positions are indicated. Data are from one experiment for MERS-nsp15H231A/NS4bH182R
and one representative of two experiments for MERS-nsp15H231A and MERS-nsp15H231A/NS4a.

PKR is strongly activated during infection with MERS-nsp15H231A/D NS4a but not MERSnsp15H231A
WT MERS-CoV blocks activation of PKR during infection, and MERS-DNS4a induced mild
phosphorylation of PKR but not eIF2α (Comar et al., 2019; Nakagawa et al., 2018; Rabouw et al.,
2016). Here we examined induction of the PKR pathway when EndoU is inactivated alone or in
combination with lack of NS4a expression. A549DPP4 cells were infected at MOI=5, protein lysates
harvested 24 and 48hpi, and processed by SDS-PAGE and Western immunoblotting for detection
of PKR activation (Fig 3.5A). As previously published, MERS-DNS4a induced PKR
phosphorylation at 24hpi but not phosphorylation of eIF2α in A549DPP4 cells. Interestingly, MERSnsp15H231A did not induce activation of PKR as no PKR or eIF2α phosphorylation was detected
above WT MERS-CoV levels at 24 or 48hpi. However, during infection of MERSnsp15H231A/DNS4a, strong activation of PKR was observed at 24 and 48 hpi, indicated by
phosphorylation of PKR and eIF2α.

Next, we examined if activation of PKR by MERS-nsp15mut/DNS4a had effects on protein
synthesis during infection. Previous reports indicate that WT MERS-CoV blocks nascent protein
synthesis due to the activities of nsp1, and our previous work found that in A549DPP4 cells, MERSDNS4a did not cause a decrease in protein synthesis compared to WT MERS-CoV (Comar et al.,
2019; Lokugamage et al., 2015). We infected A549DPP4 cells with WT MERS-CoV or MERSnsp15H231A/DNS4a at MOI=5 and prior to harvesting protein lysates we treated cells for 10
minutes with puromycin at 37°C. Protein lysates were harvested as above, the Bradford method
was used to determine protein amounts, and equal protein amounts were analyzed by SDSPAGE. Gels were either stained with Coomassie blue dye to measure total protein levels or
transferred to PVDF for Western immunoblotting to detect puromycin incorporation (Fig 3.5B). In
two of two experiments, WT MERS-CoV caused a decrease in puromycin incorporation
compared to mock at 24 and 48hpi, indicating translation arrest. Lysates from MERSnsp15H231A/DNS4a infected cells had decreased puromycin incorporation compared to WT MERS68

CoV at 24hpi, in one of two experiments and decreased puromycin incorporation compared to
WT MERS-CoV at 48hpi in the other experiment. These preliminary data suggest that activation
of the PKR pathway and phosphorylation of eIF2 α by MERS-nsp15H231A/DNS4a may induce an
increase in translation arrest above the levels of WT MERS-CoV.
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Fig 3.5 MERS-nsp15H231A/DNS4a strongly activates the PKR pathway. A549DPP4 cells were mock
infected or infected at an MOI of 5 and (A) cell lysates were harvested 24 and 48 hpi. Proteins were
separated by SDS-PAGE and immunoblotted with antibodies against phosphorylated PKR (p-PKR), PKR,
phosphorylated eIF2α (p-eIF2α), eIF2α, MERS-CoV N, and GAPDH. (B) Prior to cell lysate harvest, at 24
and 48hpi, cells were treated with puromycin (10 μg/ml) for 10 min. Proteins were separated by SDS-PAGE
and analyzed either by immunoblotting with antibodies against puromycin, MERS-CoV N, or GAPDH or
Coomassie stain for labeling of total proteins. Data are from one representative of four (A – 24 hpi), two (A48hpi), or one (B) independent experiments. Contributor: CEC, DMR, CJO
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dsRNA expression is increased when EndoU is inactive during MERS-CoV infection
Finally, we sought to examine expression of dsRNA during infection with MERS- nsp15H231A
versus WT MERS-CoV. Previous work showed that inactivation of EndoU during MHV infection
resulted in increased dsRNA expression and activation of the innate immune pathways IFN, PKR,
and OAS/RNase L (Kindler et al., 2017). In several experiments we observed increased
expression of dsRNA during infection with MERS- nsp15H231A and MERS-nsp15H231A/DNS4a
compared to WT MERS-CoV in both A549DPP4 and Vero cells fixed with 4% paraformaldehyde at
24 hpi (Fig 3.6A). Detection of dsRNA was assessed by immunofluorescence assay (IF) using the
monoclonal antibody J2 directed dsRNA and imaged using widefield microscopy. To quantify this
observation, we infected A549DPP4 and Vero CCL81 cells at MOI=5 on glass coverslips and fixed
with 4% paraformaldehyde at 24 and 48 hpi. We performed combined fluorescent in situ
hybridization (FISH)/IF to detect dsRNA by staining with J2 antibody and N +ssRNA (by FISH)
and nsp8 viral protein to detect infected cells. We observed brighter staining of dsRNA in both
MERS- nsp15H231A and MERS-nsp15H231A/DNS4a compared to WT MERS-CoV (Fig 3.6B). Fiji
software was used for quantification as described in detail in section 3.3. Due to extensive cell to
cell fusion (syncytia), we were unable to outline individual infected cells for quantification. To
estimate quantification of dsRNA we outlined infected areas of images (syncytia and single cells)
using N+ssRNA staining and called them regions of interest (ROIs). We measured the mean gray
value (MGV) of fluorescence signal of dsRNA or nsp8 within each ROI, and recorded the ratio of
dsRNA MGV over nsp8 MGV for each ROI. These ratios were compared across different
infection conditions: WT MERS-CoV, MERS-nsp15H231A, MERS-DNS4a, and MERSnsp15H231A/DNS4a (Fig 3.6C). We observed statistically significant increases in dsRNA/nsp8
ratios in both MERS-nsp15H231A and MERS-nsp15H231A/DNS4a compared to WT MERS-CoV and
not MERS-DNS4a in this one experiment. These imaging data and preliminary quantification data
are similar to observations in previous studies with MHV showing that dsRNA expression is
increased when nsp15 EndoU is catalytically inactive (Hackbart et al., 2020; Kindler et al., 2017).
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Fig 3.6 dsRNA expression is increased when EndoU is inactive during MERS-CoV infection. (A)
Representative dsRNA staining in MERS-CoV infection: A549DPP4 cells were infected at MOI=3 and fixed at
24hpi with 4% paraformaldehyde and subjected to IF to detect dsRNA by 40x widefield microscopy. Nuclei
were stained by Hoechst, shown in blue, and dsRNA stained by J2 shown in white. (B) A549DPP4 and Vero
cells were mock infected or infected at MOI=5 and fixed as above at 24 and 48hpi. Representative images of
A549DPP4 cells, MOI=5, 48hpi used for quantification are shown. N+ssRNA was stained by FISH and dsRNA
and nsp8 were stained by IF using J2 and anti-snp8 serum. Nuclei were stained by Hoechst (DAPI). Images
were taken at 20X. (C) dsRNA was quantified by graphing the ratio of dsRNA mean gray value (MGV) over
nsp8 MGV in each infected ROI. An ROI was defined by thresholding for N+ssRNA staining in Fiji. Each dot
represents the ratio for that ROI. Data shown is from one independent experiment and mean plus SD is
shown. Statistical significance compared to WT MERS-CoV determined by one-way ANOVA. *, P ≤ 0.05;
**, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001. Data that were not statistically significant are not labeled.
Contributor: CEC
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3.5 DISCUSSION
Several studies have shown that WT MERS-CoV does not induce robust innate immune
responses in host cells. Building on our previous work, here we sought to learn more about the
interactions of accessory proteins NS4a and NS4b with the dsRNA-induced innate immune
pathways: IFN, PKR, and OAS/RNase L. Furthermore, we investigated the role of the catalytic
activity of conserved coronavirus EndoU domain of nsp15 during MERS-CoV infection. EndoU
activity has been shown to limit accumulation of dsRNA and thereby block induction of IFN,
OAS/RNase L, and PKR during murine coronavirus MHV, human coronavirus 229E, and severe
agricultural pathogen porcine epidemic diarrhea virus (PEDV) infection (Deng et al., 2017; Deng
et al., 2019; Kindler et al., 2017).

Using recombinant MERS-CoVs we were able to investigate the effects of NS4a, NS4b, and
EndoU separately and together. We found that recombinant mutant viruses with (1) inactivation of
the enzymatic activity of EndoU (nsp15H231A), (2) ablation of NS4a expression (DNS4a), or (3)
inactivation of the phosphodiesterase (PDE) activity of NS4b (NS4bH182R) alone do not exhibit
large replication defects in an immune-competent airway-derived epithelial cell line, A549DPP4,
similar to what was previously published on DNS4a and NS4bH182R (Comar et al., 2019).
Interestingly, we saw that the combination of inactivation of EndoU with ablation of NS4a
expression or inactivation of the PDE, MERS-nsp15H231A/DNS4a and MERS-nsp15H231A/
NS4bH182R, caused a significant replication defect of approximately one log10 PFU/mL in A549DPP4
cells, indicating activation of innate immune pathways may be limiting infectious virus production.
Based on previously published data with MHV, it would be interesting to examine the replication
of these viruses in primary cells and/or a mouse model, as inactivation of MHV EndoU or the NS2
PDE alone severely attenuates the virus in vivo and in primary bone marrow-derived
macrophages (Deng et al., 2017; Kindler et al., 2017; Zhao et al., 2012).
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Our findings demonstrate for the first time that EndoU activity functions to block activation of the
innate immune pathways IFN, PKR, and OAS/RNase L during MERS-CoV infection. We
observed that a mutant with catalytically inactive EndoU (MERS-nsp15H231A) may cause some
mild increase in IFN activity, however a double mutant with inactivated EndoU and either ablation
of NS4a expression (MERS-nsp15H231A/DNS4a) or inactivation of NS4b PDE catalytic activity
(MERS-nsp15H231A/NS4bH182R) significantly increases IFN and ISG mRNA expression late in
infection. This suggests these proteins play redundant roles in evasion of IFN induction during
MERS-CoV infection.

In a single experiment, we observed the most robust activation of RNase L late in infection with
MERS-nsp15H231A/NS4bH182R. We also observed mild activation of RNase L during infection with
MERS-nsp15H231A, MERS- NS4bH182R, and interestingly with MERS-nsp15H231A/DNS4a. This
suggests, that unlike what we have previously observed, NS4a may play a small role in blocking
activation of the OAS/RNase L pathway, however this effect is masked by the presence of
catalytically active NS4b. Again, these proteins, nsp15 encoding EndoU, NS4a, and NS4b appear
to be playing somewhat redundant roles in preventing (EndoU and NS4a) or antagonizing (NS4b)
RNase L activity, although mutation of NS4b alone or EndoU alone do subtly activate the
pathway. Finally, the activation of RNase L at 48hpi with MERS-nsp15H231A/NS4bH182R infection
still is not to the level of a virus, SINV, that robustly activates this pathway. This indicates that
ablation of all three proteins’ activities may be necessary to robustly activate RNase L during
infection. Alternatively, another cell type may be more appropriate to examine RNase L activation
by coronaviruses.

In our previous study we found that loss of NS4a expression during infection only mildly activated
PKR (Comar et al., 2019). Here we observed the absence of NS4a expression and inactivation of
EndoU during infection (MERS-nsp15H231A/DNS4a), MERS-CoV strongly activated the PKR
pathway at 24 and 48hpi, evidenced by phosphorylation of PKR and downstream substrate
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eIF2α. Interestingly MERS-nsp15H231A, did not cause any phosphorylation of PKR, indicating that
both NS4a and nsp15 EndoU are required to fully block activation of PKR, but NS4a may play a
more significant role in blocking induction of this pathway. Our preliminary data suggest that
MERS-nsp15H231A/DNS4a activation of PKR slightly increases translational arrest, beyond the
activities of nsp1, during MERS-CoV infection.

Similar to previously published work in MHV, we observed increased expression of dsRNA during
MERS-CoV infection when the EndoU catalytic domain was inactivated (MERS-nsp15H231) as
detected by J2 monoclonal antibody in several immunofluorescence experiments. In one
experiment, we attempted to quantify this difference, however the typical quantification method of
fluorescence signal per cell was not possible due to extensive cell to cell fusion and syncytia
formation in MERS-CoV infected cells. Instead we compared the ratios in infected cell areas of
mean fluorescence intensities of dsRNA to viral protein nsp8, which should not be higher in the
mutant viruses. We saw significant increases of dsRNA/nsp8 in both MERS- nsp15H231 and
MERS-nsp15H231A/DNS4a compared to WT MERS-CoV in both Vero and A549DPP4 cells, although
the timepoints where there were significant differences differed between cell types. A major
caveat of these experiments, is that each graphed ratio represents an area of infected cells,
which could contain one or several infected cells, and these are given the same “weight”.

Our observations suggest that nsp15’s EndoU activity, NS4a, and NS4b have redundant
functions to block or evade activation of the dsRNA-induced pathways. Each protein may play a
more significant role in blocking a particular pathway, for example NS4a for PKR and NS4b for
RNase L. Unlike in the MHV system, inactivation of EndoU catalytic activity alone did not lead to
robust activation of the pathways in MERS-CoV infection, highlighting the importance of studying
the function of these proteins in the context of different coronavirus infections and considering the
roles of both conserved replicase proteins and unique accessory proteins. MERS-CoV is adept at
evading activation of these dsRNA-induced pathways. Future experiments should study which
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pathway(s) restrict MERS-CoV replication, for example by using knock out cells for MAVS, PKR,
and RNase L and examining which of these knockouts might rescue replication of MERSnsp15H231A/DNS4a or MERS-nsp15H231A/NS4bH182R to WT MERS-CoV levels.

This study highlights the need for future work in the area of host-virus interactions during infection
by highly pathogenic coronaviruses. The mechanism by which NS4b blocks IFN induction is still
not known. The effects of removal or inactivation of NS4a, NS4b, and EndoU should be examined
in primary cells and an animal model (such as mice) to more fully understand the scope of their
roles in pathogenesis during infection. EndoU is an attractive antiviral drug target for current and
future highly pathogenic coronaviruses, as it is highly conserved in coronaviruses. The function of
nsp15 EndoU of the recently emerged SARS-CoV-2, cause of the COVID-19 pandemic, should
be examined in future work. SARS-CoV-2 encodes different accessory proteins than MERS-CoV,
none of which are homologs of NS4a or NS4b, and SARS-CoV-2, unlike MERS-CoV, moderately
activates the dsRNA-induced innate immune pathways (IFN, PKR, RNase L) (Li et al., 2021).
Therefore, we hypothesize that loss of EndoU activity during SARS-CoV-2 infection may lead to
more robust activation of these pathways and detrimental effects on replication and
pathogenesis. Finally, future work should focus on further investigating the mechanism of EndoU
activity and determining how its catalytic activity is regulated during coronavirus infection.
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4.1 SUMMARY
Coronaviruses are adept at evading host antiviral pathways induced by viral double-stranded
RNA, including interferon (IFN) signaling, oligoadenylate synthetase–ribonuclease L (OAS-RNase
L), and protein kinase R (PKR). While dysregulated or inadequate IFN responses have been
associated with severe coronavirus infection, the extent to which the recently emerged SARSCoV-2 activates or antagonizes these pathways is relatively unknown. We found that SARS-CoV2 infects patient-derived nasal epithelial cells, present at the initial site of infection, induced
pluripotent stem cell-derived alveolar type 2 cells (iAT2), the major cell type infected in the lung,
and cardiomyocytes (iCM), consistent with cardiovascular consequences of COVID-19 disease.
Robust activation of IFN or OAS-RNase L is not observed in these cell types, while PKR
activation is evident in iAT2 and iCM. In SARS-CoV-2 infected Calu-3 and A549ACE2 lung-derived
cell lines, IFN induction remains relatively weak; however, activation of OAS-RNase L and PKR is
observed. This is in contrast to MERS-CoV, which effectively inhibits IFN signaling as well as
OAS-RNase L and PKR pathways, but is similar to mutant MERS-CoV lacking innate immune
antagonists. Remarkably, OAS-RNase L and PKR are activated in MAVS knockout A549ACE2
cells, demonstrating that SARS-CoV-2 can induce these host antiviral pathways despite minimal
IFN production. Moreover, increased replication and cytopathic effect in RNASEL knockout
A549ACE2 cells implicates OAS-RNase L in restricting SARS-CoV-2. Finally, while SARS-CoV-2
fails to antagonize these host defense pathways, which contrasts with other coronaviruses, the
IFN signaling response is generally weak. These host-virus interactions may contribute to the
unique pathogenesis of SARS-CoV-2.
4.2 SIGNIFICANCE
SARS-CoV-2 emergence in late 2019 led to the COVID-19 pandemic that has had devastating
effects on human health and the economy. While early innate immune responses are essential
for protection against virus invasion and inadequate responses are associated with severe
COVID-19 disease, gaps remain in our knowledge of the interaction of SARS-CoV-2 with host
antiviral pathways. We have characterized the innate immune response to SARS-CoV-2 in
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relevant respiratory tract derived cells and cardiomyocytes and found that SARS-CoV-2 activates
two antiviral pathways, oligoadenylate synthetase–ribonuclease L (OAS-RNase L), and protein
kinase R (PKR), while inducing minimal levels of interferon. This in contrast to MERS-CoV, which
inhibits all three pathways. Activation of these pathways may contribute to the distinctive
pathogenesis of SARS-CoV-2.
4.3 INTRODUCTION
Severe acute respiratory syndrome coronavirus (SARS-CoV)-2 emerged in China in late 2019,
causing the COVID-19 pandemic with extensive morbidity and mortality, leading to major
changes in day-to-day life in many parts of the world. This was the third lethal respiratory human
coronavirus, after SARS-CoV in 2002 and Middle East respiratory syndrome coronavirus (MERSCoV) in 2012, to emerge from bats in the twenty-first century. Although these viruses are all
members of the Betacoronavirus genus (Llanes et al., 2020), each has caused a somewhat
different pattern of pathogenesis and spread in humans, with SARS-CoV-2 alone capable of
spreading from asymptomatic or presymptomatic individuals. Therefore, it is important to
understand how these viruses interact with their host.

Coronaviruses are enveloped with large, positive-sense single-stranded (ss)RNA genomes of
around 30kb that can infect a diverse range of mammals and other species. Coronaviruses use
much of their genomes, including their approximately 20 kb Orf1ab conserved replicase locus, to
encode proteins that antagonize host cell responses (Perlman and Netland, 2009). As a result,
they are remarkably adept at antagonizing double-stranded RNA (dsRNA)-induced pathways that
are essential components of the host innate immune response (Cruz et al., 2011; Dedeurwaerder
et al., 2014; Koetzner et al., 2010; Kopecky-Bromberg et al., 2007; Weiss and Navas-Martin,
2005). In addition, CoV lineage-specific genes encoding accessory proteins, which are nonessential for RNA replication and variable among CoV lineages, further divide the
Betacoronavirus genus (Cui et al., 2019). These accessory proteins often have functions in
antagonizing host cell responses and thus likely contribute to differences in pathogenesis and
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tropism observed among the different lineages (Comar et al., 2019; Kikkert, 2020; Zhao et al.,
2012).

Like other RNA viruses, coronaviruses produce dsRNA early during the infection cycle as a result
of genome replication and mRNA transcription (Sola et al., 2015). Host cell pattern recognition
receptors (PRRs) sense viral dsRNA as pathogenic non-self and respond by activating several
antiviral pathways critical for early defense against viral invasion. DsRNA sensing by cytosolic
PRRs can be divided into three key pathways – interferon (IFN) production, oligoadenylateribonuclease L (OAS-RNase L) activation, and protein kinase R (PKR) activation (Fig 4.1) (Hur,
2019). Detection of dsRNA by MDA5 during coronavirus infection (Roth-Cross et al., 2008), leads
to the production of type I (a/b) and type III (l) IFN. Upon binding to its specific cell surface
receptor, IFN triggers phosphorylation of STAT1 and STAT2 transcription factors, which then
induce expression of IFN stimulated genes (ISGs) with antiviral activities (Lopusna et al., 2013;
Platanias, 2005). In parallel, dsRNA is also sensed by oligoadenylate synthetases (OASs),
primarily OAS3, which synthesize 2’,5’-linked oligoadenylates (2-5A) (Li et al., 2016; Whelan et
al., 2019), which induce dimerization and activation of RNase L, leading to degradation of viral
and host ssRNA (Dong and Silverman, 1995). Finally, dsRNA sensing by PKR induces PKR
autophosphorylation, permitting PKR to then phosphorylate the translation initiation factor eIF2a,
which results in protein synthesis shutdown and restriction of viral replication (Sadler and
Williams, 2008). While RNase L and PKR antiviral activity is not dependent on IFN production
(Whelan et al., 2019), the genes encoding OASs and PKR are ISGs, therefore these pathways
can be activated and/or reinforced by IFN production. Similarly, RNase L and PKR activation can
promote cellular stress, inflammation, and/or apoptotic death (Banerjee et al., 2014; Castelli et al.,
1997; Chakrabarti et al., 2015; Kang and Tang, 2012; Malathi et al., 2007; Zhou et al., 1997), thus
further reducing host cell viability.
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Fig 4.1 Double-stranded RNA induced innate immune responses during coronavirus infection.
Coronavirus dsRNA is recognized by cytosolic OAS, MDA5, or PKR to activate innate immune pathways.
MDA5 signals through MAVS, leading to type I and type III IFN production and subsequent ISG transcription
and cytokine responses. OASs produce 2’-5’-oligoadenylates (2-5A) that activate RNase L, which cleaves
host and viral ssRNA to trigger apoptosis and inflammation. PKR autophosphorylates before
phosphorylating eIF2a, which leads to translational arrest, cell death, and inflammatory responses. Graphic
was created with BioRender.com.

Induction and inhibition of innate immune responses during infection with SARS-CoV-2 have yet
to be fully characterized. Several recent reports implicate genetic deficiencies in IFN responses
(Bastard et al., 2020; Zhang et al., 2020) or polymorphisms in OAS genes (Pairo-Castineira et al.,
2020) with more severe COVID-19 disease, emphasizing the importance of understanding the
interactions between SARS-CoV-2 and these innate response pathways. Furthermore, while it is
known that SARS-CoV-2 enters the human body through the upper respiratory tract, it is unclear
which cell types of the upper and lower respiratory system contribute to sustained infection and
resulting disease in the airways and elsewhere. We have performed SARS-CoV-2 infections of
primary nasal epithelial cells, induced pluripotent stem cell (iPSC)-derived alveolar type 2 cells
(iAT2), and iPSC-derived cardiomyocytes (iCM), which collectively represent the host tissues
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likely affected by clinical SARS-CoV-2 infection (Hou et al., 2020; Sharma et al., 2020). We
assessed viral replication in these cell types as well as the degree of ensuing dsRNA-sensing
responses. We also employed two lung derived immune-competent cells lines, Calu-3 and A549
cells, to investigate dsRNA-induced pathway activation during SARS-CoV-2 infection.
4.4 MATERIALS AND METHODS
Patient derived nasal epithelial cells, iPSC derived AT2 cells, iPSC derived cardiomyocytes as
well as A549ACE2 cells (and derived knockout cells) and Calu-3 cells were infected with SARSCoV-2 (USA-WA1/2020 strain), and in some cases SINV or MERS-CoV and MERS-CoVDNS4ab. Infected cells were analyzed for infectious virus production, viral antigen staining, IFN
and ISG mRNA expression by qRT-PCR, PKR activation by immunoblotting for phosphorylated
PKR and eIF2a, and for RNase L activation by integrity of rRNA on a Bioanalyzer. All of these
techniques are described in Supplemental Information, Materials and Methods. Readers may to
access the data, associated protocols, and materials by contacting either of the corresponding
authors.
4.5 RESULTS
SARS-CoV-2 replicates efficiently in cells derived from upper and lower respiratory tract.
We compared the replication of SARS-CoV-2 and MERS-CoV in nasal epithelial-derived cells, a
relevant site of infection in vivo (Fig 4.2A). For each virus, replication was similar in cells from four
different individuals, although the extent of replication was somewhat variable. The trends in
replication kinetics, however, were significantly different between SARS-CoV-2 and MERS-CoV
infections. Replication of SARS-CoV-2 increased until 96 hours post infection (hpi), but then
plateaued at nearly 106 plaque-forming units (PFU)/ml. MERS-CoV replication peaked at 96hpi,
at a lower titer than SARS-CoV-2, and produced fewer PFU/mL at later timepoints. Nasal
epithelial cell cultures were stained with antibodies to identify ciliated cells, a key feature of this
cell type, and either SARS-CoV-2 or MERS-CoV nucleocapsid (N) expression (Fig 4.2B). We
detected abundant N expression in both SARS-CoV-2 and MERS-CoV infected cells, at 48hpi.
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Interestingly, robust replication occurred in cultures from all three individuals, despite relatively
low ACE2 protein expression compared to that in the Calu-3 cell line (described below)(Fig 4.2C).

We measured dsRNA-induced host responses to SARS-CoV-2 infection, including type I and type
III IFN mRNA induction, RNase L activation, and PKR activation, in the nasal cells. For qRT-PCR
analysis, we extracted RNA from SARS-CoV-2 infected cultures from four different donors at
120hpi. We verified that virus was replicating by quantifying viral genome copies from intracellular
RNA (Fig S4.1A). We then quantified mRNA expression of IFN-b (type I IFN), IFN-l (type III IFN),
select ISGs (OAS2, IFIT1, IFIH1), and the neutrophil attracting chemokine IL-8 (CXCL8), which
has been implicated in nasal inflammation during viral infection (Mukaida, 2003; Turner et al.,
1998) (Fig 4.2D). There was some induction of IFN-b and to a lesser extent IFN-l mRNA, and
minimal induction of the ISG or CXCL8 mRNAs. Interestingly, this may be at least partially due to
high basal levels of IFN (notably IFN-l) and ISG (notably OAS2) mRNAs compared with other
cell types examined below, consistent with detectable basal levels MAVS and MDA5 protein (Fig
4.2C), which would result in weak fold changes in mRNA levels compared with mock infected
cells (Fig S4.2). We found no evidence of phosphorylation of STAT1 (Fig 4.2C). In addition, we
did not detect PKR activation in SARS-CoV-2 infected cells, as indicated by the lack of
phosphorylated PKR and eIF2a. Positive controls were provided by infected Calu-3 cells for
which pSTAT1, pPKR and peIF2 were detectable and by IFN treated nasal cells (pSTAT1 only).
Activation of the OAS-RNase L pathway was not observed, as indicated by the absence of 18S
and 28S rRNA degradation in SARS-CoV-2 infected cells from two donors (Fig 4.2E), despite
abundant RNase L protein expression (Fig 4.2C). (See Table S4.1).
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Fig 4.2 Infection of nasal epithelia-derived cells by SARS-CoV-2 and MERS-CoV. Nasal cells, cultured in
air-liquid trans-wells, were mock infected or infected apically with SARS-CoV-2 (MOI=5) and in (A) MERSCoV (MOI=5). (A) At indicated times, apically released virus was quantified by plaque assay on Vero-E6 cells.
Values are means ± SD (error bars). Statistical significance (not displayed) was determined by two-way
ANOVA (*, P < 0.05). One experiment was performed using four separate donors. (B) At 48hpi, nasal cells
were fixed and permeabilized. Nucleocapsid (N) protein (red) of SARS-CoV-2 and MERS-CoV was detected
with an anti-N antibody, and cilia (green) detected with an anti-type IV b-tubulin antibody by
immunofluorescence assay (IFA). One representative image is shown from at least three independent
experiments, with four donors for each virus infection. Scale bar = 100µm. (C) At 120hpi, cells were lysed,
and proteins were analyzed by immunoblotting with antibodies as indicated. One experiment using three
separate donors was performed. Cells from a fourth donor (#13) were mock treated or treated with IFNa (500
Units/ml) for one hour before lysis and protein lysates from Calu-3 cells [mock or SARS-CoV-2 (MOI=5)]
infected Calu-3 cells 24hpi were also analyzed. (D) At 120hpi, total RNA was harvested, and mRNA
expression level quantified by qRT-PCR. CT values were normalized to 18S rRNA and expressed as fold
change over mock displayed as 2-Δ(ΔCt). Technical replicates were averaged, the means for each replicate
displayed, ± SD. One experiment was performed using three separate donors (#9, #10, #11) samples. (E)
RNA was harvested from two donors at 120hpi and rRNA integrity determined by Bioanalyzer. The position of 28S
and 18S rRNA are indicated. Data shown are from one representative experiment of two independent experiments.
(See also Figs S4.1A, S4.2). Contributors: YL, DMR, JNW, LHT
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We next examined host innate immune responses during infection of alveolar type 2 cells (AT2),
a major target of SARS-CoV-2 infection in humans (Hou et al., 2020; Ng et al., 2016; Qian et al.,
2013). We employed induced pluripotent stem cell (iPSC)-derived AT2 cells (iAT2, SPC2 line)
expressing tdTomato from the endogenous locus of surfactant protein-C (SFTPC), an AT2 cell
specific marker (Jacob et al., 2019). As in nasal cells, virus replicated efficiently, reaching a titer
of 106 PFU/ml by 48hpi (Fig 4.3A). Staining of cultures with an anti-N antibody showed that most
of the iAT2 cells were infected, without obvious cytopathic effect (CPE) (Fig 4.3B). Notably,
SARS-CoV-2 infection of iAT2 cells was robust despite ACE2 expression being below the level of
detection by immunoblotting (Fig S4.1D). We observed activation of the PKR pathway as
indicated by both PKR and eIF2a phosphorylation (Fig 4.3C). We extracted RNA from infected
iAT2 cells for qRT-PCR analysis, verified these cells were replicating virus by quantifying genome
RNA copies (Fig S4.1B), and assessed IFN/ISG induction. As with the nasal cells, we observed
weak induction of IFN-b and IFN-l mRNA from infected cells (Fig 4.3D), as well as low levels of
MDA5 and MAVS protein (Roth-Cross et al., 2008) (Fig S4.1D). We used the alphavirus Sindbis
virus (SINV) as a positive control, which we have previously shown induces robust activation of
all dsRNA-induced pathways (Comar et al., 2019). Surprisingly, we observed greater increases in
OAS2 and IFIT1 mRNA expression by SARS-CoV-2 compared with SINV (Fig 4.3D), but with
minimal induction of IFIH1 mRNA expression, consistent with low MDA5 (encoded by IFIH1)
protein expression (Figs 4.3C, S4.1D). However, we did not observe phosphorylation of STAT1
(Fig 4.3C, S4.1D), as in the SARS-CoV-2 infected nasal cells, while IFN treatment provided a
positive control for p-STAT induction in AT2 cells (Fig S4.1D) Additionally, we did not observe any
degradation of rRNA in SARS-CoV-2 infected cells, and only weak degradation by SINV perhaps
due to relatively low expression of RNase L (Fig S4.1D), suggesting minimal activation of RNase
L in iAT2 cells in general. (See Table S4.1)
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Fig 4.3 Infection of iPSC-derived AT2 cells (iAT2) by SARS-CoV-2. iAT2 cells were mock infected or
infected with SARS-CoV-2 (MOI=5) or for (D&E) SINV (MOI=1). (A) At indicated times, supernatants were
collected and infectious virus was quantified by plaque assay on Vero-E6 cells. Values are means ± SD (error
bars). Data shown are one representative experiment from at least three independent experiments. (B) At
48hpi, cells were fixed and permeabilized. Expression of nucleocapsid (N) protein (green) of SARS-CoV-2
and the expression of SFTPC promoter control tdTomato fluorescent protein (AT2 marker in red) was
examined by IFA. Channels are merged with DAPI nuclear staining. Images shown are representative from at
least three independent experiments. Scale bar = 100µm. (C) At 48hpi, cells were lysed and proteins were
analyzed by immunoblotting with antibodies as indicated. Data shown are from one representative experiment
of two independent experiments. (D) At 16 (SINV) or 48 (SARS-CoV-2) hpi, total RNA was harvested, and the
mRNA expression level was quantified by qRT-PCR. CT values were normalized to 18S rRNA and expressed
as fold change over mock displayed as 2-Δ(ΔCt). Technical replicates were averaged and the means displayed,
± SD. Statistical significance was determined by Student t test (*, P < 0.05; **, P < 0.01; ***, P < 0.001). Data
shown are from one representative experiment of two independent experiments. (E) Total RNA was harvested at
16 (SINV) or 48 (SARS-CoV-2) hpi and rRNA integrity determined by Bioanalyzer. The position of 28S and 18S
rRNA and indicated. Data shown are from one representative experiment of two independent experiments. (See
also Figs S4.1B&D, S4.2). Contributors: YL, JNW, FLC-D
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SARS-CoV-2 replicates and induces innate immune responses in iPSC-derived
cardiomyocytes.
Since many COVID-19 patients experience cardiovascular symptoms and pathology (Lindner et
al., 2020; Shi et al., 2020b), we investigated SARS-CoV-2 infection of iPSC derivedcardiomyocytes (iCM). SARS-CoV-2 replicated robustly in these cells, reaching titers of
approximately 106 PFU/ml by 48hpi (Fig 4.4A). Cells were stained with an antibody against
cardiac troponin-T (cTnT) as a marker for cardiomyocytes, and an anti-N antibody to identify
infected cells (Fig 4.4B). We detected clear CPE including syncytia in the iCM, which is typical of
coronaviruses (Belouzard et al., 2009; de Haan et al., 2004; Gombold et al., 1993; Qiu et al.,
2006; Yamada and Liu, 2009) but was not observed in infected nasal and iAT2 cells.
Interestingly, while we observed detectable ACE2 protein expression in mock infected or SINV
infected cells in two independent experiments, we observed reduced ACE2 expression upon
SARS-CoV-2 infection, consistent with a recent study (Sharma et al., 2020) (Fig S4.1D) As in
iAT2 cells, we observed phosphorylation of PKR and eIF2a, indicating that the PKR antiviral
pathway is activated (Fig 4.4C). We extracted RNA from mock infected cells and cells infected
with SARS-CoV-2 or SINV, verified that virus was replicating by quantifying viral genome (Fig
S4.1C), and quantified expression of mRNAs for IFNs and select ISGs. We found low levels of
IFN/ISG transcripts in iCM similar to the nasal and iAT2 cells (Fig 4.4D), perhaps due to the
undetectable levels of MDA5 protein expression in these cells (Fig S4.1D). SINV also induced
host mRNAs weakly, with the exception of IFN-l (Fig 4.4D). We observed no degradation of
rRNA, suggesting an absence of RNase L activation in iCM with SARS-CoV-2 or SINV (Fig 4.4E),
despite clear infection with both viruses (Fig S4.1C). This was not surprising as there was low
RNase L expression detectable by immunoblot in these cells (Fig S4.1D). (See Table S4.1)
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Fig 4.4 Infection of iPSC-derived cardiomyocytes (iCM) by SARS-CoV-2. iCM were mock infected or
infected with SARS-CoV-2 or, for panels C-E, SINV (MOI=1). (A) At indicated times, supernatants were
collected and virus quantified by plaque assay on Vero-E6 cells. Values are means ± SD. Data are one
representative experiment from at least three independent experiments. (B) At 48hpi, iCM were fixed and
permeabilized, the expression of SARS-CoV-2 N (green) of and of cTnT protein (red) was examined by IFA.
Channels are merged with DAPI nuclear staining. Images shown are representative of three independent
experiments. Scale bar = 50µm. (C) At 16 (SINV) or 48 (SARS-CoV-2) hpi, cells were lysed and proteins were
analyzed by immunoblotting with antibodies as indicated. Immunoblots were performed at least two times and
one representative blot is shown. (D) At 16 (SINV) or 48 (SARS-CoV-2) hpi, total RNA was harvested, the
mRNA expression levels were quantified by qRT-PCR. CT values were normalized to 18S rRNA and
expressed as fold change over mock displayed as 2-Δ(ΔCt). Technical replicates were averaged, the means for
each replicate displayed, ± SD (error bars). Statistical significance was determined by Student t test (*, P <
0.05; ****, P < 0.0001; ns = not significant). Data are from one representative experiment of two independent
experiments. (E) Total RNA was harvested at 16 (SINV) or 48 (SARS-CoV-2) hpi, and rRNA integrity determined
by Bioanalyzer. The position of 28S and 18S rRNA and indicated. Data shown are from one representative
experiment of two independent experiments. (See also Figs S4.1C&D, S4.2). Contributors: YL, JNW, RT
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SARS-CoV-2 replicates and induces dsRNA responsive pathways in respiratory epithelial
cell lines.
To further characterize the relationship between SARS-CoV-2 and dsRNA-induced host response
pathways, we chose two respiratory epithelium-derived human cell lines, A549 and Calu-3, both
of which are immune competent and have been used for studies of SARS-CoV (Blanco-Melo et
al., 2020) and MERS-CoV (Comar et al., 2019; Thornbrough et al., 2016). A549 cells are not
permissive to SARS-CoV-2, due to lack of expression of the SARS-CoV-2 receptor ACE2 (Fig
S4.3A). Therefore, we generated A549 cells expressing the ACE2 receptor (A549ACE2) by
lentiviral transduction, and used two single cell clones, C44 and C34, for all experiments. Both
A549ACE2 clones express high levels of ACE2 greater than the endogenously expressed ACE2 in
Calu-3 cells (Fig S4.3A) and in the primary cells discussed above (Figs 4.2C, S4.1D).

We performed single step growth curves to measure replication of SARS-CoV-2 in A549ACE2
cells, simian Vero-E6 cells, which are commonly used to prepare SARS-CoV-2 stocks, and Calu3 cells. SARS-CoV-2 replicated robustly in A549ACE2 and Vero-E6 cells (Fig S4.3B), although viral
yields were lower in Calu-3 cells (Fig S4.3C). Since Calu-3 cells also support MERS-CoV
infection, we compared SARS-CoV-2 replication to that of wild-type (WT) MERS-CoV and MERSCoV-DNS4ab, a mutant lacking host cell antagonists NS4a, a dsRNA-binding protein, and NS4b,
a 2’5’-phosphodiesterase that prevents RNase L activation and nuclear translocation of NF-kB
(Canton et al., 2018; Comar et al., 2019). Consistent with our previous work (Comar et al., 2019),
MERS-CoV-DNS4ab reduced viral titers from WT MERS-CoV levels, although they remained
higher than SARS-CoV-2 titers (Fig S4.3C). We stained A549, Vero-E6, and Calu-3 cells with
antibodies against viral N protein and dsRNA (Fig S4.3D), and observed CPE in all three cell
types, with N localized to the cytoplasm. Syncytia were observed in A549ACE2 and Calu-3 cells,
but not in Vero-E6 cells (Fig S4.3D). We also observed viral dsRNA localized to perinuclear foci
as we and others have described during infection with other coronaviruses (Comar et al., 2019;
Knoops et al., 2008; Lundin et al., 2014; Rabouw et al., 2016).
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We used qRT-PCR to quantify the induction of type I and type III IFNs and select ISGs (Fig 4.5A),
as well as the intracellular viral genome copies to verify replication (Fig 4.5B) in A549ACE2 cells
(clone 44). We found relatively low levels of both IFN-b and IFN-l mRNA at 24 and 48hpi by
SARS-CoV-2, compared to SINV (Fig 4.5A). Notably, IFN induction was greater than observed in
the nasal, iAT2, or iCM cells, possibly due in part to lower basal levels of IFN-b but not IFN-l
mRNA in the A549ACE2 cells, which allow for greater fold changes over mock infected cells (Fig
S4.2). Levels of ISG mRNAs were variable, with SARS-CoV-2 inducing moderate levels of OAS2
and IFIT1 mRNAs, but only late in infection (48hpi), similar to those induced by SINV at 24hpi
(Fig 4.5A). We observed minimal effects on mRNA levels of IFIH1 and CXCL8 at both timepoints
(Fig 4.5A). Furthermore, we did not detect any STAT1 phosphorylation at 24hpi (Fig S4.3E),
which correlates with weak ISG expression, suggesting defective IFN signaling downstream of
IFN production. Similar data for clone 33 are shown in Fig S4.4.
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Fig 4.5 SARS-CoV-2 IFN responses in A549ACE2 cell line. A549ACE2 cells (clone 44) were mock infected or
infected with SARS-CoV-2 (MOI=5) or, for panel A, SINV (MOI=1). (A) Total RNA was harvested at 24 and
48hpi and mRNA expression was quantified by qRT-PCR. CT values were normalized to 18S rRNA and
expressed as fold change over mock displayed as 2-Δ(ΔCt). Technical replicates were averaged, the means for
each replicate displayed, ± SD (error bars). (B) Viral genome copies per ug of total RNA were calculated at
24 and 48hpi by qRT-PCR standard curve. Values are means ± SD (error bars). Statistical significance was
determined by one-way ANOVA (*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; ns = not significant).
(See also Figs S4.2, S4.3, S4.4). Contributors: CEC and JNW

We used Calu-3 cells to compare IFN/ISG responses among SARS-CoV-2, WT MERS-CoV,
another lethal human CoV, and IFN antagonist-deficient MERS-CoV-DNS4ab (Fig 4.6A).
Although we observed reduced MERS-CoV-DNS4ab infectious virus production compared with
WT MERS-CoV (Fig S4.3C), we detected similar intracellular viral genome levels of all three
viruses (Fig 4.6B). We found previously that MERS-CoV-DNS4ab induces higher levels of IFNs
and ISGs compared to WT MERS-CoV, and also activates RNase L and PKR (Comar et al.,
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2019). Herein, in Calu-3 cells, we observed greater SARS-CoV-2 induction of IFN mRNAs as
compared to A549ACE2 cells (Figs 4.5A, S4.4B). Interestingly, SARS-CoV-2 induced higher IFN
mRNA levels than WT MERS-CoV at 24 and 48hpi (Fig 4.6A). Similarly, SARS-CoV-2 generally
induced more ISG mRNA than WT MERS-CoV, and even more OAS2 mRNA than MERS-CoVDNS4ab (Fig 4.6A). Induction of CXCL8 mRNA expression was weak for all viruses (Fig 4.6A).
Notably, SARS-CoV-2 induced ISG mRNAs in Calu-3 (24hpi) without the delay observed in
A549ACE2 cells. Consistent with earlier ISG mRNA induction during infection, SARS-CoV-2
infection promoted phosphorylation of STAT1 in Calu-3 cells (Fig 4.6C), as recently reported
(Lokugamage et al., 2020). SARS-CoV-2 induced phosphorylation of STAT1 as well as rapid
IFIT1 and OAS2 mRNA induction suggests a similar host response to SARS-CoV-2 as that
observed during mutant MERS-CoV-DNS4ab infection, and not that of WT MERS-CoV infection.
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Fig 4.6 SARS-CoV-2 and MERS-CoV IFN responses in the lung-derived Calu-3 cells. Calu-3 cells were
mock treated or infected with SARS-CoV-2, MERS-CoV or MERS-CoV-ΔNS4ab (MOI=5). (A) At 24 or 48hpi,
total RNA was harvested and expression of mRNA was quantified by qRT-PCR. CT values were normalized
to 18S rRNA and expressed as fold change over mock displayed as 2-Δ(ΔCt). Technical replicates were
averaged, the means for each replicate displayed, ± SD (error bars). Statistical significance was determined
by two-way ANOVA (*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; ns = not significant). (B) Viral
genome copies/ug of total RNA were calculated by qRT-PCR standard curve generated using a digested
plasmid encoding SARS-CoV-2 nsp12 or plasmid encoding a region of MERS-CoV orf1ab. Values are
means ± SD (error bars). Statistical significance was determined by two-way ANOVA (*, P < 0.05; **, P <
0.01; ns = not significant). (C) At 24hpi, Calu-3 cells were lysed and proteins harvested. Proteins were
analyzed by immunoblotting using the indicated antibodies. All data are one representative experiment of
three independent experiments. (See also Figs S4.2, S4.3). Contributors: DMR and CEC
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SARS-CoV-2 infection activates RNase L and PKR.
We found that in A549ACE2, SARS-CoV-2 promoted activation of RNase L as indicated by rRNA
degradation by 24hpi, which was more clearly observed at 48hpi, using SINV as a positive control
(Fig 4.7A). In Calu-3 cells, SARS-CoV-2 activated RNase L to a similar extent as MERS-CoVDNS4ab (Fig 4.7B), while MERS-CoV failed to activate this pathway (Comar et al., 2019;
Thornbrough et al., 2016) (Fig 4.7B). We also observed activation of PKR as indicated by
phosphorylation of PKR and eIF2a, in both A549ACE2 cells (Figs 4.7C, S4.4D) and Calu-3 cells
(Fig 4.7D) infected with SARS-CoV-2. In Calu-3 cells, SARS-CoV-2 induced PKR
phosphorylation to a similar extent as MERS-CoV-DNS4ab, while WT MERS-CoV failed to induce
a response. These data are consistent with IFN/ISG induction data, suggesting that SARS-CoV-2
may not antagonize dsRNA pathways as efficiently as MERS-CoV, but instead induces host
responses similar to those observed during MERS-CoV-DNS4ab infection.
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Fig 4.7 SARS-CoV-2 infection leads to activation of RNase L and PKR in A549ACE2 and Calu-3 cells.
A549ACE2 and Calu-3 cells were mock infected or infected with SARS-CoV-2, MERS-CoV, or MERS-CoVΔNS4ab (MOI=5). Total RNA was harvested from A549ACE2 cells (A) or Calu-3 cells (B) at 24 and 48hpi. rRNA
integrity was assessed by Bioanalyzer. 28S and 18S rRNA bands are indicated. At 24hpi, A549ACE2 cells (C)
or Calu-3 cells (D) were lysed and proteins harvested for analysis by immunoblotting using the indicated
antibodies. All data are one representative experiment of three independent experiments. (See also Fig
S4.4D&E). Contributors: CEC, DMR, JNW
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We next constructed A549ACE2 cell lines with targeted deletions of MAVS, RNASEL, or PKR, as
we have done previously for parental A549 cells (Li et al., 2017; Li et al., 2016). We could then
use these cells to determine whether activation of IFN, RNase L, and/or PKR resulted in
attenuation of SARS-CoV-2 replication (Li et al., 2017; Li et al., 2016). We validated the knockout
(KO) A549ACE2 cell lines by western blot (Fig S4.5A) and compared replication of SARS-CoV-2 in
MAVS KO, RNASEL KO and PKR KO cells with levels in WT A549ACE2 cells (Fig 4.8A).
Interestingly, there was little effect on SARS-CoV-2 replication with MAVS or PKR expression
absent. However, at 48hpi in RNASEL KO cells, virus replication was two- to four-fold higher
compared to WT A549ACE2 cells (Fig 4.8A). While the difference in replication between RNASEL
KO and WT was not extensive, it was statistically significant in three independent experiments.
As a result of higher viral titers, infected RNASEL KO cells exhibited strikingly more CPE as
compared with WT, PKR KO, or MAVS KO cells, as demonstrated by crystal violet-staining of
infected cells (Fig 4.8B).

We found that rRNA remained intact in the RNASEL KO A549ACE2 cells infected with SARS-CoV2 or SINV, which further validated these cells. However, rRNA was degraded in PKR or MAVS
KO cells, indicating RNase L activation in both of these cell types (Fig 4.8C). Similarly, the PKR
pathway was activated by SARS-CoV-2 (Fig 4.8D) and SINV (Fig S4.5B), as evidenced by
phosphorylation of PKR and eIF2a, in both RNASEL KO and MAVS KO cells. More pPKR was
detected in RNASEL KO cells than WT or MAVS KO cells, perhaps due to higher viral titer.
Moreover, phosphorylated eIF2a was observed in the absence of PKR during SARS-CoV-2
infection (Fig 4.8D) but not SINV (Fig S4.5B), suggesting that other kinases may contribute to
phosphorylation of eIF2a during infection with SARS-CoV-2 in particular (Fig 4.8D). These data
are consistent with our previous findings that SINV- and Zika virus (ZIKV)-induced activation of
RNase L does not depend on MAVS expression in A549 cells (Li et al., 2019; Whelan et al.,
2019). Similarly, our results demonstrate that the PKR pathway can also be activated
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independently of MAVS. Thus, RNase L and PKR activation occur in parallel with IFN production
(Fig 4.1), are not dependent on each other (Birdwell et al., 2016).

Fig 4.8 Replication of SARS-CoV-2 is restricted by RNase L independent of PKR or MAVS. Indicated
genes were knocked out (KO) from A549ACE2 cells using CRISPR-Cas9 engineering. (A) Cell lines were
infected with SARS-CoV-2 (MOI=1). At the times indicated, supernatant was collected and virus quantified by
plaque assay on Vero-E6 cells. Values represent mean ± SD. Statistical significance was determined by twoway ANOVA (****, P < 0.0001; ns = not significant). Data are one representative experiment from at least three
independent experiments. (B) Cells were mock treated or infected with SARS-CoV-2 (MOI=1). At 48hpi, cells
were fixed and stained with 1% crystal violet as a marker for live cells. The image is one representative
experiment from two independent experiments. (C) The indicated cell lines were mock infected or infected
with SARS-CoV-2 or SINV (MOI=1). RNA was harvested 24hpi (SINV) or 24 and 48hpi (SARS-CoV-2).
Integrity of rRNA was assessed by Bioanalyzer. 28S and 18S rRNA bands are indicated. Data are one
representative of two independent experiments. (D) Mock infected or SARS-CoV-2 (MOI=1) infected cells
were lysed at 48hpi and proteins harvested. Proteins were analyzed by immunoblotting using the indicated
antibodies. Data are from one representative of two independent experiments. (See also Fig S4.5).
Contributors: YL and HMR
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4.6 DISCUSSION
We evaluated viral replication and host responses to SARS-CoV-2 infection in primary nasal
epithelial-derived cells, iPSC-derived type II airway (iAT2) cells, as well as iPSC-derived
cardiomyocytes (iCM), another likely target of infection (Sharma et al., 2020). To complement
these studies, we used two lung-derived cell lines, Calu-3 and A549ACE2, to more mechanistically
dissect the interactions of SARS-CoV-2 with host antiviral pathways. Infection of nasal cells, iAT2
cells, and iCM resulted in high levels of SARS-CoV-2 replication, while only iCM exhibited
obvious CPE (Figs 4.2-4.4). Syncytia formation was observed in both A549ACE2 and Calu-3 cell
lines, with dsRNA localized to perinuclear areas, typical of CoV infection (Fig S4.3D). The protein
expression level of the SARS-CoV-2 host receptor ACE2 (Lu et al., 2020; Wan et al., 2020; Zhou
et al., 2020) was either low (nasal cells) or undetectable (iAT2 cells), indicating that high levels of
receptor are not necessary for productive infection (Figs 4.2-4.4, S4.3). This is similar to previous
observations in the murine coronavirus system where viral receptor CEACAM1a is only weakly
expressed in the mouse brain, a major site of infection, and particularly in neurons, the most
frequently infected cells (Bender et al., 2010).

We compared SARS-CoV-2 and MERS-CoV replication in nasal epithelial cells, and found that
SARS-CoV-2 replicates to higher titer than MERS-CoV, and that the time period for shedding of
virus is much longer (Fig 4.2A). We suggest that this longer period of replication in nasal cells and
stronger immune responses in Calu-3 cells may in part explain why SARS-CoV-2 is less virulent,
yet more contagious than MERS-CoV (Oh et al., 2016; Sanche et al., 2020).

As we have observed among murine cells, we saw vastly different levels of basal expression of
both IFN and ISG mRNAs among the cell types (Fig S4.2) (Li and Weiss, 2016; Zhao et al., 2013;
Zhao et al., 2011). Higher basal levels of innate immune response mRNAs typically result in a
lower threshold for activation of corresponding responses. Interestingly, we observed significantly
higher basal levels, especially IFN-l, in (uninfected) nasal cells as compared to iAT2 cells and
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iCM (Fig S4.2A). As major barrier cells, we speculate that this may be important for protection as
these cells are more often exposed to infectious agents in the environment. Indeed, it is well
documented that IFN-l serves as an added defense for epithelial cells, which may explain some
of the differences observed in basal gene expression between nasal cells and iCM (Ank et al.,
2008; Forero et al., 2019; Galani et al., 2017). As previously reported in heart tissue, the iCM
expressed undetectable or low levels of both MDA5, and RNase L (Uhlén et al., 2015; Zhou et al.,
1997), which is possibly to protect the heart from excessive inflammation.

We found that in A549ACE2 cells, SARS-CoV-2 induced low levels of IFN-l and IFN-b mRNAs and
somewhat higher ISG mRNA by 48hpi, as compared with SINV, which we used as a control for
robust activation of IFN (Figs 4.5A, S4.4B). We observed greater increases in IFN induction in
Calu-3 compared to A549ACE2 (Fig 4.6A), which may be at least partially due to higher basal levels
of IFIH1 (MDA5) expression in the Calu-3 cells (Fig S4.2). Calu-3 cells were employed to directly
compare the host response to SARS-CoV-2 infection with that of MERS-CoV and mutant MERSCoV-DNS4ab, which lacks the NS4a and NS4b proteins that inhibit IFN production and signaling
(Canton et al., 2018; Comar et al., 2019; Rabouw et al., 2016). In Calu-3 cells, SARS-CoV-2
induced more IFN mRNA than WT MERS-CoV, approaching the level of MERS-CoV-DNS4ab
(Fig 4.6A). Furthermore, SARS-CoV-2 induced higher levels of ISG mRNAs than MERS-CoV
and, in the case of OAS2, higher than MERS-CoV-DNS4ab as well. Similarly, SARS-CoV-2 and
MERS-CoV-DNS4ab, but not WT MERS-CoV, promoted STAT1 phosphorylation (Fig 4.6C).
Overall, our results displayed a trend of relatively weak IFN responses induced by SARS-CoV-2
in airway epithelial cells with limited ISG induction, which is consistent among betacoronaviruses.
This is in agreement with recent reports that multiple SARS-CoV-2 proteins inhibit both IFN
induction and signaling pathways (Miorin et al., 2020; Xia et al., 2020). Additionally, our data
show that enhanced IFN/ISG responses in Calu-3 cells restrict virus production, while lower host
responses in A549ACE2 cells correlate with higher viral titers (Fig S4.3). Considering how robust
ACE2 expression appears dispensable for infection of some cell types (nasal, iAT2, Calu-3),
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these data also indicate that stronger innate immune responses may be more effective at
restricting SARS-CoV-2 replication than low ACE2 expression level.

SARS-CoV-2 activated RNase L and PKR, although to different extents among the cell types
(Table S4.1), unlike MERS-CoV and mouse hepatitis virus (MHV), which shut down these
pathways (Comar et al., 2019; Ye et al., 2007; Zhao et al., 2012). PKR was activated in SARSCoV-2 infected iAT2 cells (Fig 4.3C) and iCM (one/two experiments) (Fig 4.4C), but not in nasal
cells (Fig 4.2C). However, RNase L activation was not detected in these cell types (Figs 4.2E,
4.3E, 4.4E). Activation of both RNase L and PKR were observed in A549ACE2 and Calu-3 cells
during infection with SARS-CoV-2 (Figs 4.7, S4.4). In Calu-3 cells, this contrasted MERS-CoV
and was more similar to MERS-CoV-DNS4ab. Overall, our findings suggest SARS-CoV-2 is less
adept at antagonizing host responses than MERS-CoV. Previous studies have shown that
MERS-CoV NS4a binds to dsRNA, reducing its accessibility to PKR (Comar et al., 2019; Rabouw
et al., 2016) and NS4b prevents RNase L activation by degrading 2-5A (Comar et al., 2019;
Thornbrough et al., 2016). Current understanding of SARS-CoV-2 protein function infers an
absence of these types of protein antagonists, therefore it is not surprising that both of these
pathways are activated during infection. Indeed, MERS-CoV-DNS4ab attenuation compared to
WT MERS-CoV, as well as lower SARS-CoV-2 titers than those of MERS-CoV (Fig S4.3C), may
be at least in part due to RNase L and PKR activation in addition to IFN/ISG induction in Calu-3
cells.

KO of MAVS and the consequent loss of IFN production had no significant effect on viral titer or
cell death. Similarly, PKR KO had no effect on viral titer and infected cells still produced
detectable levels of phosphorylated eIF2α. This is consistent with a previous report describing
activation of both PKR and PKR-like ER Kinase (PERK) contributed to eIF2α phosphorylation
during SARS-CoV infection (Krahling et al., 2009). Our results therefore raise the possibility that
SARS-CoV-2 infection activates multiple kinases of the integrated stress response, all of which
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target eIF2α. We have previously found that MERS-CoV infection inhibits host protein synthesis
independent of PKR, so that PKR phosphorylation during MERS-CoV-DNS4ab infection did not
lead to further reduction (Comar et al., 2019).

Increased, albeit modest, replication and enhanced cell death in SARS-CoV-2 infected RNASEL
KO cells indicates that this pathway indeed restricts replication and downstream cell death
caused by SARS-CoV-2 (Fig 4.8A&B). In addition, RNase L was activated in MAVS KO cells
consistent with previous findings that RNase L activation can occur independently of virusinduced IFN production in A549 cells (Li et al., 2019; Whelan et al., 2019). The activation of
RNase L in MAVS KO cells was not due to increased RNA replication and dsRNA relative to WT
cells as the same levels of SARS-CoV-2 genomes was detected in WT and KO cells (Fig S4.5C).
We extend these findings to demonstrate that PKR activation, like OAS-RNase L, can occur
independently of MAVS signaling, perhaps explaining the phosphorylation of PKR and eIF2a in
iCM, despite the weak IFN induction (Fig 4.4). This underscores the importance of the RNase L
and PKR antiviral pathways, which can be activated early in infection upon concurrent dsRNA
sensing by OAS, PKR, and MDA5 receptors before IFN is produced, or alternatively in cells
infected by virus that produce low levels of IFN only late in infection, as we observe here with
SARS-CoV-2. Further studies are required to determine whether activation of PKR or RNase L
during SARS-CoV-2 infection results in functional outcomes characteristic of these pathways,
including inhibition of protein synthesis, apoptosis, or induction of inflammatory responses (Fig
4.1). Interestingly, we observed possible RNase L-induced apoptosis in the SARS-CoV-2 infected
A549ACE2 WT, MAVS KO, and PKR KO cells, when compared with mock infected counterparts
(Fig 4.8B). However, RNASEL KO cells displayed the most cell death among the four cell lines,
suggesting that virus-induced cell lysis in the RNASEL KO cells where viral titers are highest (Fig
4.8B) is more detrimental to cells than RNase L-induced programmed cell death.
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4.7 SUPPLEMENTAL INFORMATION
Supplemental Figures

Table S4.1 Pathway activation during SARS-CoV-2 infection.
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Fig S4.1 Genome replication in nasal cells, iAT2, and iCM. Nasal (A) and iAT2 cells (B) were infected at
MOI=5 with SARS-CoV-2, and (C) iCM at MOI=1 with SARS-CoV-2 or SINV. Total RNA was harvested at
48hpi (SARS-COV-2) or 16hpi (SINV) for iAT2 and iCM cells and 120hpi for nasal cells. Viral genome copies
per ug of harvested RNA were calculated by qRT-PCR standard curve generated using a digested plasmid
encoding SARS-CoV-2 nsp12. Values are means ± SD (error bars). For SINV (C), cycle threshold (CT) values
of SINV nsP4 polymerase sequences were normalized to 18S rRNA to generate DCT values (DCT = CT gene
of interest - CT 18S rRNA). Technical triplicates were averaged and displayed using the equation 2-(DCT). (D)
Cells were infected with SARS-Cov-2 [Calu-3 and AT2 (MOI=5); iCM (MOI=1)], lysed at 24 hpi or treated with
IFNa (500 Units/ml), lysed after one hour and proteins harvested for analysis by immunoblotting using the
indicated antibodies. Data are from one representative experiment of two independent experiments.
Contributors: DMR, JNW, YL
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Fig S4.2 Host basal mRNA expression of uninfected cells. Total RNA was harvested from mock treatment
from all indicated cell types after 24 hours of incubation. mRNA expression levels of IFNB, IFNL1, OAS2,
IFIT1, IFHI1, and CXCL8 were quantified by qRT-PCR. CT values were normalized to 18S rRNA to generate
DCT values (DCT = CT gene of interest - CT 18S rRNA). (A) Basal level of gene expression is displayed for
nasal cells, iAT2 and iCM, Calu-3 cells and two clones of A549ACE2 cells, displayed as 2-ΔCt. (B) Fold
expression over A549ACE2 C44 values were calculated by subtracting ΔCT values from the indicated cell line
from A549ACE2 C44 ΔCT values, displayed as 2-Δ(ΔCT). Biological replicates were averaged and values are
means ± SD (error bars). Data were generated from at least two independent experiments. Contributors:
DMR and JNW
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Fig S4.3 Infection of A549ACE2 and Calu-3 cell lines. (A) Parental A549 cells, two A549ACE2 clones, and
Calu-3 cells were grown in culture before lysis and protein harvest. Protein expression was analyzed by
immunoblotting using the indicated antibodies. (B) Vero-E6 or A549ACE2 (clone 44) cells were infected with
SARS-CoV-2 (MOI=1). At the indicated times, supernatant was collected and virus quantified by plaque assay
on Vero-E6 cells. Values are means ± SD (error bars). (C) Calu-3 cells were infected with SARS-CoV-2,
MERS-CoV or MERS-CoV-ΔNS4ab (MOI=1). Supernatant was collected at the indicated times and virus
quantified by plaque assay on Vero-E6 cells (SARS-CoV-2) or VeroCCL81 cells (MERS-CoV and MERS-CoVΔ4ab). Values represent means ± SD (error bars). Statistical significance was determined by Student t test
(**, P < 0.01). Data shown are one representative experiment of three independent experiments. (D) Vero-E6,
A549ACE2 (clone 34), and Calu-3 cells infected with SARS-CoV-2 (MOI = 1) and at 24hpi (Vero-E6 and A549
ACE2
) or 48hpi (Calu-3), cells were fixed, permeabilized and stained with anti-N antibodies (green) and antidsRNA antibody (J2, red) by IFA. Channels are merged with DAPI nuclear staining. Images shown are
representative from two independent experiments. Scale bar = 25µm. (E) A549 C44 cells were treated with
IFNa (500 U/ml) for one hour, lysed and proteins harvested. Protein expression, along with lysates of mock
infected and SARS-CoV-2 infected C34, C44 and Calu-3 cells, lysed at 24hpi, were analyzed by
immunoblotting using the indicated antibodies. The arrow indicates the phosphorylated STAT1 band.
Contributors: CEC, DMR, YL, HMR
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Fig S4.4. SARS-CoV-2 replication and host responses in a second lung epithelia-derived A549ACE2 cell
line clone (C34). (A) Vero-E6 or A549ACE2 cells were infected with SARS-CoV-2 at MOI=1 and supernatant
harvested at indicated times post infection. Infectious virus was quantified by plaque assay on Vero-E6 cells.
Values are means ± SD (error bars). (B) A549ACE2 cells (C34) were mock infected or infected with SARS-CoV2 or SINV at MOI=5 and total RNA harvested at 24 (SINV) or 24 and 48 (SARS-CoV-2) hpi. Expression of
IFNB, IFNL1, OAS2, IFIT1, IFIH1, and CXCL8 mRNA was quantified by qRT-PCR. CT values were normalized
to 18S rRNA to generate DCT values (DCT = CT gene of interest - CT 18S rRNA). Fold change over mock values
were calculated by subtracting mock infected DCT values from virus infected DCT values, displayed as 2-Δ(ΔCt).
Statistical significance for each gene was determined by one-way ANOVA (***, P < 0.001; ****, P < 0.0001;
ns = not significant). Technical replicates were averaged, the means for each replicate displayed, ± SD (error
bars). (C&D) A549ACE2 cells were infected at MOI=5, lysed at 24hpi, and proteins harvested for analysis by
immunoblotting using the indicated antibodies. (E) A549ACE2 cells were infected at MOI=1 (SINV) or MOI=5
(SARS-CoV-2) and total RNA harvested at 24 (SINV) or 24 and 48 (SARS-CoV-2) hpi. Integrity of rRNA was
assessed by Bioanalyzer. 28S and 18s rRNA bands are indicated. All data are representative of two or three
independent experiments. Contributors: CEC and JNW
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Fig S4.5 Protein expression in A549ACE2 cells. (A) A549ACE2 KO cell lines were grown in culture with or
without 1000U IFN-α treatment for 24 hours. Cells were lysed and proteins harvested for analysis by
immunoblotting using the indicated antibodies. (B) Mock infected or SINV (MOI=1) infected A549ACE2 WT or
KO cells were lysed at 24hpi and proteins harvested. Proteins were analyzed by immunoblotting using the
indicated antibodies. (C) Cell lines (WT and KO) were infected with SARS-CoV-2 (MOI=1) and total RNA
harvested at 48hpi. Viral genome copies per ug of harvested RNA were calculated by qRT-PCR standard
curve generated using a digested plasmid encoding SARS-CoV-2 nsp12. Values are means ± SD (error bars).
There were no statistically significant differences between WT and each KO cell type, as determined by oneway ANOVA. All data are from one representative of two independent experiments. Contributors: YL and
HMR
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Materials and Methods
Viruses. SARS-CoV-2 (USA-WA1/2020 strain) was deposited by the Centers for Disease Control
and Prevention and obtained through BEI Resources, NIAID, NIH: SARS-Related Coronavirus 2,
Isolate USA-WA1/2020, NR-52281 and propagated in Vero-E6 cells. The genome RNA was
sequenced was found to be identical to GenBank: MN985325.1. Recombinant MERS-CoV and
MERS-CoV-DNS4ab were described previously (Comar et al., 2019) and were propagated in
Vero-CCL81 cells. Sindbis virus Girdwood (G100) was obtained from Dr. Mark Heise, University
of North Carolina, Chapel Hill, and was prepared as previously described (Suthar et al., 2005).
All infections and virus manipulations were conducted in a biosafety level 3 (BSL-3) laboratory
using appropriate and approved personal protective equipment and protocols.
Cell lines. African green monkey kidney Vero cells (E6) or (CCL81) (obtained from ATCC) were
cultured in Dulbecco’s modified Eagle’s medium (DMEM; Gibco catalog no. 11965),
supplemented with 10% fetal bovine serum (FBS), 100 U/ml of penicillin, 100 μg/ml streptomycin,
50 μg/ml gentamicin, 1mM sodium pyruvate, and 10mM HEPES. Human A549 cells (verified by
ATCC) were cultured in RPMI 1640 (Gibco catalog no. 11875) supplemented with 10% FBS, 100
U/ml of penicillin, and 100 μg/ml streptomycin. Human HEK 293T cells were cultured in DMEM
supplemented with 10% FBS and 1 mM sodium pyruvate. Human Calu-3 cells (clone HTB-55)
were cultured in MEM supplemented with 20% FBS without antibiotics.
Primary cell cultures. Human sinonasal air liquid interface (ALI) cultures. ALI cultures were
established from enzymatically dissociated human sinonasal epithelial cells (HSEC) as previously
described (Lee et al., 2017; Lee et al., 2014) and grown to confluence with bronchial epithelial
basal medium (BEBM; Lonza, Alpharetta, GA) supplemented with BEGM Singlequots (Lonza),
100 U/ml penicillin and 0.25 µg /ml amphotericin B for 7 days. Cells were then trypsinized and
seeded on porous polyester membranes (2-3× 104 cells per membrane) in cell culture inserts
(Transwell-clear, diameter 12 mm, 0.4 µm pores; Corning, Acton, MA). Five days later the culture
medium was removed from the upper compartment and the epithelium was allowed to
differentiate by using the differentiation medium consisting of 1:1 DMEM (Invitrogen, Grand
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Island, NY) and BEBM (Lonza), supplemented with BEGM Singlequots (Lonza) with 0.1 nM
retinoic acid (Sigma-Aldrich), 100 UI/ml penicillin, 0.25 µg /ml amphotericin B and 2% Nu serum
(Corning) in the basal compartment. Cultures were fed every three days for 6 weeks prior to
infection with SARS-CoV-2. The day prior infection, the cells were fed and the apical side of the
cultures were washed with 100µl of warm PBS X 3.
Alveolar 2D cultures. iPSC (SPC2 iPSC line, clone SPC2-ST-B2, Boston University) derived
alveolar epithelial type 2 cells (iAT2) were differentiated and maintained as alveolospheres
embedded in 3D Matrigel in CK+DCI media, as previously described (Jacob et al., 2019). For
generation of 2D alveolar cells for viral infection, alveolospheres were dispersed into single cells,
then plated on pre-coated 1/30 Matrigel plates at a cell density of 125,000 cells/cm2 using
CK+DCI media with ROCK inhibitor for the first 48h and then the medium was changed to
CK+DCI media at day 3 and infected with SARS-CoV-2 virus.
Cardiomyocytes. Experiments involving the use of human iPSCs were approved by the
University of Pennsylvania Embryonic Stem Cell Research Oversight Committee. The iPSC line
(PENN123i-SV20) used for cardiomyocyte generation was derived by the UPenn iPSC core as
previously described (Pashos et al., 2017; Yang et al., 2015a). This line has been deposited at
the WiCell repository (Wicell.org). iPSCs were maintained on Geltrex (Thermofisher Scientific)coated plates in iPS-Brew XF (Miltenyi Biotec) media at 37oC in 5% CO2/5% O2/90% air
humidified atmosphere. Cells were passaged every 5-7 days using Stem-MACS Passaging
Solution (Miltenyi Biotec). Differentiation of SV20 into cardiomyocytes (iCMs) was performed
using previously described protocols (Laflamme et al., 2007; Palpant et al., 2017). In general,
iCMs were >95% positive for cardiac Troponin T staining by FACS. Day 18-25 differentiated cells
were replated and used for viral infection experiments.
Generation of A549ACE2 cells. A549ACE2 cells were constructed by lentivirus transduction of
hACE2. The plasmid encoding the cDNA of hACE2 was purchased from Addgene. The cDNA
was amplified using forward primer 5′-ACTCTAGAATGTCAAGCTCTTCCTGGCTCCTTC-3′ and
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TTGTCGACTTACGTAGAATCGAGACCGAGGAGAGGGTTAGGGATAGGCTTACCAAAGGAGG
TCTGAAC ′-3 (contained V5 tag sequences). The fragment containing hACE2-V5 was digested
by the XbaI and Sall restriction enzymes from the hACE2 cDNA and was cloned into pLenti-GFP
(Addgene) in place of green fluorescent protein (GFP), generating pLenti-hACE2-V5. The
resulting plasmids were packaged in lentiviruses and transduced into A549 cells which were
cultured, selected with hygromycin, cloned and screened for ACE2 expression as previously
described (Comar et al., 2019).
CRISPR/Cas9 engineered cells. RNASEL, PKR and MAVS KO A549ACE2 cells (clone 44) were
constructed using the same Lenti-CRISPR system and guide RNA sequences as previously
described (Li et al., 2017; Li et al., 2016).
Viral growth kinetics and titration. The nasal ALI cultures were apically infected with SARSCoV-2 (MOI=5) or MERS-CoV (MOI=5). Viral stocks were diluted in nasal cell media, 50µl was
added to each well, the cells were incubated in 37°C for one hour, then the virus was removed
and the cells were wash three times with 200µl of PBS. For viral growth curves, at indicated time
points, 200µl of PBS was added to the apical surface, collected 5 minutes later and frozen for
subsequent analysis of shed virus by plaque assay. The inserts were transferred to new 24-well
plates with fresh media after each collection. For iAT2 or iCM, cells were plated in 12 or 6-well
plates, 4X105 cells (iAT2) or 6.25X105 cells per well (iCM), cells were infected with SARS-CoV-2
at MOI=5 (iAT2) or MOI=1 (iCM). At 6, 24, 48 hours postinfection, 200μl of supernatant were
harvested and stored in -80°C for infectious virus titration. For infections, cell lines were plated in
12-well plates, A549 and Vero-E6 at 5X105 cells per well and Calu-3 at 3X105 cells per well.
Viruses were diluted in serum-free RPMI (A549 infections) or serum-free DMEM (Vero infections)
or serum-free MEM (Calu-3 infections) and added to cells for absorption for 1 hour at 37°C. Cells
were washed three times with PBS and fed with DMEM or RPMI +2% FBS for Vero and RPMI
infections, respectively, or 4% FBS in MEM for Calu-3 infections (Thornbrough et al., 2016). For
virus titration 200µl of supernatant was collected at the times indicated and stored at -80°C for
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plaque assay on Vero-E6 (SARS-CoV-2) or Vero-CCL81 (MERS-CoV) cells as previously
described (Scobey et al., 2013).
Interferon treatment. Cells were treated with 500U/ml universal interferon-a (PBL assay
science) for one hour and then lysed and prepared for western immunoblotting as described
below.
Immunofluorescent staining. For nasal ALI culture, following 48 hours of infection, the cultures
were fixed in 4% paraformaldehyde at room temperature for 30 minutes. The transwell supports
were washed 3 times with PBS prior to excision of the membrane containing the cells. The cells
were permeabilized with 0.2% Triton X-100 in PBS and then immersed in PBS with 0.2% Triton
X-100, 10% normal donkey serum, and 1% BSA for 60 min at room temperature. Primary
antibody incubation was incubated overnight at 4ºC (Type IV tubulin, Abcam ab11315, rabbit anti
SARS-CoV-2 Nucleocapsid protein, GeneTex, Irvine, CA). Visualization was carried out with
Alexa Fluor®-conjugated donkey anti-mouse or anti-rabbit IgGs (Thermo-Fisher) (1:1000; 60 min
incubation at room temperature). Confocal images were acquired with an Olympus Fluoview
System (Z-axis step 0.5μm; sequential scanning). For iAT2, the cell monolayer was fixed using
4% paraformaldehyde (PFA) for 30min, 1X PBS was used to removed PFA and proceed with
antibody staining. Fixed cells were treated with a blocking solution containing 0.1% Triton X-100
and 5% donkey serum in 1X PBS for 30min. Immunostaining was performed using the SARSCoV-2 nucleocapsid antibody at 1:1000 dilution in blocking solution incubated for 30min. After
washing primary antibody away, a secondary Alexa Fluor 488®-conjugated donkey anti-rabbit
IgG (H+L) antibody( Thermo-Fisher) was used at 1:400 dilution in blocking solution and incubated
for 30min. Secondary antibody was washed away with 1X PBS and DAPI was used for nuclear
staining at 2.5µg/ml. iCM were fixed in 4% paraformaldehyde and permeabilized with 0.1% Triton
X-100 for 15 min. Cells were blocked with 10% normal donkey serum (Sigma D9663) in 0.2%
Tween 20 (Biorad 170-6531) for 1hr. Antibodies against cardiac troponin T (cTnT, Abcam
ab8295; 1:100 mouse) and SARS-CoV-2 nucleocapsid were incubated with cells in blocking
solution overnight at 4 °C. Donkey anti-mouse Alexa Fluor 647®-conjugated (Invitrogen A31571)
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and Donkey anti-rabbit Alexa Fluor 488®-conjugated (Invitrogen A21206) were diluted 1:250 in
blocking solution and incubated with cells for 2hr at RT. Slides were mounted in Slowfade Gold
anti-fade reagent with DAPI (Invitrogen S36939). Images were acquired with BZ-X710 all-in-one
fluorescence microscope equipped with BZ-X Viewer software (Keyence Corporation). At the
indicated times post-infection, A549ACE2 or Calu-3 cells were fixed onto glass coverslips (Calu-3
coverslips were coated with rat tail collagen type-1: Cell Applications, Inc. Cat. # 122-20) with 4%
paraformaldehyde for 30 minutes at room temperature. Cells were then washed three times with
PBS and permeabilized for 10 minutes with PBS+0.1% Triton-X100. Cells were then blocked in
PBS and 3% BSA for 30-60 minutes at room temperature. Primary antibodies were diluted in
blocking buffer and incubated on a rocker at room temperature for one hour. Cells were washed
three times with blocking buffer and then incubated rocking at room temperature for 60 minutes
with secondary antibodies diluted in blocking buffer. Finally, cells were washed twice with
blocking buffer and once with PBS, and nuclei stained with DAPI diluted in PBS (2ng/uL final
concentration). SARS-CoV-2 nucleoprotein and dsRNA (J2,1:1000, Scions) were detected.
Secondary antibodies were from Invitrogen: goat anti-mouse IgG Alexa Fluor 594®-conjugated
(A-11005) for J2 and goat anti-rabbit IgG Alexa Fluor 488®-conjugated (A-11070) for
nucleocapsid. Coverslips were mounted onto slides for analysis by widefield microscopy with
Nikon Eclipse Ti2 using a Nikon 40x/0.95NA Plan APO objective and NikonDS-Qi1Mc-U3 12 bit
camera. Images were processed using Fiji/Image J software.
Western immunoblotting. Cells were washed once with ice-cold PBS and lysates harvested at
the indicated times post infection with lysis buffer (1% NP-40, 2mM EDTA, 10% glycerol, 150mM
NaCl, 50mM Tris HCl) supplemented with protease inhibitors (Roche complete mini EDTA-free
protease inhibitor) and phosphatase inhibitors (Roche PhosStop easy pack). After 5 minutes
lysates were harvested, incubated on ice for 20 minutes, centrifuged for 20 minutes at 4°C and
supernatants mixed 3:1 with 4x Laemmli sample buffer. Samples were heated at 95°C for 5
minutes, then separated on 4-15% SDS-PAGE, and transferred to polyvinylidene difluoride
(PVDF) membranes. Blots were blocked with 5% nonfat milk or 5% BSA and probed with
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antibodies (table below) diluted in the same block buffer. Primary antibodies were incubated
overnight at 4°C or for 1 hour at room temperature. All secondary antibody incubation steps were
done for 1 hour at room temperature. Blots were visualized using Thermo Scientific SuperSignal
west chemiluminescent substrates (Cat #: 34095 or 34080). Blots were probed sequentially with
antibodies and in between antibody treatments stripped using Thermo Scientific Restore western
blot stripping buffer (Cat #: 21059).
Primary Antibody

Antibody
species

Blocking buffer

Dilution

Catalog number

pPKR (phospho-T446) [E120]

rabbit

5% milk/TBST

1:1000

Abcam 32036

PKR (D7F7)

rabbit

5% milk/TBST

1:1000

peif2α (S51)

rabbit

5% BSA/TBST

1:1000

eif2α

rabbit

5% BSA/TBST

1:1000

GAPDH (14C10)

rabbit

5% milk/TBST

1:2000

SARS-CoV-2 N

rabbit

5% milk/TBST

1:2000

MERS-CoV N

mouse

5% milk/TBST

1:2000

pSTAT1 (Tyr701)

rabbit

5% BSA/TBST

1:1000

STAT1

mouse

5% BSA/TBST

1:1000

ACE2

rabbit

5% milk/TBST

1:1000

MAVS

rabbit

5% milk/TBST

1:1000

V5

rabbit

5% milk/TBST

1:1000

RNase L

mouse

5% milk/TBST

1:1000

MDA5

rabbit

5% milk/TBST

1:1000

goat anti-rabbit IgG

HRP linked

same as primary

1:3000

goat anti-mouse IgG

HRP linked

same as primary

1:3000

Cell Signaling Technology
12297S
Cell Signaling Technology
9721S
Cell Signaling Technology
9722S
Cell Signaling Technology
2118S
GTX135357 (Gentex)
40068-MM10 (Sino
Biological)
Cell Signaling Technology
7649
Santa Cruz (C136): SC-464
Cell Signaling Technology
4355S
Cell Signaling Technology
24930S
Cell Signaling Technology
13202S
Robert Silverman laboratory
(Cleveland Clinic) (Dong and
Silverman, 1995)
Cell Signaling Technology
5321S

Secondary Antibody
Cell Signaling Technology
7074S
Cell Signaling Technology
7076S

Table S4.2 Western blot antibodies

Quantitative PCR (qRT-PCR). A549, Calu-3, and iAT2 cells were lysed at indicated times post
infection in RLT buffer and DNase-treated before total RNA was extracted using the RNeasy Plus
Mini Kit (Qiagen). RNA from iCM and nasal cells was extracted using TRIzol-LS (Ambion), and
DNase-treated using the DNA-freeTM Kit (Invitrogen). RNA was reverse transcribed into cDNA
with a High Capacity cDNA Reverse Transcriptase Kit (Applied Biosystems). cDNA was amplified
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using specific qRT-PCR primers (see Table below), iQÔ SYBRÒ Green Supermix (Bio-Rad), and
the QuantStudioÔ 3 PCR system (Thermo Fisher). Host gene expression displayed as fold
change over mock-infected samples was generated by first normalizing cycle threshold (CT)
values to 18S rRNA to generate DCT values (DCT = CT gene of interest - CT 18S rRNA). Next,
D(DCT) values were determined by subtracting the mock-infected DCT values from the virusinfected samples. Technical triplicates were averaged and means displayed using the equation 2D(DCT)

. For basal expression levels, CT values were normalized to 18S rRNA to generate DCT

values (DCT = CT gene of interest - CT 18S rRNA), and displayed as 2-ΔCt. Basal expression levels
were also calculated as fold change over A549ACE2 clone 44 using the equation 2-Δ(ΔCT). Δ(ΔCT)
values were calculated by subtracting ΔCT values from each cell type from the ΔCT value of
A549ACE2 clone 44. Absolute quantification of SARS-CoV-2 and MERS-CoV genomes was
calculated using a standard curve generated from serially diluted known concentrations of a
digested plasmid containing the region of interest. For SARS-CoV-2, construct pcDNA6B-nCoVNSP12-FLAG encoding the RDRP gene (gift from Dr. George Stark, Cleveland Clinic) was
digested with Xho1 For MERS-CoV, cDNA MERS-D1 (Scobey et al., 2013) containing basepairs
12259–15470 of the MERS-CoV genome was digested with BgII. Each was purified by Qiagen
QIAquick PCR Purification Kit. Copy numbers were generated by standard curve analysis in the
QuantStudioÔ 3 software, and copy numbers per ug RNA were calculated based on the volume
of cDNA used in the qPCR reaction, and concentration of RNA used to generate cDNA. Primer
sequences are as follows:
IFNL1
OAS2
IFIT1
IFNB
GAPDH
IFIH1
CXCL8
18S rRNA
SARS-CoV-2
genome (nsp12/RdRp)
MERS-CoV genome
(nsp7)
Table S4.3 qRT-PCR primers.

Forward primer (5’ to 3’)
CGCCTTGGAAGAGTCACTCA
TTCTGCCTGCACCACTCTTCACGAC
5’-TGGTGACCTGGGGCAACTTT
GTCAGAGTGGAAATCCTAAG
GCAAATTCCATGGCACCGT
GCACAGAGCGGTAGACCCTGCTT
GAGAGTGATTGAGAGTGGACCAC
TTCGATGGTAGTCGCTGTGC
GGTAACTGGTATGATTTCG

Reverse primer (5’ to 3’)
GAAGCCTCAGGTCCCAATTC
GCCAGTCTTCAGAGCTGTGCCTTTG
AGGCCTTGGCCCGTTCATAA
ACAGCATCTGCTGGTTGAAG
TCGCCCCACTTGATTTTGG
AGGCCTTGGCCCGTTCATAA
CACAACCCTCTGCACCCAGTTT
CTGCTGCCTTCCTTGAATGTGGTA
CTGGTCAAGGTTAATATAGG

GCACATCTGTGGTTCTCCTCTCT

AAGCCCAGGCCCTACTATTAGC
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rRNA degradation assay. RNA was harvested with buffer RLT (Qiagen RNeasy #74106) or
Trizol-LS (Ambion) and analyzed on an RNA chip with an Agilent Bioanalyzer using the Agilent
RNA 6000 Nano Kit and its prescribed protocol as we have described previously (Cat #: 50671511) (Thornbrough et al., 2016).
Statistical analysis. All statistical analyses and plotting of data were performed using GraphPad
Prism software. SARS-CoV-2 and MERS-CoV replication trends in nasal cells were analyzed by
two-way ANOVA comparing averaged titers from all four donor cells for each virus at each
timepoint. MERS-CoV and MERS-CoV-DNS4ab viral replication and primary cell qRT-PCR gene
expression between SARS-CoV-2 and SINV were analyzed by paired Student t test. qRT-PCR
analysis in A549ACE2 cells was analyzed by one-way ANOVA, comparing SARS-CoV-2 at each
timepoint to SINV. qRT-PCR analysis in Calu-3 cells was analyzed by two-way ANOVA,
comparing SARS-CoV-2 at each timepoint to MERS-CoV and MERS-CoV-DNS4ab. SARS-CoV-2
replication in A549ACE2 WT cells compared with A549ACE2 KO cells was analyzed by two-way
ANOVA. Displayed significance is determined by p-value (P), where * = P < 0.05; ** = P < 0.01;
*** = P < 0.001; **** = P < 0.0001; ns = not significant.
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CHAPTER 5: CONCLUSIONS
5.1 SUMMARY
The goal of my dissertation was to understand how the highly pathogenic coronaviruses, MERSCoV and SARS-CoV-2, interact with and evade the antiviral dsRNA-induced cytoplasmic
pathways, IFN, PKR, and OAS/RNase L. In this chapter I will summarize our findings, discuss the
implications of our work, and highlight questions for future directions of study.

In Chapter 2, we defined the roles of accessory proteins NS4a and NS4b during MERS-CoV
infection. Previous work on these proteins had primarily been done in the context of
overexpression rather than in the context of coronavirus infection. We used several recombinant
MERS-CoVs (MERS-DNS4a, MERS-DNS4ab, MERS-NS4bH182R, and MERS-NS4bNLSmut) to study
the roles of accessory proteins NS4a and NS4b during infection. We examined activation of the
IFN, PKR, and OAS/RNase L pathways in an airway epithelial-derived cell line that we
engineered to express the MERS-CoV receptor, A549DPP4. We showed that MERS-DNS4a,
MERS-DNS4ab, MERS-NS4bH182R, and MERS-NS4bNLSmut infection caused only mild increases in
IFN and ISG mRNA expression compared to WT MERS-CoV infection. We showed that loss of
NS4a expression (MERS-DNS4a infection) did not lead to RNase L activation during infection and
that deletion of NS4a and NS4b together (MERS-DNS4ab) did not increase rRNA degradation
above levels observed during MERS-NS4bH182R infection. Furthermore, we showed that MERSDNS4a infection led to phosphorylation of PKR without downstream eIF2α phosphorylation. Early
overexpression studies may have exaggerated the antagonistic effects of NS4a and NS4b on the
innate immune pathways. Our results clarified the function of these proteins in the context of
infection, as we observed only mild to moderate activation of dsRNA-induced innate pathways
during infection with MERS-CoV recombinant mutants. Therefore, we hypothesized that other
viral proteins, particularly nsp15, have overlapping functions to block these pathways, and we
explored this in chapter 3.
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Building on our work in chapter 2, we investigated the role of the endoribonuclease (EndoU)
domain of the conserved coronavirus protein nsp15 in blocking dsRNA-induced innate immune
pathway activation during MERS-CoV infection. To do this, we used several recombinant MERSCoVs: MERS-nsp15H231A, MERS-DNS4a, MERS-nsp15H231A/DNS4a, MERS- NS4bH182R, and
MERS-nsp15H231A/NS4bH182R.

We showed that MERS-nsp15H231A/DNS4a and MERS-nsp15H231A/NS4bH182R had significant
replication defects in innate immune competent A549DPP4 cells. We observed increases in IFN
and ISG mRNA expression during MERS-nsp15H231A/DNS4a and MERS-nsp15H231A/NS4bH182R
infection compared to WT MERS-CoV. We found that RNase L is activated during infection with
MERS-nsp15H231A/NS4bH182R and observed slight activation of RNase L during MERS-nsp15H231A
and MERS-nsp15H231A/DNS4a infection compared to WT MERS-CoV. We found that MERSnsp15H231A/DNS4a infection induced robust PKR activation as evidenced by phosphorylation of
both PKR and eIF2α. Our preliminary data suggest that MERS-nsp15H231A/DNS4a caused a slight
increase in translation arrest over WT MERS-CoV, and we hypothesize that this is due to PKR
activation. Finally, we demonstrated that EndoU catalytic activity limits dsRNA expression during
MERS-CoV infection, as evidenced by increased dsRNA accumulation during MERS-nsp15H231A
and MERS-nsp15H231A/DNS4a infection compared to WT MERS-CoV. Ultimately, we determined
that nsp15’s EndoU catalytic activity plays a conserved role in blocking dsRNA-induced innate
immunity during coronavirus infection. However, both accessory proteins NS4a and NS4b block
or antagonize the same pathways as EndoU, highlighting redundancy in the MERS-CoV genome.

In Chapter 4, we examined the interactions between the newly emerged SARS-CoV-2 and the
three dsRNA-induced innate immune pathways: IFN, PKR, and OAS/RNase L. We used a variety
of relevant cell types: patient-derived nasal epithelial cells, induced pluripotent stem cell-derived
alveolar type 2 cells (iAT2) and cardiomyocytes (iCM), as well as two lung-derived cell lines,
Calu3 and A549ACE2. Robust activation of IFN or OAS/RNase L was not observed in the primary
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nasal, iAT2, iCM cells, while PKR activation was detected in iAT2 and iCM. In both Calu3 and
A549ACE2 cells, SARS-CoV-2 caused mild induction of IFN/ISG mRNA expression and moderate
PKR and OAS/RNase L activation. This is in contrast to WT MERS-CoV, which blocked activation
of these three pathways during infection. Furthermore, we observed increased replication and
cytopathic effect of SARS-CoV-2 during infection of A549ACE2 cells knocked out for RNASEL,
suggesting the OAS/RNase L pathway restricts SARS-CoV-2. Ultimately, in chapter 4 we found
that SARS-CoV-2 does not evade induction of the cytoplasmic dsRNA-induced innate immune
pathways as adeptly as MERS-CoV.
5.2 GENERAL DISCUSSION AND FUTURE DIRECTIONS
MERS-CoV Accessory Proteins: NS4a and NS4b
As we show in chapter 2, loss of expression of NS4a and/or loss of expression, nuclear
localization, or phosphodiesterase (PDE) activity of NS4b during infection does not confer severe
consequences on the virus during infection of A549DPP4 cells. However, it is possible that
functions of these proteins cannot fully be appreciated in immortalized cell lines. Future studies
should examine the role of these proteins during infection of primary cells or even animal models.
It is possible that while the effects on cell lines are small, they may be exaggerated in primary
cells. Furthermore, it is possible that NS4a and NS4b are important for pathogenesis in the host
or reservoir organism.

Interestingly, two studies find deletions in the ORF4a and ORF4b accessory genes from MERSCoV sequences in vivo. In a small cohort of patients, a 48 nucleotide (16 amino acid) in frame
deletion was identified in ORF4a (Lamers et al., 2016a). The effects of this mutation on NS4a
dsRNA binding activity or innate antagonist functions are unknown, however the deletion covered
one of the β sheets of the dsRNA-binding αβββα architecture. In virus sequences from African
camels, deletions in ORF4b were identified that lacked both the PDE domain and the nuclear
localization signal (Chu et al., 2018). These studies suggest the role of these accessory proteins
may not be required for pathogenesis in the human or camel host, but instead be advantageous
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in the ancestral/natural reservoir of bats. Understanding whether these proteins are involved in
innate immune evasion in the bat host is an active area of investigation by our collaborator, Dr.
Tony Schountz. The related bat Merbecoviruses, HKU4 and HKU5, also encode NS4a and NS4b
proteins, although these proteins exhibit some interesting differences from those of MERS-CoV.
In overexpression experiments NS4a of HKU4 did not bind poly IC, a dsRNA mimic, and did not
prevent IFN promoter activity (Siu et al., 2014). HKU5 NS4b appears to be exclusively nuclear
localized when overexpressed, and as such it antagonizes RNase L activity less efficiently than
its MERS-CoV homolog (Matthews et al., 2014; Thornbrough et al., 2016). Future work should
focus on understanding the roles of NS4a and NS4b during infection of bats or bat cells and
parsing out the differences in function between MERS-CoV, HKU4, and HKU5 NS4a and NS4b
proteins during infection.

The differences between bat Merbecovirus and MERS-CoV accessory proteins suggests that
NS4a and NS4b might have alternative functions not examined in this dissertation. Indeed, NS4a
was implicated in a recent study to inhibit the pro-viral host factor SIRT1 from modulating NFκB
signaling (Weston et al., 2019). The mechanism by which NS4b dampens IFN and ISG mRNA
expression is still to be determined. Furthermore, the role of the nuclear localization of NS4b to
date has only been shown to block NFκB translocation to the nucleus by competitively binding its
importin (Canton et al., 2018). In chapter 2 we propose a function of NS4b to block IFN mRNA
expression through its nuclear localization signal and its PDE activity. It is unclear if there are
other roles for NS4b in the nucleus and if the PDE activity has any function in the nucleus. These
questions remain to be answered and should be priorities for future directions of study.
MERS-CoV nsp15 (EndoU)
We were compelled to study the role of conserved coronavirus nsp15’s EndoU domain in MERSCoV infection after it was reported that EndoU activity limited dsRNA accumulation and blocked
activation of the three dsRNA-induced innate immune pathways in mouse hepatitis virus (MHV)
infection (Deng et al., 2017; Kindler et al., 2017). Initially, we hypothesized that, like in the case of
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MHV, inactivation of EndoU activity would lead to severe attenuation of the recombinant virus
(MERS-nsp15H231A) and robust activation of innate immune pathways during MERS-CoV
infection. However, we did not observe severe attenuation of MERS-nsp15H231A or robust
activation of IFN, PKR, or OAS/RNase L during infection with MERS-nsp15H231A compared to WT
MERS-CoV. Instead we found that inactivation of the catalytic activity of EndoU in combination
with mutation of either ORF4a or ORF4b accessory genes was needed produce a mutant that
had marked attenuation. Results of our analysis of the dsRNA-induced innate immune pathways
are as follows:

IFN: In MERS-nsp15H231A/DNS4a and MERS-nsp15H231A/NS4bH182R infection we observed
significant increases in IFN and ISG mRNA expression compared to WT MERS-CoV. While IFN
induction was significant, it was still moderate in comparison to other viruses, such as Sindbis
virus, which do not so strongly block IFN induction. One future direction should be to determine if
the increased IFN mRNA expression observed also leads to increased IFN protein expression
and release by enzyme-linked immunosorbent assay and increased ISG protein expression by
western blot. Another interesting question is how the MERS-nsp15H231A/NS4bH182R mutant, which
activates RNase L, also leads to increased IFN production. This could indicate connections
between the IFN pathway and other dsRNA-induced responses.

PKR: Inactivation of EndoU catalytic activity as well as ablation of NS4a expression was required
to observe robust activation of PKR during MERS-CoV-infection. It is curious that MERSnsp15H231A infection did not cause any detectable PKR phosphorylation but MERS-DNS4a did,
indicating that NS4a may be a stronger PKR antagonist during infection.

RNase L: MERS-nsp15H231A/NS4bH182R infection of A549DPP4 cells led to marked RNase L
activation. We also observed mild activation during MERS-nsp15H231A and MERSnsp15H231A/DNS4a infection, indicating that NS4a does play a small role in blocking RNase L
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activation. However, this is overshadowed by the presence of NS4b PDE activity. Therefore, it is
possible that ablation of NS4a expression combined with inactivation of both the PDE and EndoU
enzymatic activities may be needed to fully activate the RNase L pathway, due to functional
redundancy. It may also be possible that A549DPP4 cells are not the best system for examining
RNase L activation and a different cell type or primary cells may show more robust activation of
RNase L when infected with MERS-CoV mutants.

As mentioned above, attenuated replication was observed for both MERS-nsp15H231A/DNS4a and
MERS-nsp15H231A/NS4bH182R. Our first priority of future experiments will be to determine which of
the innate immune pathways are responsible for this attenuation. I hypothesize that knock out of
PKR will rescue replication of MERS-nsp15H231A/DNS4a and that knock out of RNASEL will
rescue replication of MERS-nsp15H231A/NS4bH182R. Knock out of MAVS may partially rescue
replication of both viruses, however due to only moderate induction of IFN, I do not expect that
MAVS knock out will fully rescue replication. It is also possible that inactivation of two or more of
these pathways may be necessary to rescue replication; for example, in MHV infection, knock out
of both PKR and RNASEL was required to rescue growth of MHV nsp15 EndoU mutant to levels
similar to WT MHV (Kindler et al., 2017).

While performing these experiments, I observed significant cytopathic effect during infection with
MERS-nsp15H231A/DNS4a compared to WT MERS-CoV. I also observed nuclear blebbing, a sign
of apoptotic cell death, in MERS-nsp15H231A/DNS4a infected cells by widefield microscopy while
imaging for dsRNA expression. Therefore, an important future direction for this work will be to
determine if there is increased cell death during infection with MERS-nsp15H231A/DNS4a and also
MERS-nsp15H231A/ NS4bH182R. I hypothesize that there is increased apoptosis during infection
with MERS-nsp15H231A/DNS4a and MERS-nsp15H231A/ NS4bH182R compared to WT MERS-CoV,
due to activation of PKR and RNase L, respectively. Supporting this hypothesis, increased
apoptosis was observed in MHV-nsp15 EndoU mutant infection of bone marrow derived
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macrophages (Deng et al., 2017). Future experiments should focus on determining if increased
apoptosis is observed during MERS-CoV infection and if so, which antiviral pathway(s) is
responsible.

In chapter 3 we observed increased expression of dsRNA during MERS-nsp15H231A and MERSnsp15H231A/DNS4a infection compared to WT MERS-CoV, similar to what was previously reported
for MHV (Hackbart et al., 2020; Kindler et al., 2017). As discussed in chapter 1 section 1.4, two
groups recently examined what RNA is cleaved by EndoU during MHV infection. Ancar et al.
concluded that the substrate is positive sense RNA, as cleavage sites across the full-length
positive sense genome were detected with no sites detected in negative sense RNA (Ancar et al.,
2020). However, a caveat is that negative sense RNA is present at very low levels compared to
positive sense RNA, so cleavage in negative sense RNA may have been below the limit of
detection. In contrast, Hackbart et al. identified cleavage of the poly(U) region of negative sense
RNA and proposed that this limits generation of IFN-stimulating poly U RNA motifs. A caveat of
this work is that their method was a more biased approach, and they primarily pulled down
negative sense RNA instead of positive sense RNA (Hackbart et al., 2020). Future work on
EndoU should focus on clarifying specifically what RNAs are cleaved during infection and how
these RNAs are targeted for cleavage. For example, while cleavage sites are detected across
positive sense RNA, it is not known if these are full length genomic RNAs that could otherwise be
assembled into virus particle or if those RNAs could be defective RNAs that the virus removes to
prevent activation of innate immunity. Future work should also focus on determining how EndoU
cleavage is regulated during infection and whether any host or other viral proteins are involved in
this regulation.

In chapter 3 we demonstrated that the MERS-CoV genome encodes proteins with redundant
functions to limit or evade activation of the dsRNA-induced innate immune pathways. This
redundancy had important implications for observations of the function of EndoU during MERS
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infection. Thus, while the function of EndoU catalytic activity is likely conserved across
coronaviruses, the presence or absence of accessory proteins with redundant functions will likely
determine the outcomes observed in experiments during infection with viruses that have inactive
EndoU catalytic domains. This is also an important consideration beyond studying the basic
biology of EndoU during coronavirus infections. When considering the EndoU catalytic domain as
an antiviral drug target, it is imperative to understand the functions of the accessory proteins for
that specific virus and to determine if targeting EndoU catalytic activity alone would be enough to
limit virus replication. For example, targeting EndoU catalytic activity as a treatment for MERSCoV may be less effective than another coronavirus such as MHV (or possibly SARS-CoV-2).
This principle also applies when considering a virus with inactivated EndoU catalytic domain as a
possible vaccine candidate.
SARS-CoV-2 versus MERS-CoV
In chapter 4 we examined how the recently emerged SARS-CoV-2 interacts with the dsRNA
innate immune pathways: IFN, PKR, OAS/RNase L. Using Calu3 cells, we were able to examine
the differences in innate immune induction between SARS-CoV-2, MERS-CoV, and MERSDNS4ab. We found that SARS-CoV-2 activated all three pathways moderately, more similar to
MERS-DNS4ab than WT MERS-CoV. While MERS-CoV and SARS-CoV-2 encode conserved
proteins that likely play similar roles in evading or antagonizing innate immunity (such as nsp1,
nsp14, nsp15, nsp16) this difference highlights the nuances of the unique subgenera-specific
accessory proteins and their effects on virus pathogenesis. SARS-CoV-2 does not encode a PDE
(like MHV NS2 or MERS-CoV NS4b) or a dsRNA binding protein (like MERS-CoV NS4a), so we
predict that this is likely why SARS-CoV-2 infection leads to activation of RNase L and PKR. We
hypothesize that inactivation of the SARS-CoV-2 nsp15 EndoU catalytic domain would lead to
more robust activation of RNase L and PKR during SARS-CoV-2 infection, more similar to results
observed with MHV than our results with MERS-CoV. This is an active area of investigation in the
Weiss lab - understanding the role that nsp15’s EndoU activity plays in SARS-CoV-2 innate
immune antagonism and pathogenesis. Another future direction and area of interest is studying
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the roles of SARS-CoV-2 accessory proteins, such as ORF6, in innate immune evasion and viral
pathogenesis.

We hypothesize that these differences in innate immune activation and evasion between WT
MERS-CoV and SARS-CoV-2 may contribute to the differences in severity of disease between
MERS-CoV and SARS-CoV-2. Possibly, MERS-CoV causes more severe disease outcomes than
SARS-CoV-2 because it is better at evading induction of IFN and other innate immune defenses.
This is in addition to other contributors, such as receptor usage and cell tropism, that likely factor
into disease severity, pathogenesis, and transmission dynamics. Supporting this, studies in mice
of MERS-CoV and SARS-CoV show that the timing of IFN response is important in determining
outcomes of infection where early IFN treatment/signaling can limit virus replication but delayed
IFN treatment/signaling causes worse inflammation/pathology (Channappanavar et al., 2016;
Channappanavar et al., 2019). These themes likely hold true for SARS-CoV-2 as well. Therefore,
if SARS-CoV-2 is less adept than MERS-CoV at evading innate immune induction, it may cause
less severe disease outcomes as its controlled better by host defenses early on in infection.
Accordingly, one hypothesis as to why SARS-CoV-2 causes a wide range in symptoms between
patients is that the timing and magnitude of IFN or other innate immune responses may differ.
Such that, those patients with robust and early IFN responses more easily control virus replication
than patients with delayed or impaired responses. Understanding how and why SARS-CoV-2
causes such a wide array of disease in patients is an active area of investigation for many
groups, and our work adds important insight on SARS-CoV-2 interactions with the innate immune
pathways.
5.3 CONCLUDING REMARKS
My dissertation work has filled many gaps in our understanding of how MERS-CoV evades
induction of dsRNA-induced innate immune pathways (IFN, PKR, OAS/RNase L) and how SARSCoV-2 interacts with these pathways. While many questions remain to be answered, these results
shed light on the host-pathogen interactions between two highly pathogenic human
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coronaviruses, MERS-CoV and SARS-CoV-2, and the human innate immune system. The
COVID-19 pandemic has demonstrated how important basic research on pathogens is, as prior
research on coronaviruses informed our knowledge and understanding of the newly emerged
SARS-CoV-2. Past and current research on these coronavirus-host pathogen interactions will
also help us to be more prepared in the likely event of future emergence of novel coronaviruses.
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APPENDIX: DETECTION OF CORONAVIRUS +ssRNA BY
FLUORESCENT IN SITU HYBRIDIZATION
A1.1 SUMMARY
There has been little characterization of the localization of positive sense single-stranded (+ss)
RNAs during coronavirus infection. One group used click chemistry to detect synthesis of nascent
viral RNAs during coronavirus infection (Hagemeijer et al., 2012), but this method could not
distinguish between different RNA types such as genome vs mRNA (FigA1.1A). Here we used
Fluorescent in situ Hybridization (FISH) staining and microscopy to detect genome +ssRNA
(probes in ORF1ab region) or Nucleocapsid (N) +ssRNA (see Figure A1.1A,B) in cells infected
with murine coronavirus MHV, MERS-CoV, or SARS-CoV-2. We showed that +ssRNAs are
readily detectable by FISH in coronavirus infected cells and localization of genomic RNA vs N
+ssRNA differs in infected cells. These tools will be useful in future studies of MHV, MERS-CoV,
and SARS-CoV-2.

Fig A1.1 FISH probe design. (A) Coronavirus RNAs present in replication and chosen sites for FISH probe
design. (B) FISH probes in A actually represent several fluorescently labeled oligos pooled together – see
section A1.3 for sequences.
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A1.2 RESULTS
MHV FISH for genome RNA and N +ssRNA
Bone marrow-derived macrophages from C57/Bl6 mice (B6 BMMs) were infected at MOI=5 and
fixed for FISH staining at 6 and 9 hours post infection (hpi). Detection of viral +ssRNA was done
by FISH and imaged using widefield microscopy (FigA1.2A) and confocal microscopy (FigA1.2B).
We observed expression of N +ssRNA at 6 and 9 hpi and slight expression of genome +ssRNA at
6hpi and abundant expression at 9hpi (FigA1.2A). We also observed different localization of
genome +ssRNA and N +ssRNA, with genome exhibiting punctate localization and N broadly
distributed throughout the cytoplasm (FigA1.2B).
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Fig A1.2 MHV FISH staining. B6 BMMs were mock infected or infected at MOI=5 with MHV and fixed at the
indicated hours post infection (hpi) with 4% paraformaldehyde for FISH staining. (A) Imaging done by
widefield microscopy at 40X and images processed in Fiji. Images are from one representative of several
independent experiments. (B) Imaging done by confocal microscopy at 100X and images processed in Fiji.
Images are from one independent experiment.

MERS-CoV FISH/IF for genome RNA or N +ssRNA and N protein
A549DPP4 and Vero CCL81 cells were infected at MOI=3 and fixed for FISH/IF staining at 24 hpi.
Detection of viral +ssRNA was done by FISH, Nucleocapsid protein detected by IF, and imaged
using widefield microscopy. We observed abundant expression of genome (FigA1.3A-B) and N
+ssRNA (FigA1.3C-5).
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Fig A1.3 MERS-CoV FISH/IF staining. Cells were mock infected or infected at MOI=3 with MERS-CoV and
fixed at 24 hours post infection (hpi) with 4% paraformaldehyde for FISH/IF staining. Imaging done by
widefield microscopy at 40X and images processed in Fiji. Images are from one independent experiment.
Genome +ssRNA and Nucleocapsid protein (Nprotein) in (A)A549DPP4 cells and (B) VeroCCL81 cells. N
+ssRNA and Nucleocapsid protein (Nprotein) in (C) A549DPP4 cells and (D) VeroCCL81 cells.
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SARS-CoV-2 FISH for genome RNA and N +ssRNA
A549ACE2 and VeroE6 cells were infected at MOI=1 and fixed for FISH staining at 24 and 48 hpi.
Detection of viral +ssRNA was done by FISH, and imaged using widefield microscopy. We
observed abundant expression of genome and N +ssRNA by 24hpi (FigA1.4).
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Fig A1.4 SARS-CoV-2 FISH staining. Cells were mock infected or infected at MOI=1 with SARS-CoV-2
and fixed at the indicated hours post infection (hpi) with 4% paraformaldehyde for FISH staining. Imaging
done by widefield microscopy at 40X and images processed in Fiji. Images are from one independent
experiment. (A) A549ACE2 C44 cells (B) A549ACE2 C34 cells (C) Vero E6 cells
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A1.3 MATERIALS AND METHODS
Cells. African green monkey kidney Vero cells (E6) or (CCL81) (obtained from ATCC) were
cultured in Dulbecco’s modified Eagle’s medium (DMEM; Gibco catalog no. 11965),
supplemented with 10% fetal bovine serum (FBS), 1mM sodium pyruvate, and 10mM HEPES.
Human A549 cells were cultured in RPMI 1640 (Gibco catalog no. 11875) supplemented with
10% FBS, 100 U/ml of penicillin, and 100 μg/ml streptomycin. Bone marrow derived
macrophages (BMMs) were harvested and differentiated from C57/Bl6 bone marrow as
previously described (Zhao et al., 2012).
Viruses. MHV is mouse hepatitis virus strain A59. SARS-CoV-2 (see chapter 4 section 4.7, from
BEI), MERS-CoV (see chapter 3 section 3.1 – WT MERS-CoV derived from BAC). For infections
viruses were diluted in serum free media (DMEM or RPMI as above) and adsorbed on cells for 1
hour at 37°C (or 4°C for MHV). After 1 hour, cells were fed back with 2% FBS media (or 10%
FBS for MHV). All MERS-CoV and SARS-CoV-2 virus manipulations were performed in BSL3
conditions with approved protocols and protective equipment.
Immunofluorescence (IF) and fluorescent in situ hybridization (FISH) staining. At indicated
times post-infection cells were fixed with 4% paraformaldehyde (MERS-CoV AND SARS-CoV-2)
or 10% formalin (MHV) for 30 minutes at room temperature. Cells were then washed three times
with PBS and then dehydrated with increasing amounts of ethanol: 50%, 70%, and 100% for 5
minutes each. Samples were stored at 100% ethanol at -20 degrees C. Prior to staining, cells were
rehydrated with 70% then 50% ethanol for 2 minutes each, washed with PBS once and then used
for either FISH or combined FISH/IF.

For FISH, cells were washed with 2X SSC for 5 minutes and then 5 minutes with FISH wash buffer
(10% formaldehyde in 2x SSC, see Table A1.1). FISH probes complementary to the N gene of
(N+ssRNA) conjugated to CAL Fluor Red 610 (Stellaris custom orders) were diluted 1:50 in
nuclease free water. FISH probes complementary to the ORF1ab genes (genome) were conjugated
to C3-Fluorescein (Stellaris custom orders, see Table A1.1). Probes were diluted 1:50 in
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hybridization buffer (10% w/v dextran sulfate in 10% formaldehyde in 2x SSC) and incubated with
samples overnight at 37°C in a dark humid chamber. Samples were washed with FISH wash buffer
for 30 minutes at 37°C, nuclei stained with DAPI diluted in FISH wash for 5 minutes at room
temperature, and then cells were washed for 5 minutes with 2X SSC. Coverslips were mounted
onto slides using Invitrogen™ ProLong™ Diamond Antifade Mountant for analysis by fluorescent
microscopy. For combined FISH/IF, cells were permeabilized for 10 minutes with PBS+0.1% TritonX100. Cells were then blocked in PBS+0.1% Triton-X100 and 2% BSA containing RNaseOUTTM
(InvitrogenTM Cat #10777019) for 30 minutes at room temperature. Primary antibodies were diluted
in block buffer and incubated at room temperature for one hour. Cells were washed three times
with PBS and then incubated at room temperature for 30 minutes with secondary antibodies diluted
in block buffer. All steps from secondary antibody on were carried out in the dark. Cells were
washed three times with PBS, and then fixed again with 4% paraformaldehyde for 10 minutes at
room temperature. At this step FISH protocol was carried out as described above. MERS-CoV N
protein was detected by anti-nucleocapsid (40068-MM10 Sino Biological) at 1:1000. Secondary
antibodies were diluted 1:1000, all from Invitrogen: anti-mouse F(ab’)2 fragment AF488 (Cat #:
A11017) or AF594 (Cat #: A11020).

Widefield microscopy was done using either Nikon Eclipse Ti2 using a Nikon 40x/0.95NA Plan
APO objective and NikonDS-Qi1Mc-U3 12-bit camera or Nikon Eclipse Ti2 using a Nikon 40x Apo
LWD objective and Hamamatsu digital camera C13440. Confocal microscopy done by
100x/1.4NA objective on Olympus IX71 inverted microscope with Visitech VT iSIM scan head,
and Hamamatsu ORCA Flash 4.0 sCMOS camera. ImageJ/Fiji was used for all image processing
and preparation.

135

probe name:

MHV genome

MHV N+ssRNA

MERS-CoV genome

MERS-CoV N+ssRNA

SARS-CoV-2 genome

SARS-CoV-2 N+ssRNA

conjugated fluorophore:

C3-Fluorescein

CAL Fluor Red 610

C3-Fluorescein

CAL Fluor Red 610

C3-Fluorescein

CAL Fluor Red 610

tcctttaactttcggttctt

ggtttacagaggagcttctg

agtggcacagttagagacac

ttttggattacgtcctctac

ccataacatgaccatgaggt

tgattttggggtccattatc

acagcattccaaagctggaa

ttcttgaggattccattacc

agagaagtggctccttttta

agtgttatttggtgcagctc

tactgaatgccttcgagttc

aacgtaatgcggggtgcatt
agttgaatctgagggtccac

tgcaatgccatcatagttga

ggagttgggttgagtagttg

tttcacaagcaatgagcctc

taagcccagtgtaccaagag

cctttattaccgttcttacg

gggaagcacacccaaattag

agtaatggggaaccacactc

tattttgctttcctgtgaca

ccaggtggaaaggtaagagg

aatgcactcaagagggtagc

gttctccattctggttactg

gggttggaccgtaaaaaggt

ggaactgggtaatgccagaa

gtaggcactaatgggttttc

ttggcattaagaggtacacc

ccagttgttcggacaaagtg

cgacgttgttttgatcgcgc

ataaaacggccattacccag

ttggcaataggcactccttg

tcaagtgactccttaccata

taatttttctgtcctgtctc

tttcagaacgttccgtgtac

agacgcagtattattgggta

tggctgtgactggaacgaac

ttgctctgaagcggggattc

cattaccacaacttccacac

cagttgcttaattccattcc

tggtgacgcaactggataga

tgttgagtgagagcggtgaa

acagggaacaactccttcat

tgtgtctataccaatatccc

caaacccttggatagcattc

tccagtgtagtagaagtacc

gaaaggcacatttggttgca

gggaatttaaggtcttcctt

agtagcaagagtctgcagac

ggtgttttaaaagaacggcg

ccagatgattggacttcgac

ttaacagcccggaatgggag

tggctttaacaaaatcgccc

aattggaacgccttgtcctc

cattggctgcgagaagatga

ccctgtgccaagatagtaaa

ttagcaaaggggcaagtagc

atggacccaaacgatgccat

agtaaccacaagtagtggca

catctggactgctattggtg

aatccacatagccaaactgc

tggctgtttgcaacccagaa

gctacgccaccaaagataag

tcccaaaagttgaaggagca

tccaaaggcaatagtgcgac

cttcggtagtagccaatttg

ttgccttacaaccaactact

tccctttcgacaatatcaga

tcgttgacaacgaactctcc

gaatcattgttagggttccg

cctgtatggttacaacctat

accacgaattcgtctggtag

atatagcgtctgtctcttga

aacctagtaggaatagcctc

ccagagagaattgcgaggac

gggcgcgaattgtgtaacaa

cattaagaccttcggaacct

gatctttcattttaccgtca

tgatagacatcgtccaatcc

ttccagagccttcaacataa

cagtgactgctacgtcatag

ccctcaatgtggaagttttt

actgaacaacaccacctgta

tttgttagcaccatagggaa

acaggtggcgaatttgcaag

cgaaccagatcggctagcag

ataaggtgcagtaatggcgg

tgattgactattgcctccag

tcaaggacgggtttgagttt

cagttgcaacccatatgatg

agcttgaccactcttaatca

attatttggcccacgggatt

atcttgcaagatgcggacta

ttaagctagaggctcttgaa

accttccttaaacttctctt

gattgcagcattgttagcag

acttagtggccactttaaca

caggttttacagtagaggca

atgcaaaagttgcataccct

ctagatctggaagagtttct

gaatgtctgaacactctcct

tagaagccttttggcaatgt

acctcctgtacaaaggttat

aagagcagcaatttcttcgg

acctcccttaagtctaaaga

cagatggacctggagaagtg

acttctgtgggaagtgtttc

acgagaagaggcttgactgc
tgttgcgactacgtgatgag

cttcataaaccttactgcca

ctttaccgagcttagccaaa

ctgagacttgttcctttact

aagtagatcacctcctactg

acagcttcactagtaggttg

acccacaggcataacatatg

tttgcttcgttacttgcttg

tctacttcagaacactcctc

gcttgtagtctgttcagaag

acaaactggtgtaccaacca

gcctggagttgaatttcttg

caatctcacccaccaaacaa

ttgtttggagtcctcttttg

atcttctgcttcatcgagag

ctttactttgccagactcaa

atcatattaggtgcaagggc

caggagaagttcccctactg

tgattacttttggctgcgat

cagagcctccaaaattctga

cttcttcttgcacagattca

aagtaacctttgttggtgca

cagcaaagcaagagcagcat

gttatcaacaaccacagggt

ggatcactagttccaagttt

atcaggcacaacaggagttt

aacttttggtggaagtgcgc

gtcttgttgaccaacagttt

agctggttcaatctgtcaag

gtactctcaactgcgtcaag

ccttgatatgttaatggggc

ctctgcaagaatggggaact

aacattctgtgtctgttcgg

aagaccaaaagcttgcacca

cttatttaaggctcctgcaa

tttaccagacattttgctct

ttttgtgcctatcacatcat

aagaaggcaccaactgttgg

agatgtgtgttagcagcatt

gaagatcaccaaagtttccc

cacagcagttaaaacaccct

tagtggcagtacgtttttgc

catctgcatctacaacatcc

ccaattctaatttagatcca

agtgttagcagagttgtctg

tcagtgccgagtttattcaa

ttggcacttttctcaaagct

gcttgtgttacattgtatgc

tgagtcttcagcatcatcat

agcaccaccagaattctttt

aacacccttgttcctaagaa

tcagcaatttggggccaacg

tacatagccaagtggcattg

tttgttctggaccacgtctg
tggtccccaaaatttccttg

atttcaaatgcctccacttg

atacacatctttggtgggtt

tagggcacgttaactctacg

aaaagcactggctgtaggag

ctagttgtgtagattgtcca

tagaatgcagacaacgcctc

actgcacctgaatattgcag

attgttaactgctgtgtcgt

gtttaaattgcgacataccc

acacttttatcacctctctt

agttccttgtctgattagtt

agcaggcgaatagaatccac

accaggtagagtactatcaa

aaacgcatccaagctgtgat

tcatcattgttctgatgggt

tctaggtggaatgtggtagg

caatttgcggccaatgtttg

ccaaaggtagactctgcatt

acactttcatgatagtctca

gatcaacggggccatataac

accgaaggaagtacacaggg

atgtcattgacatgtccaca

gaagcgctgggggcaaattg

gtttgtccacaaagcattgg

ggtaggcattcaaattctca

catctggagcaccaaatgtg

tcaagtttaatggctccact

gctccatccaaataagttgg

atgcgcgacattccgaagaa

ccaccttgtggaaggataat

cttttctttggggctttggg

cagaacagcataactcagcc

aggttcagacatttggtctg

gtggtagtactcaaaagcct

cgaaggtgtgacttccatgc

tctcgcactccaaaatgcaa

gctttgcaacgcttacatta

gcagatcttcaacagtttgc

tgagtgatgctaccttgcac

gggtatttccactttttagt

ctgtgtaggtcaaccacgtt

ccactttaccatcaatttgc

atttcgctgcacagagcttt

atcgctactgtatttttggc

aacacttggacgggtgcgag

cttgtagagcaggtggatta

atttggatctttgtcatcca

ggcagattcatagcattcac

ctggggttaattctctactt

gtgtagacactaccagctaa

acatcaatcattggaccagg

ccacaagttttacacaccac

ttgtatgcgtcaatatgctt

gaagtgatagcgctttggta

tgagccaacagacttctatc

agtgtcaaactcagccaaca

accacactggtaattaccag

ggtaaggcttgagtttcatc

ttagcctgcacaaagacacg

cactacgccatcatcaagga

tggtttgcctttatacatgg

gtaaagcaccgtctatgcaa

gaagagtcacagtttgctgt

aacactcgcctccttaaatg

tagagtcatcttctaaccca

aggttcaactggtgtagact

cttgcgtttggatatggttg

atcatccaaatctgcagcag

ttattagcgagtaaagccct

tgttgaagtgctaccacatc

gtatacaccaggtatttggt

ggattgttgcaattgtttgg

gtgacatttatgccatcaca

caacgggagtacctgaatca

ctggttttagatcttcgcag

gatcacctttatccaacgta

gcgcaacttatccatactta

aagcagcggttgagtagatt

tttactaccgcacgtacatg

acaaccgtagggttgatttc

acaaccgtctacaacatgca

ccacactaccaccagtaaaa

agaccgtcacaagcagaaga

tacattcgactcttgttgct

actccacacactttacatca

tagagcatgtatgccaaacc

ctttacctccattagcatag

atagacaccatcaaccttct

tcctcttatagcagagcaag

gtactaccagcacagaatgt

caatactatgtcccaccaat

gttgaccgtctctacgataa

agtgacaagtctctcgcaac

tgagagatttcagcgatgct

aaacacatgcagacctagct

ttctttgcaagttcagcttc

Table A1.1 FISH probes. FISH probes are pooled together for use. All probes sequences are listed in 5’ to 3’
direction.
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